Nef pathogenesis in transgenic mice by Simard, Marie-Chantal.
Nef Pathogenesis in Transgenic Mice 
By 
Marie-Chantal Simard 
A thesis submitted to the Faculty of Graduate Studies and Research in partial 
fulfillment of the requirements of the degree of Doctor of Philosophy 
© Marie-Chantal Simard, J anuary 2006 
Department of Medicine 
Division of Experimental Medicine 
McGill University 
Montréal, Québec 
1+1 Library and Archives Canada Bibliothèque et Archives Canada 
Published Heritage 
Branch 
Direction du 
Patrimoine de l'édition 
395 Wellington Street 
Ottawa ON K1A ON4 
Canada 
395, rue Wellington 
Ottawa ON K1A ON4 
Canada 
NOTICE: 
The author has granted a non-
exclusive license allowing Library 
and Archives Canada to reproduce, 
publish, archive, preserve, conserve, 
communicate to the public by 
telecommunication or on the Internet, 
loan, distribute and sell th es es 
worldwide, for commercial or non-
commercial purposes, in microform, 
paper, electronic and/or any other 
formats. 
The author retains copyright 
ownership and moral rights in 
this thesis. Neither the thesis 
nor substantial extracts from it 
may be printed or otherwise 
reproduced without the author's 
permission. 
ln compliance with the Canadian 
Privacy Act some supporting 
forms may have been removed 
from this thesis. 
While these forms may be included 
in the document page count, 
their removal does not represent 
any loss of content from the 
thesis. 
• •• 
Canada 
AVIS: 
Your file Votre référence 
ISBN: 978-0-494-32385-4 
Our file Notre référence 
ISBN: 978-0-494-32385-4 
L'auteur a accordé une licence non exclusive 
permettant à la Bibliothèque et Archives 
Canada de reproduire, publier, archiver, 
sauvegarder, conserver, transmettre au public 
par télécommunication ou par l'Internet, prêter, 
distribuer et vendre des thèses partout dans 
le monde, à des fins commerciales ou autres, 
sur support microforme, papier, électronique 
et/ou autres formats. 
L'auteur conserve la propriété du droit d'auteur 
et des droits moraux qui protège cette thèse. 
Ni la thèse ni des extraits substantiels de 
celle-ci ne doivent être imprimés ou autrement 
reproduits sans son autorisation. 
Conformément à la loi canadienne 
sur la protection de la vie privée, 
quelques formulaires secondaires 
ont été enlevés de cette thèse. 
Bien que ces formulaires 
aient inclus dans la pagination, 
il n'y aura aucun contenu manquant. 
Abstract 
In order to study the functions of SIV Nef in vivo, in a small animal model, 
transgenic (Tg) mice expressing the SIV mac239 nef gene, under the control of the human 
CD4 gene promoter (CD4C) were generated. The transgene was found to be expressed in 
the same cells targeted by the virus, in vivo. These CD4C/SHIV -nef IV Tg mice develop a 
severe AIDS-like disease, inc1uding premature death, failure to thrive/weight loss, 
wasting, thymic atrophy, exhibit an especially low number of peripheral CDS+ T cells as 
well as low number of peripheral CD4+ T cells, diarrhea, splenomegaly, kidney 
(interstitial nephritis, segmental glomerulosc1erosis), lung (lymphocytic interstitial 
pneumonitis) and heart disease. In addition, these Tg mice fail to mount a c1ass-switched 
antibody response after immunization with ovalbumin, pro duce anti-DNA autoantibodies 
and sorne of them develop P.Carinii lung infection. These CD4C/SHIV-nef'Iv Tg mice 
develop an AIDS-like disease very similar to that of CD4CIHIV Tg mice, except that the 
kidney and cardiac diseases were more severe, and that a thymic developmental defect 
was observed. Heart enlargement was very severe in CD4C/SIV Tg mice during early 
breeding on the C3H background. Histopathological lesions in the heart of these mice 
were also multifocal and were similar to those found in CD4CIHIV Tg mice. Data from 
echocardiography analysis are not yet available for these Tg mice. The low number of 
peripheral CDS+ and CD4+ T cells likely reflects a thymic defect and may be similar to 
the DiGeorge-like "thymic defect" immunophenotype described in a subgroup of HIV-1 
infected ehildren. Ontogeny studies show that the Tg miee were born with a smaller 
thymus and that this phenotype is not progressive in nature. As young as embryonic day 
17, the thymie absolute cell numbers are lower in the Tg mice when compared to their 
ii 
non-Tg controis and there is a defect in thymocyte maturation in the transition between 
DN3 and DN4, with a failure to generate normal numbers of DP cells. Fetal liver 
transplantation studies have ruled out a significant impairment of the thymic epithelium 
and have suggested that this defect is likely a direct consequence of abnorÎnal T cell 
progenitors in the thymus. 
Therefore, it appears that SIV Nef alone expressed in mice, in appropriate cell 
types and at sufficient levels, can elicit many of the phenotypes of simian and human 
AIDS. These Tg mice should be instrumental in studying the pathogenesis of SIV Nef-
induced phenotypes. 
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Résumé 
Afin d'étudier les fonctions de Nef provenant du virus de l'immunodéfience 
simienne (SIVmac239) in vivo, un modèle de souris transgéniques (Tg) exprimant le gène 
nef sous la régulation du promoteur CD4 humain (CD4C) fut construit. Le transgène est 
exprimé dans les mêmes cellules que celles infectées par le virus, in vivo. Ces souris 
transgéniques (CD4C/SHIV-netIV) développent un syndrome sévère, similaire à celui du 
SIDA. Ces phénotypes incluent la mort prématurée, la perte de poids/croissance attardée, 
cachexie, atrophie du thymus, un nombre particulièrement bas de cellules T CDS+ ainsi 
que CD4+ en périphérie, diarrhée, splénomégalie, maladie du rein (néphrite interstitielle, 
glomerulosclérose segmentée), maladie du poumon (pneumonie interstitielle) ainsi 
qu'une maladie du coeur. De plus, ces souris sont incapables de générer une réponse 
immunitaire suite à une immunisation avec la protéine ovalbumine (OV A), la présence 
d'auto-anticorps (anti-ADN) fut détectée et certaines d'entres elles développent une 
infection pulmonaire (P.Carinii). Ces souris (CD4C/SHIV-nefIV) développent un 
syndrome similaire au SIDA tout comme les souris (CD4C/HIV Tg) qui expriment le 
gène nef du virus de l' immunodéficience humaine (Vlli) à l'exception que les maladies 
du rein et du coeur sont plus sévères chez les premières. L'augmentation du volume du 
coeur chez les souris Tg (CD4C/SIV Tg) fut observe très tôt lors du croisement des souris 
Tg avec des souris C3H. Les lésions histopathologiques du coeur sont multifocales et sont 
similaires à celles retrouvées dans les souris Tg (CD4C/HIV Tg). Des données en 
échocardiographie ne sont pas encore disponibles pour ces souris. Le nombre 
particulièrement bas de cellules T CDS+ et CD4+ en périphérie semble reflété un défaut 
développemental du thymus, semblable à celui rapporté chez les enfants souffrant du 
IV 
syndrome de DiGeorge et dans un sous-groupe d'enfants infectés par le VIH. Des études 
de l'ontogénie thymique ont démontré que les souris Tg naissent avec un thymus plus 
petit que la normale et que ce phénotype progresse avec le temps. Aussi tôt qu'au 17ème 
jour du développement embryonnaire, le nombre absolu de cellules retrouvées dans le 
thymus est plus bas chez les souris Tg que chez leurs contrôles non-transgéniques. Le 
défaut de maturation des thymocytes consiste en un bloc lors de la transition des cellules 
DN3 vers les cellules DN4, avec une incapacité quai-totale pour le thymus de générer des 
cellules doubles positives. Des transplantations de cellules de foie fœtal ont démontré que 
l'épithélium du thymus ne semblait pas jouer un grand rôle dans ce phénotype et ont 
suggéré que ce dernier était inhérent aux cellules exprimant le transgène et possiblement 
une résultante de cellules progénitrices anormales. 
Ces résultats suggèrent que l'expression du gène nef uniquement, dans un modèle 
de souris Tg, dans les cellules appropriées et à un niveau d'expression suffisant, permet 
de recréer un syndrome similaire au SIDA. Ces souris Tg pourront servir à étudier la 
pathogénèse du gène nef et les phénotypes induits par ce gène. 
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Preface 
This thesis is submitted to the McGill University Faculty of Graduate studies and 
research in a manuscript-based-format in accordance with the McGill University 
"Guidelines for Thesis Preparation" which reads as follows: 
Candidates have the option of including, as part of the thesis, the text of one or more 
papers submitted, or to be submitted, for publication, or the clearly-duplicated text (not 
the reprints) of one or more published papers. These texts must conform to the 
"Guidelines for Thesis Preparation" with respect to font size, line spacing and margin 
sizes and must be bound together as an integral part of the thesis. (Reprints of published 
papers can be included in the appendices at the end of the thesis.) 
The thesis must be more than a collection of manuscripts. All components must be 
integrated into a cohesive unit with a logical progression from one chapter to the next. In 
order to ensure that the thesis has continuity, connecting texts that provide logical bridges 
preceding and following each manuscript are mandatory. 
The thesis must conform to all other requirements of the "Guidelines for Thesis 
Preparation" in addition to the manuscripts. The thesis must include the following: (a) a 
table of contents; (b) a brief abstract in both English and French; (c) an introduction 
which clearly states the rational and objectives of the research; (d) a comprehensive 
review of the literature (in addition to that covered in the introduction to each paper); (e) a 
final conclusion and summary; (f) a thorough bibliography; (g) Appendix containing an 
ethics certificate in the case of research involving human or animal subjects, 
microorganisms, living cells, other biohazards and/or radioactive material. 
As manuscripts for publication are frequently very concise documents, where appropriate, 
additional material must be provided (e.g., in appendices) in sufficient detail to allow a 
clear and precise judgment to be made of the importance and originality of the research 
reported in the thesis. 
In general, when co-authored papers are included in a thesis the candidate must have 
made a substantial contribution to all papers included in the thesis. In addition, the 
candidate is required to make an explicit statement in the thesis as to who contributed to 
such work and to what extent. This statement should appear in a single section entitled 
"Contributions of Authors" as a preface to the thesis. The supervisor must attest to the 
accuracy of this statement at the doctoral oral defense. Since the task of the examiners is 
made more difficult in these cases, it is in the candidate's interest to clearly specify the 
responsibilities of all the authors of the co-authored papers. 
When previously published copyright material is presented in a thesis, the candidate must 
include signed waivers from the publishers and submit these to the Graduate and 
Postdoctoral Studies Office with the final deposition, if not submitted previously. The 
candidate must also include signed waivers from any co-authors of unpublished 
manuscripts. 
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Irrespective of the internaI and external examiners reports, if the oral defense committee 
feels that the thesis has major omissions with regard to the above guidelines, the 
candidate may be required to resubmit an amended version of the thesis. See the 
"Guidelines for Doctoral Oral Examinations," which can be obtained from the web 
(http://www.mcgill.ca/fgsr). Graduate Secretaries of departments or from the Graduate 
and Postdoctoral Studies Office, James Administration Building, Room 400, 398-3990, 
ext. 00711 or 094220. 
In no case can a co-author of any component of such a thesis serve as an extemal 
examiner for that thesis. 
The present thesis consisting of 7 chapters covers as a theme the pathogenesis of 
Nef in a mouse transgenic model. Chapter 1 is a literature review and introduction 
relevant to the research project. The experimental results are inc1uded in Chapter 2, 3, 4 
and 5. Chapter 2 consists of the experimental results of a published paper. Chapter 3 and 
4 consist of the experimental results of papers who will be submitted for publication. 
Chapter 5 is a published book chapter. Each of these papers have their own abstract, 
introduction, materials and methods, results, discussion and reference li st. Connecting 
texts are inc1uded in each preface of the chapter. Chapter 6 is a general discussion. 
Chapter 7 presents the c1aims for original research. Other experimental results that 1 
obtained are inc1uded in the appendices. At the end, the whole reference li st is attached 
for the reader' s convenience. 
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Chapter 1 
Literature review 
1- Nef Structure and Functions 
Nef is a 25-34 kDa accessory protein, present in HIV-l, HIV-2 and SIV 
lentiviruses. The HIV-l Nef gene is 206 amino acids in length, whereas the HIV-2 and 
SIV Nef genes are 256 and 263 amino acids in length, respective1y. Nef is post-
translationally modified by becoming phosphorylated and having a myristic acid 
irreversibly attached to its N-terminus. These modifications result in Nefbeing targeted to 
the cellular membrane. 
The Nef structure (Fig. 1.1) comprises an N-terminal membrane targeting 
sequence (residues 2-7), a conserved glutamic acid rich region (residues 60-71) and a Pro-
X-X-Pro repeat (residues 69-78), reminiscent of an SH3 binding site 47. The 3-D structure 
of Nef comprises a polyproline helix (residues 69-78), three helices (residues 81-94, 105-
118 and 194-198) and a five-stranded antiparallel ~-sheet 52,53. 
When Nef sequences from various sources were compared, five blocks were 
conserved in most isolated Nef genes. These blocks most likely represent residues likely 
to be structurally and functionally important. These five blocks were residues 64-90 
(black A), residues 91-96 (polypurine tract), residues 106-114 (block B), residues 130-
148 (block C) and residues 179-190 (block D). Each of these blocks comprises elements 
of secondary structure. Thus, the polyproline helix and helix 1 are located in block A and 
the polypurine tract as weIl as helix 2 are located in block B, whereas strands of the ~ 
sheet are located in block C and D 52,53. Nef is actively transcribed early after infection, 
with the nef RNA messengers representing up to 80% of the early rnRNA load of the 
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cell . 
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Despite having conserved sequences, there is a considerable variation in the amino 
acid sequence of Nef, with heterogeneity of amino acid residues being up to 17% and 
almost as high as the heterogeneity found in the gp-120 (envelope) gene 121. Most 
differences in the sequence will not have any effect on the functions served by Nef, 
whereas mutations of the myristoylation site at the second glycine and a region 
encompassing amino acids 41 through 49 of Nef, were found to profoundl y affect RIV-l 
pathogenecity. As that region encompasses the region needed to target Nef to the 
membrane, this suggests that Nef has to be membrane bound for most of its functions to 
3 take place . 
Nef has had many different appellations, such as 3: open reading frame (3' orf), 
open reading frame E' (orf E'), open reading frame F (orf F) and open reading frame B 
(orf B). Nef was finally classified as an accessory protein, since it was found to be non-
essential and even deleterious for viral replication in vitro, and called Nef, an acronym for 
. 1 111 
negatIve factor' . 
Subsequently, it was found to be required for viral replication and pathogenicity, 
in vivo, as Nef-deleted SIV viruses failed to establish a productive infection or Simian 
AIDS in macaques 76. In addition, in rhesus monkeys infected with a SIV mac239 clone 
containing a premature stop codon in nef, full nef ORF revertants were seen, indicating a 
strong selective pressure, in vivo, for an open functional form of nef to generate a 
pathogenic SIV 75. 
In agreement with these results, several scientists reported that humans infected 
with Nef-deficient RIV -1 viruses remained asymptomatic for a long period of time (over 
a decade) 32,80,92,130. Nonprogression (NP) in RIV is a rare event characterized by a tight 
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host-virus equilibrium in which there are stable, high CD4 cell counts and low viral 
replication in the absence of treatment. To be qualified as long-term nonprogressors 
(LTNP), individuals must have a serologically documented duration ofHIV-l infection of 
approximately 9.5 years, a stable or increasing slope of CD4+ T cells over time and 
maintenance of absolute CD4 + T cells within the normal range. The largest described 
cohort of such individuals is the Sydney blood Bank Cohort (SBBC), which consists of 
several individuals who became infected with an attenuated strain of HIV -1 via 
contarninated blood products from a common blood donor between 1981 and 1984 32,91,92. 
Viral attenuation has been attributed to gross deletion in the nef/long terminal repeat 
(LTR) region of the HIV-l genome, confirming the requirement of Nef for a pathogenic 
HIV -1 virus. Along the same line of results, HIV -1 Nef was found to be necessary and 
sufficient to cause an AIDS-like disease in a mouse transgenic (Tg) model 56,57 and the 
same was confirmed for SIVmac239 Nef gene in a parallel Tg mouse model 142. 
Since not all the long-term nonprogressors (LTNP) were found to harbor a nef-
defective HIV genome, the genetic makeup of an individual seems to play a crucial role 
in determining susceptibility to infection and to progression and it raises the question 
whether long-term nonprogression essentially results from a particular set of genes or 
whether there is also a benefit from strong immune responses that are independent of 
these genes. 
One favorable genetic makeup is demonstrated by HLA heterozygosity of class 1 
loci (A,B,C) which is associated with delayed AIDS onset, whereas individuals who were 
homozygous for one or more loci progressed rapidly to AIDS and death. The HLA class 1 
alleles B*35 and Cw*04 were consistently associated with rapid development of AIDS-
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defining conditions in Caucasians. The extended survival of (28 to 40%) of HIV-1 
infected Caucasians patients who did not develop AIDS for 10 or more years can be 
attributed to their being full y heterozygous at HLA locus are able to present a greater 
variety of antigenic peptides than are homozygotes, resulting in a more productive 
immune response to a diverse array of pathogens. Therefore, it takes longer for escape 
mutants to arise in heterozygotes than in homozygous individuals. Appreciable fraction of 
Rapid Progressor (RP) and Long Term (LT) survivors can be attributed to HLA genotype. 
The attributable fraction for RP (within 6 years of infection) to AIDS is 8 to Il % for class 
1 homozygosity, 7 to 26% for bearers of B*35 or Cw*04, and 19 to 32% for bearers of 
both. Alternatively, 28 to 40% who avoid AIDS for 10 or more years do so because they 
are fully heterozygous for alleles other than the AIDS-associated ones (B*35 and Cw*04). 
Rapid disease progression after HIV -1 infection is correlated with decreased NK cell 
activity, as B*35 and Cw*04 haplotypes are associated with reduction in NK number and 
activity 23,73. Greater number of CD8+ T cell responses are HLA-B-restricted. Variation in 
viral setpoint, in absolute CD4 count and rate of disease progression in the cohort, is 
strongly associated with particular HLA-B alleles. Greater selection pressure is imposed 
on HIV-1 by HLA-B alleles (4.4 fold) 77. Certain HLA-B antigens have been associated 
with lack of progression to AIDS. Homozygosity for HLA-Bw4 alleles was significantly 
associated with the ability to remain AIDS free and to maintain a normal CD4 T cell 
count, as the HLA-B molecules encoded by these alleles serve as ligands for natural killer 
cell inhibitory receptors (KIR), which inhibit NK lysis of autologous targets41 • 
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Other alleles, such as PML, TSGIOI and PPIA, were estimated to be responsible 
for lengthening or shortening by up to 2.8 years the period from 500 CD4 T cells/J..LL to 
<200 CD4 T cellS/J..LL 4• 
Tumor susceptibility gene 101 (TSGIOl) encodes a host cellular protein that is 
appropriated by HIV -1 gag in the budding process of viral particles from infected cells. 
Two polymorphic sites in the TSGIOI 5' area were identified that were associated with 
the rate of AlOS progression, among Caucasians. Three single-nucleotide polymorphisms 
(SNPs), specify three haplotypes termed A, B and C where haplotype C is associated with 
relatively rapid AlOS progression11 . 
As HIV replicates more efficiently in activated cells and viral levels consitently 
increase when the immune system of HIV -infected individuals is activated by exogenous 
stimuli such as opportunistic pathogens, it can explain the more aggressive course of HIV 
infection in sub-Saharan Africa than in developed countries, reflecting the immune 
activation associated with frequent and chronic infection by parasites and other pathogens 
38. Henceforth, progression can be tied to several factors that do not prec1ude one another. 
The combination of high frequencies of anti-HIV-l p24-specific CD4 Thl cells 
and anti-HIV-l gp41-specific IgG2 antibodies were found to be the best predictors for the 
persistence of long-term nonprogression in a cohort of LTNP. In addition, these responses 
were found to be independent of the host gene variants known to limit HIV -1 entry, 
henceforth probably reflecting an immunity-based control of the virus104• In accordance 
with these results, LTNP were also found to have high levels of anti-HIV-l CD8 memory 
cytotoxic T lymphocytes 21,124. 
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The independence from genetic factors of these predictors (CD4 Thl and IgG2 
levels) in LTNP provides the evidence that LTNP are mostly a result of a better immune 
control of HIV -1 and gives hope that future strategies to control HIV -1 might confer a 
LTNP status to all HIV-infected individuals105• 
CD4 is a 55 kDa type 1 integral cell surface membrane glycoprotein, expressed on 
the surface of T helper (Th) cells as well as monocytes and macrophages. This protein 
functions as coreceptor for the T cell receptor (TCR) , therefore participating in T cell 
activation. CD4 was also identified as primary cellular receptor used by HIV and SIV to 
255 
enter cells ' . 
One of the first roles that was attributed to Nef was the acceleration of endocytosis 
and lysosomal degradation of the transmembrane glycoprotein CD4, therefore 
dramatically reducing the steady state levels of CD4 on the cell surface of infected cells 
2,55. The normal route for CD4 trafficking involves endocytosis via c1athrin-coated pits 
followed by resorting and return to the plasma membrane (recycling). Nef will interfere 
with this normal traffic and cause the internalization and lysosomal degradation of the 
CD4 molecules, instead of the receptor being recyc1ed to the surface 5,44,103. This 
endocytosis of Nef will affect CD4 molecules that have already reached the cell surface, 
whereas it is thought that it has virtually no effect on CD4 synthesis or transport to the 
. . 30 114 123 
exocytlc machmery , , . 
To recruit CD4 into the endocytotic pathway, Nef acts as an adapter between the 
CD4 molecule and c1athrin-coated pits components. CD4 contains its own internalization 
motif: a four hydrophobic amino acids motif including two leucine residues in the 
membrane proximal region of its cytoplasmic tail. This site is generally concealed by the 
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tyrosine kinase p56 Lck associated with the CD4, permitting CD4 to be maintained at the 
cell surface 25,123. Nef will disrupt this complex to reveal that intemalization motif and 
directly bind the dileucine motif in the CD4 cytoplasmic region 26,97. The residues that 
will enter in contact with the CD4 molecule are WL (57-58) as weIl as residues G95, 
G96, L97, R106 and LI 10, present in the Nef core domain 52,53. 
AP complexes or adaptor proteins comprise four different heterotetrameric protein 
2879 . 
complexes known as AP-I, AP-2, AP-3, and AP-4 '. Each of these complexes IS 
composed of two large subunits (a and ~), one medium subunit (/-1), and one small (cr) 
subunit. These AP complexes are essential components of the c1athrin-coated pits as they 
select and link molecules that will become the cargo of the c1athrin molecules, therefore 
taking an active role in the assembly of the c1athrin-coated pits. AP2 is thought to mediate 
endocytosis from the plasma membrane whereas AP-I, AP-3 and AP-4 are part of the 
protein sorting events from the trans-Golgi network and lor endosomes to lysosomes. AP-
2 mediated c1athrin endocytosis sometimes requires the help of an accessory protein that 
will bind to its a or ~ subunit. These accessory proteins are single subunit adaptors that 
help in the assembly of the c1athrin-coated pits and the selection of the cargo molecules 
(e.g., EpsI5, epsin, amphiphysin, API80, and autosomal recessive hypercholesterolemia) 
67,118,162 
After binding the CD4 intemalization motif, a highly conserved dileucine motif in 
Nef will recruit the AP-2 subunits via its /-12 chain causing the endocytosis of the CD4 
rnolecule. In the early endosorne, Nef will interact via its EE155 diacidic sequence with the 
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~-COP subunit of the COPI coatamers and target the CD4 molecule for lysosomal 
degradation 6,20,96,117. 
This downmodulation of CD4 by Nef increases the release and infectivity of virus 
particles by preventing an association between the env-coded gp120 protein and the CD4 
molecule, a complex that would pre vent the virion from being released by sequestering it 
inside the cell 18,87,127. This decreased number of viral receptors on the surface of an 
infected cell seems to prevent reinfection of the same cell by the virus, a phenomenon 
called superinfection that would lead to the premature cell death by overloading its 
biosynthesis capabilities 14,58. Nef may also affect T cell activation by preventing the 
expression of CD4-p56 Lck complexes at the cell surface and therefore may have found a 
mechanism to regulate the activation state of its ho st ceIl, possibly rendering cell infection 
. 114,122 
eaSler . 
MHC-I molecule presents foreign antigens on the surface of cells, allowing 
recognition and killing of infected cells by cytotoxic T lymphocytes. Viruses have 
developed elaborate immunoevasive tools to prevent antigen presentation and therefore 
achieve a much higher replication rate and dissemination. MHC-I downregulation aids 
infected cells in evading specific cytotoxic lymphocytes and virions with less MHC-1 on 
their surface could be more easily transmitted to a new host given the exquisite sensitivity 
of the immune system to foreign MHC. 
Nef has been shown to downregulate the surface expression of MHC 1 cell surface 
molecules 136 and lead to accelerated development and propagation of virions. Analysis 
of Nef alle1es from HIV -l-infected patients demonstrated a correlation between the 
temporal control of MHC-I downregulation 22 and the two broad clinical stages of AIDS: 
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asymptomatic chronic HIV infection (clinical latency) followed by HIV infection! AIDS 
68. Nef alleles from asymptomatic patients were shown to be unable to downregulate 
MHC-I molecules whereas Nef alleles from patients that progressed to AIDS were able to 
downregulate MHC-I molecules 15.27. In the same line of obse~ations, macaques infected 
with an SIV virus containing a mutated Nef unable to downregulated MHC-I molecules 
did not develop simian AIDS until Nef reverted to its native sequence, capable of MHC-I 
d 1 · 109 ownregu ahon . 
Surprisingly, the molecular mechanism of Nef-induced MHC-I downregulation is 
fundamentally different from that of Nef-mediated CD4-downregulation. It was shown to 
be due to retenti on of MHC 1 in the trans-Golgi compartment 48,49,90,98, via a nonc1athrin 
PI3K1small GTPase ADP ribosylation factor (ARF6) endosomal pathway 15. The Nef 
acidic c1uster 62EEEE65 will bind to a protein called phosphorin acidic c1uster sorting 
protein-l (PACS-l) and AP-l and target Nef to the trans-Golgi network (TGN). This 
sorting of Nef to the TGN primes the SH3 binding motif and permits the activation of 
PI3K that will catalyse the formation of PIP3 at the cell periphery and recruit a small 
GTPase ADP ribosylation factor ARF6 GEF (ARNO) that will in tum activate ARF6 and 
increase the rate of ARF6-dependent MHC-I endocytosis and block the recyc1ing of 
MHC-I to the cell surface and deliver it to the TGN. Two addition al motifs were found to 
be critical for Nef mediated MHC-I downregulation: an SH3 domain binding site 
72PXXp75 and the Met20 within the amphipathic a helix. Both these motifs are protein 
kinases binding sites and are therefore implicated in cellular signaling but their specifie 
roles in this Nef-mediated MHC-I downregulation (Fig. 1.2) are not c1early known 15,129. 
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Figure 1.2. MHeI downregulation by Nef frorn (Blagoveshchenskaya, 2002) 
Nef has been shown to enhance virion infectivity by dowregulating the cell 
surface expression of molecules such as CD4 in order to facilitate viral budding and 
MHCI, in order to escape immune recognition. Nef has also been shown to enhance 
virion infeètivity by perturbing the cell activation pathway(s), influencing viral 
replication in the host and possibly causing dysfunction of immune cells. 
Both HIV and SIV Nef were shown to interact with LcK, HcK, Lyn and Fyn. 
HIV-l Nef decreasing LcK kinase activity by 9 fold and SIV Nef increasing it 26. Nef 
activates HcK which in turn associates with the Macrophage colony-stimulating factor 
(M-CSF) receptor complex. M-CSF is a primary cytokine for monocytes/macrophages 
and regulates their development and various effector functions. The formation of the 
molecular complex leads to a diminished tyrosine-phosphorylationlactivation of the 
receptor in response to M-CSF causing an inhibition of M-CSF-mediated proliferation of 
TF-l-fms and macrophages differentiation. Potentially explaining such phenotypes as 
defective phagocytosis of opportunistic pathogens by monocytes/macrophages of RIV-
infected individuals and may explain the differential cytokine/chemokine pattern 
produced in HIV-l infected persons, possibly creating a favorable environment for HIV-l 
virus production. It may also lead to abnormal tissue distribution of cells of the lineage, 
thereby facilitating the transfer of HIV -1 virus to bystander CD4 T cells 146. 
Elevated Fyn-specific kinase activity may play a role in maintaining the low viral 
load characteristic of the asymptomatic state as Fyn protein levels as disease progresses 
reach normal (uninfected individuals) levels 116. 
HIV-l Nef was found to bind to human thioesterase II protein (hTE) in a yeast 
two-hybrid assay. As other alleles causing AIDS were not found to bind to that protein, 
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hTE might not play a critical role in Nef function and its in vivo relevance to pathogenesis 
remains unc1ear24• 
HN Nef binds to the SH3 domain of Src kinases and this binding is necessary for 
enhanced growth of viruses but is dispensable for downregulation of CD4129• 
Another proposed way Nef might facilitate pathogenesis would be via HN -1-
matrix (MA) phosphorylation as it's a Nef-associated kinase (NAK) target and as MA 
phosphorylation was found to facilitate viral nuc1ear exportl49. 
Nef induces production of two CC-chemokines: macrophage inflammatory 
proteins la and l~, by HN-l-infected macrophages, inducing chemotaxis and activation 
of resting T lymphocytes, permitting productive infection 150. 
Nef interacts with Vav, leading to an increased activity of Vav and its downstream 
effectors. Cytoskeletal changes and activation of c-Jun-N-terminal kinase (JNK) were 
observed. As Vav and JNK control the process of negative selection of thymocytes, it 
could explain the short survival and reduced production of CD4+ T cells in AIDS patients 
37 
Raft-Iocalized Nef primes resting T cells for activation by increasing the levels of 
signaling molecules within rafts, and TcR activation is enhanced by the capacity of Nef to 
promote raft fusion 34. 
In a yeast-two hybrid assay, Nef was found to interact with receptor for activated 
C Kinase 1 (Rack!) who acts as a Nef intracellular docking site, bringing Nef and PKCs 
together43• 
Approximately 5-10% of the total cellular pool of Nef is localized within lipid 
rafts. Nef in lipid rafts was recruited into the immunological synapse within minutes after 
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antibody (Ab) engagement of the TcR/CD3 and CD28 coreceptors, resulting in a 50% or 
more increase number of cells expressing the transcription factors NF-KR or NFAT 40,161. 
Nef interacts with p53 directly with its N terminus, resulting in the destabilization 
of p53, thereby decreasing its proapoptotic, transcriptional and DNA binding activities; 
prolonging the viability of infected cells5o• 
Nef can activate calcium signaling in T lymphocytes independently of TcR, and 
thereby potently synergize with inducers of the Ras pathway to cause a dramatic (-100 
fold) increase in NFAT-dependent transcription, such as IL-2 and FasL99-102, such as 
demonstrated via the interaction of Nef with Inositol Triphosphate receptor to activate 
calcium signaling in T cells102 and the enhanced production of IL-2 in Jurkat cells 
expressing Nef 132. 
GAT A are a family of transcription factors that bind to the consensus DN A motif 
(Aff) GATA (AlG) through a zinc-finger domain. GATA-l is expressed in erythroid 
cells, megakaryocytes, eosinophils and mast cells of the hematopoietic lineages and plays 
an essential role in normal erythropoiesis and in the maturation of megakaryocytes. 
GATA-3 was found to be needed for normal B-selection and proliferation in the DN to 
DP transition, having a proeminent role in positive selection of thymocytes, in promoting 
the development of CD4+ T cells and blocking the development of CD8+ T cells. In 
peripheral T cells, it modulates cell survival and migration behavious and plays a 
dominant role in the differentiation of CD4 T cells to a Th2 fate 59,128. Through random 
phage library screening, Nefwas found to bind to GATA-l and GATA-3 139. 
BAD (like Bax, Bak and Bcl-Xs) is a pro-apoptotic member of the Bcl-2 family. 
The protein forms a heterodimer with, and thus inactivates, pro-survival members of the 
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same family like Bel-2 and Bel-XL. Once phosphorylated on distinct serine residues, Bad 
releases Bel-2 and associates with 14-3-3't, a process which inactivates Bad and 
stimulates pro-survival signaling. Active protein kinase C Theta (PKCe) protects T cells 
from Fas-induced apoptosis, as BAD is a PKCe substrate. Nef was found to associate 
with PKCe the pro-apoptotic BAD protein was found to be phosphorylated by the Nef-
asssociated phosphatidylinositol-3-PAK 164 possibly resulting in the protection of infected 
cells from apoptosis 144. 
Nef-associated P AK appears to mediate the effects of Rac and Cdc42 to promote 
viral replication and pathogenesis of RIV, and PAK activity is required for survival of 
infected cells, JNK activation, cytoskeletal rearrangements , and the production of viral 
partieles 16. 
Nef induction of Fas ligand (FasL) expression on the surface of the virally 
infected T cells and the subsequent interaction of FasL with specific cytotoxic T 
lymphocytes, may lead to bystander cell killing and thus forms an important mechanism 
of immune evasion. As RIV -1 also enhances Fas expression on virally infected cells, it is 
unelear how these hosts avoid rapid cell-autonomous apoptosis mediated through cis 
ligation of Fas by FasL. RIV -1 Nef associates with and inhibits apoptosis signalin-
regulating kinase 1 (ASK1), a serine/threonine kinase that forms a common and key 
signaling intermediate in the Fas and tumour-necrosis factor -a (TNFa) death-signalling 
pathways. The interaction of Nef and ASK1 inhibits both Fas- and TNFa-mediated 
apoptosis, as well as the activation of the downstream c-Jun kinase. This leads to the 
hypothesis that Nef promotes killing of bystander cells through the induction of Fas-L, 
while simultaneously protecting the RIV-1 -infected ho st cell from these same pro-
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apoptotic signaIs through its interference with ASKI function by preventing stimulus-
coupled release of thioredoxin from ASKI. 
The first way that Nef prevents infected cells apoptosis (Fas- and tumor necrosis 
factor) 1S by blocking an outide-in signal coming from cytotoxic T 
cells or autoreactive Fas ligand molecules, the second is a sensor of the cellular 
homeostasis, by blocking an inside-in signal 165. 
At the molecular level, Nef interacts with components of the T cell 
supramolecular activation complex (SMAC). The SMAC is formed during polarization 
events that follow T cell interaction with antigen-presenting cells. Soon after antigen 
recognition by T cells, TcR, coreceptors, adhesion molecules, and signaling and 
cystoskeleton components accumulate and form supramolecular clusters at the T cell-
APC contact site, termed immunological synapse. The immunological synapse provides a 
focal point for initiation of SMAC formation and the generation of intracellular signals, 
by structuring in time and space the complex communication between the T lymphocyte 
and the APC, in a way to ensure efficient antigen recognition and controlled T cell 
activation, and to provide stimuli to the APC. Two key components of the SMAC are T 
cell receptor (TCR) ç chain and the src family tyrosine kinase, LcK. The formation and 
organization of the SMAC are associated with accumulation of detergent-insoluble 
membrane structures, also known as lipid rafts. Rafts are enriched for cholesterol and 
glycosphingolipids, such as GMl, and provide a vehicle for compartmentalization of 
TcR-associated signaling. Following activation, rafts fuse into larger structures, and this 
is associated with reorganization of the actin component of the cytoskeleton througha 
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VavlRac-dependent signaling pathway. Nef interacts directly with actin, and induces 
cytoskeletal rearrangements through interactions with the adaptor protein Vav, and P AK. 
Moreover, post-translational myristylation of Nefs N-terminal, which is required 
for many of the protein's functional interactions provides a membrane anchor for Nef and 
promotes its association with T cell rafts. As corroborated by the fact that Nef was found 
to interact with PAK only in lipid rafts 85. Nef acts at two levels to promote T cell 
responses; it increases the amount of the key TcR-signaling molecules LcK and TcR ç-
chain found within rafts in resting ceIls, and has a marked effect on raft fusion following 
activation. These changes have the capacity to prime the cells for activation, and to 
increase the magnitude and duration of the response 33,85 
HIV-l infection was found to impair the formation of immunological synapses. 
Conjugation of T cells with APCs and the subsequent clustering of TcR and Lck at the 
contact zone, were strongly inhibited in a Nef-dependent manner. Nef inhibited the LcK 
targeting to the immunological synapse. LcK is the first tyrosine kinase activated after 
TcR engagement. Its activity promotes inside-out signaling to integrins, necessary for T 
cell-APC adhesion and induces actin cytoskeleton remodeling needed for TcR clustering. 
LcK is localized at the plasma membrane and in an intracellular pericentrolar 
compartment that overlaps with early endosomes. Upon antigen recognition, LcK from 
membrane and vesicular translocates to the APC contact site, where it becomes 
transiently activated. In HIV -infected ceIls, LcK targeting to the immunological synapse 
is inhibited by Nef who retains this kinase in the recycling endosomal compartment. Nef 
was also found to decrease TcR accumulation at the synapse by altering its trafficking at 
the endocytosis and to a lesser extent, at the recycling step. These effects of Nef were 
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found to be independent of Nef CD4 and CD28 downregulation. By altering synapse 
formation and the TcR activation cascade, Nef might prevent apoptosis that result from 
repetitive TcR stimulation. This, together with enhanced IL-2 secretion, might increase 
the life span of infected cells and facilitate viral spread. This process might also favor the 
development of quiescent, latently infected lymphocytes 155. 
Activation of signal transducers and activators of transcription (STATs) is 
involved in the response of a wide number of cytokines, growth facors, and hormones. 
Typically, binding of cytokines with specific receptors lacking intrinsic kinase activity in 
its cytoplasmic tail induces receptor aggregation and recruitment of members of Janus 
Kinases. These become activated by phosphoryting themselves and tyrosine residues of 
the receptor cytoplasmic tai!. The receptor phosphotyrosines serve as docking site for the 
binding of inactive ST AT through the src-homology 2 (SH2) domains. ST AT monomers 
become phosphorylated at a constant tyrosine residue and dimerize. The activated 
dimmers translocate to the nucleus thereby binding to specific DNA response elements, 
ultimately influencing gene expression programs. Nef specifically activates both a and b 
isoforms ofthe STATl, through the secretion of soluble factors 39. 
Nef suppresses immunoglobulin class-switch DNA recombination by inducing 
inhibitor of nuclear factor-kB (iKRa) and suppressor of cytokine signaling SOCS 
proteins, which block CD40 ligand and cytokine signaling via NF-KR and STAT 
transcription factors. Thus leadind to the evasion of HIV -1 from protective T -cell 
dependent IgG and IgA responses 115,120 
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2-Introduetion to Thymopoiesis: Thymie Stages of Maturation 
During embryonic development in mammals, primitive hematopoietisis begins de 
nova in the blood islands of the yolk sac, in which only erythropoiesis occurs. Definitive 
hematopoietic stem cells that will give rise to aIl blood cell lineages are thought to 
originate from the aorta, gonads and mesonephros (AGM) region and to settle in the fetal 
liver and later in the spleen. Finally, the site of hematopoiesis is transferred to the bone 
(BM) 36,69,108 marrow . 
T lymphocytes are the effector cells of the cell-mediated immunity and were 
called "T" lymphocytes, since their precursors come from bone marrow and mature in the 
!hymus. The thymus is composed of 2 lobes and is situated in the anterior mediastinum. 
Each lobe is further divided into several lob~les, each of these lobules consisting of an 
outer cortex and an inner medulla (Fig 1.3), the former one having a more dense 
population of thymocytes than the latter one. 
Bone marrow-derived progenitor cells move into the thymus parenchyma through 
vessels at the corticomedullary junction and then migrate to the subcapsular region. As 
the thymocytes mature within the thymus, they follow a very thight pattern of maturation 
that can be followed by surface expression of CD4 and CD8 molecules as well as other 
cell surface molecules. At the first stage, called the double negative stage (DN), 
thymocytes express none of these molecules (CD4-CD8-), than they express both at the 
double positive (DP) stage (CD4+CD8+) and finally they express either CD4 or CD8 
along with the TcRlCD3 complex at the last single positive stage (SP). 
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(A) Thymus 
Figure 1.3. Thymus cortex and medulla 
(B) Thymus schema 
Medulla 
(M) Cortex 
(C) 
(C) Thymus histology 
(A) organ (B) Schematic representation of the thymus, with cortex (C) and medulla (M) regions (C) Histology of the 
thymus, with with cortex (C) and medulla (M) regions 
When normal, healthy thymocytes are viewed by F ACS technique, using 
monoclonal antibodies to stain the CD4 and CD8 cell surface receptors, a rocket shape 
can be seen. The tail of the rocket is composed of DN cells (left lower quadrant), whereas 
the tip of the rocket is composed of DP cells and each wing is composed of one type each 
of SP cells (CD4 or CD8 SP cells). Therefore, the thymocytes maturation process starts at 
the base of the rocket, passes by the tip and ends at the wings (Fig. 1.4). 
An increased level of the expression of the TcR on thymocytes migrating from the 
cortex to the medulla correlates with a more mature phenotype. At the DN stage, 
thymocytes maturation can be followed using the expression of the CD44 and CD25 cell 
surface molecules. These molecules can identify four stages of DN thymocyte maturation 
(DN1 to DN4), as seen in the following figure (Fig. 1.4). DN1 cells are CD44+CD25-, 
DN2 are CD44+CD25+, DN3 are CD44-CD25+ and the final stage (DN4) is composed of 
CD44-CD25- cells. Therefore, as the cells are getting closer to becoming DP cells, they 
will express no CD44 and CD25 molecules (Fig. 1.5). 
The DN cells are mostly found in the subcapsular region, whereas the DP cells are 
found in the cortex and the SP in the medulla. DN1 thymocytes are mostly found in the 
deep cortex, DN2 thymocytes in the mid-cortex and DN3 thymocytes in the outer-
cortical and subcapsular regions of the thymus (Fig. 1.6) 113. Therefore one can make 
sorne assurnptions on the rnaturity of a thyrnocyte based on the region in which the 
thyrnocyte resides in the thymus, as thymocytes will execute these migrations like a 
choreographed ballet to achieve maturity (Fig. 1.7) 119. 
Recombination at the TcR ~ locus starts at the DN2 stage. The rearrangered ~ 
chain will form heterodimer with the pre-Ta (pTa) chain and will go to the surface as a 
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Figure 1.4. Two-color cytofluorometric analysis (CD4 versus CD8) of a normal mouse thymus 
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Figure 1.6. Migration of thymocytes in the thymus follow maturation steps adapted from (Prockop and Petrie, 2000). 
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Figure 1.7. Schematic representation ofthymic regions adapted from (Prockop and Petrie, 2000). 
pre-TcR. The Beta (~) selection consists of ligand independent signaling via this pre-TcR 
and occurs at the DN3 stage. This will permit the maturation to the DN4 stage and 
subsequent maturation to the DP stage 86,160. ~ selection includes the down-modulation of 
CD25, pre-Ta, RAG-1 and RAG-2 and termination of rearrangement at the TcR-~ locus 
(allelic exclusion) 94. 
The CD25 expressing cells (DN2 or DN3) can be divided into 2 groups. The E 
subset consisting of small resting cells which did not productively rearrange their TcR ~ 
genes and the L subset consisting of large cycling cells in which ~ selection has taken 
place. The position of the gate defining the L subset is set according to the fact that 
RAGT'- thymocytes do not contain this subset of cells and can therefore serve as a 
negative control (Fig. 1.8) 61. 
In the DP population, the CD4+CD8+ cells have 3 possible developmental fates: a 
majority will retain the CD4+CD8+ phenotype, become small and die in situ, whereas a 
minority (10-15%) will mature into CD4+CD8- or CD4-CD8+. Only the blast subset 
contains precursors for mature T cells, whereas the small DP thymocytes are post-mitotic 
nonmature cells that will die in the thymus, within 3-4 days of their last division, without 
.., Il b h .. 1 1 d 54,137,138 gIvmg nse to mature ce s ecause t ey are not pOSItIve y se ecte . 
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Figure 1.8. CD25 expressing cells, L gate definition, adapted from (Lagresle, 2002) .. 
Positive and negative selection occurs at the DP stage. Negative selection will 
remove thymocytes which bear a TcR potentially autoreactive (binding with strong 
avidity), whereas positive selection will permit the survival of thymocytes which bear a 
TcR binding with low to medium avidity to self MHC molecules. This selection is 
reminiscent of the Goldilocks story, with only the just right being allowed to be. Since 
only one blast in ten was found to transcribe the TcRa gene and only the ones with the 
appropriate avidity will be allowed to mature, only 5% of the total thymocytes will 
eventually survive and mature 54,138. Only DP cells with a high level of TcR a~ result 
f . . l' d '11 . h . . b SP Il 54,147 rom posItIve se ectlOn an WI contmue t eH maturatlOn to ecome ce s . 
During T cell maturation in the thymus, the MCH class 1 (MHCI) cell surface 
molecule is differentially expressed on different subpopulations of thymocytes. Of note, 
the expression of MHCI on DP thymocytes is lower than that on more mature SP 
89 thymocytes . 
It is thought that a proper level of interaction between MHCI and TcR-CDS cell 
surface receptor as well as in between MHCII and TcR-CD4 cell surface receptors would 
be important for thymocyte maturation to be normal. This hypothesis was confirmed 
when experiments showed that an ectopie expression of MHCI on thymocytes leads to 
thymocyte depletion in a Tg model 135. It was found that up-regulation of the MHCI cell 
surface receptor on DP thymocytes could be used as a surrogate marker of MHCI up-
regulation on thymic epithelial cells. An up-regulation of the MHCI cell surface receptor 
on these cells was also found to lead to thymocyte depletion in normal thymuses, whereas 
it leads to the selection of CDSlo thymocytes that normally would have been not been 
1 d · HIV+ . 74 se ecte ln patients. 
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The known factors that influence lymphocyte numbers are: 
1- Production rate of lymphocyte precursors from hematopoietic stem cells 
2- Thymic and bone marrow output 
3- Peripherallymphocyte expansion and survival 
The CD5 cell surface receptor is another molecule that can be used to track 
thymocyte development. The CD5 (Ly-l) antigen is expressed on mature T lymphocytes 
with a higher level of expression on CD8+ than on CD4+ T cells. In the thymus, 95% of 
thymocytes can be stained with an anti-CD5 monoclonal antibody 60,78,93,151. 
The level of CD5 expression is, in part, determined by the strength of the TcR ap 
signal. Therefore, CD5 expression is lower on DP than on SP thymocytes, which are 
mature cells having received their TcR signal 8,9,42,88,107. The CD5 cell surface receptor is 
thought ta be a negative regulator of antigen receptor signaling in the development of 
thymocytes. It negatively regulates by rendering thymocytes hyper-responsive to antigen 
. l' d he' he' l' 112 receptor stlmu atlon an t erelore targetmg t em lor negatlve se ectIOn . 
The CD69 cell surface receptor is induced by TcR signaling and is a marker of 
cells that are in the process of being positively and negatively selected. During the later 
stages of maturation, the most mature cells decrease their expression of the HSA cell 
. . 13 63 66 141 147 148 154 
surface receptor and mcrease the expreSSIOn of CD44 and MHCI ' , , , , , . 
The CD2 antigen, originally called the erythrocyte rosette receptor, is expressed 
. 6272158 
on more than 95% of thymocytes and most of the penpheral T lymphocytes ' , . The 
majority of DN cells express a low level of the CD2 cell surface marker, whereas the DP 
express an intermediate level and the SP express a high level 35. This cell surface marker 
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was found to be important in the passage from DN to DP 131 and it may act as a negative 
regulator of thymocyte sensitivity to signaIs received during positive selection. The 
mechanism for such an action is unknown, but the upregulation of CD2 is definitely a 
k f . . l' 153 mar er 0 posItIve se ectIon . 
The following table (Table 1.1) adapted from 86 summarizes various phenotypes 
seen in the thymus as a result of deficiencies of different molecules comprising the pre-T 
complex. 
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Deficiency Resulting phenotype 
PTa Block at DN3 stage (CD44-CD25+), no 
DN4 generated 
TcR~ Block at DN3 stage (CD44-CD25+), no 
DN4 generated 
TcRa Block at DP stage, no SP generated 
CD31 Block at DN3 stage (CD44-CD25+), no 
DN4 generated 
CD38 Block at DP stage, no SP generated 
CD3e Block at DN3 stage (CD44-CD25+), no 
DN4 generated 
CD3~ Partial defect at DN to DP transition 
Lck Partial defect at DN to DP transition 
LckIFyn Block at DN3 stage (CD44-CD25+), no 
DN4 generated 
CD45 Partial defect at DN to DP transition 
Zap-70/Syk Block at DN3 stage (CD44-CD25+), no 
DN4 generated 
SLP-76 Block at DN3 stage (CD44-CD25+), no 
DN4 generated 
LAT Block at DN3 stage (CD44-CD25+), no 
DN4 generated 
Vay Partial defect at DN to DP transition 
Rho Block at DN to DP transition, no DP 
generated 
RAG Block at DN3 stage (CD44-CD25+), no 
DN4 generated 
Table 1.1 Summary of various thymocytes maturation block 
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One can marvel at all the steps, signaling, molecules expression needed for the 
thymocytes to mature and become functional. Especially when one considers the number 
of cells that populate the immune system and the rapidity at which these cells are replaced 
bythe body. 
33 
3-HIV-l Nef and the Thymus, in vivo and in vitro 
In humans, thymopoietic epithelial space actually begins to atrophy at the age of one 
year and shrinks in volume by approximately 3% per year through. middle age, then 
shrinks by less than 1 % per subsequent year, throughout the rest of life. In contrast to the 
mouse thymus, in which the total size shrinks with age, the human thymus does not lose 
its volume during aging. Instead the thymie epithelial compartment is replaced by 
. 1 143 penvascu ar spaee . 
A diminished thymie volume, determined by ehest radiography is associated with 
HIV-I infection in children 51,70,71,81,106,126,159 and HIV+ children with abnormally small 
thymuses were found to progress faster to death. HIV-Înfected children have low counts 
of CD4+CD45RA + cells, whieh are believed to originate from the thymus. This finding 
gave a possible explanation to the bimodal pattern of progression seen in pediatrie AIDS. 
A minority of children have a rapidly progressive disease, usually developing AIDS-
defining conditions by 1 year of age and rarely surviving beyond the second year, 
whereas a majority will progress slowly to AIDS 7. 
The hypothesis is that sorne children infected with a virus strain that is especially 
deleterious to the thymus would experience an early disruption of their thymie 
environment. This would result in incapacity to compensate for the loss of peripheral 
lymphocytes caused by HIV or SIV by producing new ones and by a total incapacity to 
produce T cells before they are almost totally 10st due to viral infection. These thymie 
strains will result in early death of these children. On the opposite, children infected with 
a strain that does not preferentially target the thymus should live longer 106. This 
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hypothesis was confirmed by mathematical models of interactions between immune cells 
and virus, these models capturing pediatrie disease dynamics came to the conclusion that 
infection in the thymus not only can supplement peripheral infection but can help explain 
the faster progression in pediatrie cases, as well as the early and high viral burden seen in 
a lot of HIV -infected children compared to HIV -l-infected adults 81. 
In accordance, HIV+ infants with a thymie defect reminiscent of the Di George 
syndrome (congenital thymie deficiency with low counts of CD4+ and CDS+ as weIl as 
CDS+ B cells) 83,163 were found to progress much faster than the HIV+ infants not 
considered to have a thymic defect, whereas the virus load were found to be similar in 
both groups. This subgroup of fast progressors was called the DiGeorge-like subgroup 
and the time of mortality differed by a minimum of 2 to 3 years 83,110. The children 
thymic defect group was found not only to have low counts of CD4+, but also of CDS+ 
cens and CDS+ B cens. On the contrary, in children who were not part of the thymie 
defect group, increased numbers of CDS+ cens were found. 
CDS+ B cens normally constitute more than 60% of the total number of B ceIls in 
the first year of life, decreasing to adult levels (10-30 %) by the age of three years old. 
These cells constitute a large proportion of the small population of B cells found in the 
thymus and have been postulated to be involved in negative selection of autoreactive T 
cell clones in humans and possibly induce self tolerance 64. 
Furthermore, when tried in vitro, the virus isolated from children progressing 
rapidly had more affinity for thymocytes and had an effect on thymopoiesis different than 
a virus isolated from a children who progressed in a slower fashion 82. 
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The high thymic activity in children could represent both an advantage and a 
detriment in the context of RIV infection. An active thymus may offer more target T cells 
for RIV to infect in comparison to an adult involuted thymus and lead to a faster and 
more drastic immunodeficiency. On the other hand, if the thymus is not directly affected 
by the particular RIV strain, a greater output of naive T cells from the thymus may be a 
factor that helps compensate for the loss of T cells in periphery, especially when one 
considers the very high viralload reported in RIV+ infants. 
In the rhesus macaque SIV infection model, the thymus is also affected, showing 
thymic involution as rapidly as 8 weeks post-infection. This atrophy starts even before the 
animaIs develop immunodeficiency. Shrinkage and folding of the thymic capsule with a 
totalloss of the parenchyma without an increase in the fatty tissue is seen in these animals 
12 
Selective thymocyte depletion prior to the loss of peripheral T cells was observed 
in RIV+ children. The lobules from the RIV+ infected thymus showed a 65% reduction in 
thymocyte number when compared to non-infected controls and a complete loss of the 
corticomedullary junction was seen. The remaining cells in the thymus were DN and 
1 H· 126 CD3+CD4+CD8 0, whereas CD4+ SP and CD3+CD4+CD8 1 were almost absent . 
In adults or children, RIV was found to cause 3 phenotypes in the thymus: 1-
Precocious involution: defined as that which antedates the changes incurred with age and 
is out of proportion to the patient's stress. The morphologic features found were: a) 
normal anatomic location, configuration and blood vessels in the thymus b) reduction in 
the size and weight and c) severe lymphocytic depletion of cortex and medulla with 
obscured cortico-medullary differentiation and thymic epithelial injury indicated by 
36 
microcystic change in the majority of Hassall' s corpuscules 2- Dysinvolution: designated 
as severe involution of the thymus that mimics the histologie features of thymic dysplasia 
3- Thymitis: denotes an inflammatory reaction in the thymus characterized by 
lymphomononuclear or plasmacytic infiltration, medullary lymphoid follicles, or 
dll 1 · 1 d' 117071140 me u ary mu tmuc eate gIant ce s . . . 
Thymic lymphocytes 156, especially DP ones 31,45 as well as thymic epithelial cells 19 
were highly susceptible to in vitro infection with HIV-l. Furthermore, intermediates of T 
cell differentiation such as DP celIs, CD3-CD41..ow+CDS- and CD16+ thymic clones were 
also found by PCR analysis to be infected by HIV -1 134. AlI these cells were found to 
express at sorne levels, the CD4 cell surface receptor used by HIV to infect the cens 29. 
A very surprising result is the one that shows the susceptibility of triple-negative 
(TN) (CD3-CD4-CDS-) thymic cens to in vitro infection by HIV-1, as demonstrated by a 
low percentage of TN cens being positive (between 0.2 and 0.5%) by ISH. The TN cens 
that bear the CD 1 a cell surface could be infected, whereas TN that were CD 1 a- cens 
could not. In the thymus, two cell populations constitutively express the CD 1 a cell 
surface receptor: cortical immature thymocytes and thymic dendritic cells (DCs) 10. These 
TN cells were found negative for the expression of the cell surface molecule CD4 by flow 
cytometry assays. Therefore the hypothesis is that the virus still uses the CD4 cell surface 
molecule to infect TN cells as they surely still express a sufficient amount of CD4 
molecules on their surface to allow infection. This theory is supported by the fact they 
were found to express CD4 mRNA by PCR analysis and by OKT4 monoclonal antibody 
(mAb) blocking the infection of TN CD1a+ cells. One cannot rule out the fact that 
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another receptor than CD4 might be used by HN to enter these cells, as that receptor 
might be blocked by OKT4 mAb via an allosteric effect 157. 
In immortalized celllines and isolated PBMC, nef was found to downregulate the 
MHCI cell surface molecule. In apparent contrast with these results found in vitro, HN-l 
infection can also correlate with an MHCI up-regulation in the thymus. The experiments 
showing this MHCI up-regulation used human thymus implants in SCID-hu Thy-Liv 
mouse and established a correlation between the extent of the thymocyte depletion and 
the MHCI up-regulation 84. 
Other experiments using isolated subpopulations of human thymocytes, in human 
thymic organ culture and in the SCID-hu Thy/Liv mouse showed a modest but 
statistically significant MHCI downregulation in productively infected thymocytes, 
whereas MHCI was dramatically up-regulated on most (infected or not) thymocytes 74. 
This dramatic MHCI up-regulation (5 to 9 fold higher levels) was especially seen on DP 
thymocytes 84. This MHCI up-regulation on thymic epithelial cells may lead to high 
avidity interactions with developing DP thymocytes and result in the selection of 
dysfunctional CD3+CD81ow T cells because of a supranormallevel of negative selection 
74 
The mechanism for this MHCI up-regulation was found to be an interaction 
between HN-l and type 2 predendritic cells (preDC2). This interaction induced the 
secretion of INF-a and indirectly, up-regulation of the MHC c1ass 1 cell surface molecule 
on the INF-a~ receptor-positive thymocytes, regardless of them being infected or not by 
HIV_1 74. 
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This up-regulation of the MHC class 1 ceIl surface molecule might have a 
detrimental effect on thymopoiesis by causing a disruption of the regular selection milieu 
of the thymus. Thymic selection is extremely dependent on the extent of the avidity of the 
MHCI and TcR-CDS coreceptor signaling complex. This increase of the MHCI cell 
surface molecule on the surface of thymocytes and thymic epithelial cells impacts on the 
avidity of the interaction between itself and the CDS cell surface receptor 74. 
In accordance with this, studies using high-avidity murine models of T cell 
selection have shown that mature selected thymocytes displayed decreased CDS cell 
surface density 65,152. This decreased CDS cell surface density will lower the overall 
affinity of the TeR-CDS signaling complex with the high avidity MHCI cell surface 
receptor and might allow thymocytes to escape negative selection. This was confirmed by 
the finding of mature, non-functional CD3+CDS+ thymocytes with a downregulated CDS 
cell surface molecule in HIV -l-infected thymus. This could explain the presence of non-
functional T cells in HIV+ patients despite the production of new lymphocytes when the 
patients are under HAART (highly active anti retroviral therapy). It can also explain why 
the control of the virus replication is not sufficient in order for the patients to reconstitute 
. 46,74 125 133 
a proper Immune system ". 
The loss of T lymphocytes seen in HIV+ patients is a composite of peripheral T 
cells depletion by HIV and an impossibility of adequately replacing the lost T cells. The 
peripheral T cells that are lost can be either replaced by producing new cells via the 
thymus or by peripheral expansion of existing naïve or memory cells. The thymus 
contributes more to the restoration of the immune system at younger ages whereas 
peripheral expansion contributes more in older people 95. 
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The degree of thymus restoration is determined by the number of available 
competent precursors. The DP population is not under homeostatic control and is directly 
proportional to the number of DN cells. Therefore, no increase in the rate of division or 
survival of the DP population will be seen in mice with a small DN compartment. Mice 
with less than 1 % of the normal number of SP thymocytes have reduced numbers of naïve 
cells and develop an oligoclonal repertoire via peripheral expansion. The mature 
lymphocytes have a really large expansion potential, one cell being sufficient to 
repopulate whole periphery. This peripheral expansion will lead to a skewed repertoire 
and a possible gap in the immune protection, since this cannot generate new T cell 
specificities, this role being unique to the thymus. 
In conclusion, RIV may cause this thymus disruption phenotype by: 
1- Directly killing thymocytes 
2- Killing Des required for normal thymocytes development 
3- May damage thymic epithelial cells required for normal thymopoiesis 
4- May inhibit thymocyte signaling necessary for their maturation 
17,82,145,157 
40 
4- Research Models Pros and Cons and Research Rationale 
Nef was found to have conserved roles in enhancing pathogenecity in HIV and 
SIV, despite its different sequences and despite using different parts of its genome to 
interact with sometimes different effectors, depending on the alleles studied. All previous 
research did either use the original model to study AIDS: human cohorts to study HIV, 
monkeys to study SIV, cell culture or transgenic (Tg) mice expressing HIV/SIV or SHIV 
alleles in different cells and organs. All these models show sorne advantages and sorne 
caveats: 
Human cohorts 
Advantages: (i) Proper cells expressing the virus (ii) presence of virus replication (iii) 
correct levels of protein expression (iv) possibility to run studies for a long period 
because of longevity 
Caveats: (i) Limited possibility to study whole organs and to get samples, except post-
mortem or in rare cases of surgery (removal of thymus in kids undergoing cardiac 
procedures). In addition, when samples are collected, only ex vivo research could be done, 
with no possibility of performing experiments in vivo. (ii) presence of anti-retroviral 
therapy that can cause toxicities or effects that may wrongly be attributed to the virus and 
can interfere with research as exemplified by lipodystophy caused by HIV but 
exacerbated by HAART (iii) no absolute way of knowing the specific time of infection, 
for most cases (v) different mode of acquisition of HIV infection for all subjects (vi) 
kinetics studies post-infection almost impossible to do because of impossibility to infect 
subjects (vii) change in virus due to superinfection in the course of a study if subject does 
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get involved in unsafe behavior (unprotected sex, intraveinous drugs use) (viii) change in 
virus due to mutation caused by improper medication compliance 
Monkey models 
Advantages: the· same ones as for humans cohort can be attributed to the monkey model: 
(i) Proper cells expressing the virus (ii) presence of virus replication (iii) correct levels of 
protein expression (iv) possibility to run studies for a long period because of longevity as 
well as (v) possibility to harvest whole organs and (vi) post-infection kinetics studies are 
possible because subjects are sacrificed at a specifie time (vii) choice of infection route 
and of virus genome (viii) possibility to do mutation analysis or to study effects the 
effects of a particular protein 
Caveats: (i) RIV and SIV Nef do not aIways interact with the same effectors of in the 
same way when they interact with the same one (ii) the model is costly and requires space 
and specifie housing conditions (iii) use of large animais for research is badly viewed by 
general public (iv) mosaic viruses between human and monkey viruses (SRIV) were 
found to be less pathogenic 
Transgenic mouse model 
Advantages: (i) This model is less costly than the monkey model because of less space 
and specifie housing requirements (ii) the absence of anti-retroviral therapy (iii) the 
possibility to harvest whole organs (iv) post-infection kinetics studies are possible 
because subjects are sacrificed at a specifie time (v) choice of virus: RIV or SIV or 
mosaic (SRIV) (vi) possibility to do mutation analysis or to study effects the effects of a 
particular protein 
Caveats: (i) absence of virus replication and not only the proper cells express the virus (ii) 
usage of promoter drives expression of protein in a much larger proportion of cells than 
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the one infected in humans of monkeys (iii) not always similar to the human model 
henceforth results cannot always be extrapolated (iv) as breeding continues genetic 
markers from one species can be lost and phenotypes lost at the same time (v) study 
length hindered by relatively short longevity of subjects 
Cell culture 
Advantages: (i) small space requirement (ii) easy to obtain (iii) can test several 
hypothesis, multiple alleles, multiple stimuli, etc 
Caveats: (i) restrieted numbers of cells depending on sample (iii) what is seen ex-vivo 
might not reflect what is seen in vivo, hencefort results cannot always be extrapolated to 
human model (iv) all effectors might not be present (example: soluble factor secreted by 
another cell than the infected one) 
Research rationale: 
As the pros and cons of all models were taken into account, the Tg model was 
the one that seemed best to answer sorne of the questions we had. In contrast to the other 
Tg models expressing either HIV or SIV Nef (Skowronski EMBO p.703, Brady EMBO 
p.4923, Dickie Virology p. 431, Dickie 2000 p. 777, Lindemann 1994 p.797, Larsen 1998 
p.260), the model we used expresses HIV or SIV Nef in cells that are targeted by the 
virus in natural infection. This results in a systemic disease called AIDS-like disease that 
resembles pediatrie human AIDS in its features 57,142). Hencefort, this model can serve to 
study the effects of a particular protein expression on diverse organs and cells and help 
shed sorne light on the cellular and molecular mechanisms leading to pathogenecity. 
If SIV mac239 Nef does not cause the same disease than HIV -1 Nef, it could prove 
that despite similarities in structure and functions, these two alleles did not use the same 
effectors to cause disease and it would hamper the results obtained in the monkey model, 
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especially when it came to vaccine research, target identification for pharmaceutical drugs 
or effector molecules to reconstitute a proper immune sytem. If the two alleles did not 
cause the same disease in mice, it could mean that vaccines proven to be effective in the 
monkey model might be ineffective in humans and it could also mean that possible targets 
for pharmaceutical drugs represented by the effectors that Nef uses to cause pathogenesis 
might be different in the two models and a drug capable of reconstituting a proper 
immune system or to prevent Nef s ability to cause a thymic defect in the monkey model 
might be useless in HIV-infected humans. 
In order to see if HIV Nef and SIV Nef did cause the same disease and used the 
same effectors to do so, these alleles were compared in the same biological system, the 
transgenic mouse. 
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APPENDICE 
Previously, we have reported that Tg mice expressing HIV-1 NlA-3 Nefunder the 
control of the CD4 promoter develop a severe AIDS-like disease. These Tg mice develop 
several characteristic phenotypes, such as premature death, wasting, diarrhea, atrophy of 
the lymphoid organs, progressive and preferential loss of CD4+ T cells, lymphocytic 
interstitial pneumonitis, interstitial nephritis and segmental glomerulosclerosis 29,30 and 
cardiac disease (Kay et al., submitted)] resembling the ones seen in HIV+ patients. 
The presence of this AIDS-like disease in Tg mice strongly suggested that at least 
sorne of the HIV-1 Nef effectors were conserved in mice and humans. Since SIV and 
HIV -1 Nef molecules are structurally distinct and potentially interact with different 
effectors, we explored whether SIV Nef would have similar pathogenic effects in Tg mice 
to HIV -1 Nef and validate SIV as an AIDS model. 
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ABSTRACT 
ln order to study the functions of SIV Nef in vivo, in a small animal model, we 
constructed transgenic (Tg) mice expressing the SIV mac239 nef gene in the natural target 
cells of the virus, under the control of the human CD4 gene promoter (CD4C). These 
CD4C/SHIV-nef'IV Tg mice develop a severe AIDS-like disease, including premature 
death, failure to thrive/weight loss, wasting, thymic atrophy, exhibit an especially low 
number of peripheral CDS+ T cells as well as low number of peripheral CD4+ T cells, 
diarrhea, splenomegaly, kidney (interstitial nephritis, segmental glomerulosclerosis), lung 
(lymphocytic interstitial pneumonitis) and heart disease. In addition, these Tg mice fail to 
mount a class-switched antibody response after immunization with ovalbumin, produce 
anti-DNA autoantibodies and sorne of them develop P.Carinii lung infection. All these 
results suggest a generalized Nef-induced immunodeficiency. The low number of 
peripheral CDS+ and CD4+ T cells is likely to reflect a thymic defect and may be similar 
to the DiGeorge-like "thymic defect" immunophenotype described in a subgroup of 
HIV-l infected children. Therefore, it appears that SIV Nef alone expressed in mice, in 
appropriate cell types and at sufficient levels, can elicit many of the phenotypes of simian 
and human AIDS. These Tg mice should be instrumental in studying the pathogenesis of 
SIV Nef-induced phenotypes. 
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INTRODUCTION 
Nef is an accessory gene present in the genomes of HIV-1, HIV-2 and SIV. A 
functional SIV or HIV -1 Nef is critical for many of the same in vitro and in vivo 
phenotypes induced by these viruses [for reviews, see ref: 15,34,52,55,68]. In vivo, infection of 
rhesus monkeys with a nef-deleted SIV mac239 caused a chronic infection with low viral 
loads and rare progression to AIDS 41. In addition, rhesus monkeys infected with a 
SIV mac239 clone containing a premature stop codon in nefwere found to mutate rapidly to 
ORF nef revertants, indicating a strong selective pressure, in vivo, for an open functional 
form of nef to generate a pathogenic SIV 41. In agreement with these observations, 
humans infected with a nef-deleted form of HIV -1 have maintained low viral loads for 
more than a decade 16,42. 
In vitro, both SIV and HIV -1 Nef were found to be involved in the 
downregulation of cell surface expression of CD4 1,6,9,22,24,54, and of the major 
histocompatibility complex (MHC) class 1 molecules on human infected cells 59 and to 
enhance virion infectivity 2,13,15,28,41,63. In addition, SIV and HIV -1 Nef associate with a 
serine/threonine kinase, the Nef-associated kinase (NAK) which is a member of the p21-
activated kinase (PAK) family 4,57. 
Although SIV and HIV-1 Nef proteins appear to be functionally similar, they are 
nonetheless distinct molecules with clear differences: (a) SIV Nef is larger than HIV-1 
Nef 43 and the molecules share little amine acid homology. The most homologous regions 
are the N-terminal myristylation region and a highly conserved core region 43; (b) The 
genomic organization of SIV and HIV -1 nef are distinct: SIV nef coding sequences 
overlap with the env coding sequences, while the HIV -1 nef coding sequences do not; (c) 
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SIV Nef harbors SH2 binding domains at its N-terminus, not present in HIV-l Nef 21; (d) 
In contrast to HIV -1 Nef, SIV Nef is unable to downregulate mouse CD4 cell surface 
expression 22,23, whereas they were both found, in vitro, to be able to downregulate mou se 
CD8 cell surface marker 22; (e) SIV Nefbinds poo;ly to the Hck SH3 domain, while HIV-
1 Nef binds tightly to it 14,27; (t) SIV Nef has been reported to activate Hck and Lck, while 
HIV-l Nef inhibits Lck kinase 27; (g) In contrast to SIV and HIV-2 Nef, HIV-l Nef does 
not interact with the zeta chain of the T cell receptor 8,37,58; (h) To downregulate the 
human cell surface CD4 receptor, SIV Nef uses either two tyrosine motifs or a leucine-
based motif whereas the HIV-l Nef uses a leucine-based motif only 1,12,24,38; (i) HIV-l 
Nef contacts the AP-2 complex via its C-terminus while SIV Nef binds to it via its N-
terminus 49; (j) Although HIV-l Nef can replace SIV Nef and generate infectious viruses, 
such chimeric viruses (SHIV) less consistently yield high virus loads and AIDS in 
infected rhesus macaques than the parental SIV 3,39,43,50,61. 
We have previously reported a novel in vivo assay for the nef gene of HIV -1 in transgenic 
(Tg) mice. These Tg mice, expressing Nef in the natural target cells of the virus 
(immature CD4+CD8+ T cells, mature CD4+ T cells, macrophages and dendritic cells) 
under the regulatory sequences of the human CD4 gene (CD4C), developed a severe 
disease with multiple phenotypes [premature death, wasting, diarrhea, atrophy of the 
lymphoid organs, progressive and preferential loss of CD4+ T cells, lymphocytic 
interstitial pneumonitis, interstitial nephritis and segmental glomerulosclerosis 29,30 and 
cardiac disease (Kay et al., submitted)] resembling those reported in AIDS. More 
recently, we reported that these CD4CIHIV Tg mice exhibit impaired germinal center 
formation and produce elevated levels of autoantibodies 53. The appearance of this AIDS-
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like disease in CD4C/HIV Tg mice strongly suggested that at least sorne of the HIV-1 
Nef effectors were conserved in mice and hurnans. Since SIV and HIV -1 Nef rnolecules 
are structurally distinct and potentially interact with different effectors, we explored 
whether SIV Nef would have similar pathogenic effects in Tg mice to HIV -1 Nef. 
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MATERIALS AND METHODS 
Transgene Construction and Generation of Tg Mice : 
The HIV -1 nef ORF in the construct CD4C/HIVMutG 29,30 was replaced with the 
SIV mac239 nef ORF. The SIV mac239 cloned DNA 26 was obtained through the AIDS 
Research and Reference Reagent Program a division of AIDS, NIAID. The SIV Nef was 
amplified with two oligonucleotides in order to generate a MluI site at the 5' end and a 
Not} site at the 3' end (oligo GACGCGTCTACAATATGGGTGGAG and oligo 
AGCGGCCGCTGTTTCAGCGATTT, respectively). The PCR product was confirmed by 
sequencing in both orientations. This amplified fragment was then inserted into the MluI-
Not! site created in the CD4C/HIV cassette described previously 29,30, therefore replacing 
the HIV-INu-3 nef Transgene DNA was isolated from the vector by an AatII digestion 
and purified to produce Tg mice as described previously 29,30. These mice were bred as 
heterozygotes on the C3H background. Aged-matched non-Tg littermates were used as 
controls. 
Tg and non-Tg mice were maintained in a specifie pathogen-free (SPF) animal 
facility. Nine non-Tg CDl mice are housed as sentinels in each of the same SPF rooms 
than the Tg and non-Tg experimental animaIs. These mice are divided in 2 cages and each 
cage is placed on one of the cage racks in each SPF room. A bedding sample of every 
cage of each rack is placed in the relevant sentinel cage. Every three months, the sentinels 
are tested serologically and once a year the sentinels are tested serologically, 
bacteriologically and for the presence of parasites. 
Serological evaluation (Scan Plus (SPM) done by the rodent Health Surveillance 
Program, University of Miami) revealed no infection with the following agents: Mouse 
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Hepatitis Virus (MHV), Sendai Virus, Mycoplasma pulmonis/arthritidis, Pneumonia 
virus of Mice (PVM) , Minute Virus of Mice (MVM) , Theiler' s Murine 
Encephalomyelitis Virus (GD VII) , Rotavirus (EDIM) and Lymphocytis Choriomeningitis 
(LCMV). The mice are also negative for the presence of several respiratory and enteric 
bacteria (over 80 pathogenic and non-pathogenic bacteria as weIl as over 35 species of 
fungi are screened). The serological test is performed by standard ELISA procedures. The 
reagents are individually prepared in tissue culture and titrated for optimal reactivity. The 
samples are run with known negative and positive controls. To be considered positive, the 
sample's readings (O.D) must be 2 times the reading of the negative sample. AlI positive 
or questionable samples are confirmed by IFA and/or outside reference laboratory. As for 
the cultures, they are placed on differential media inc1uding Mackonkey, CAN, TSA, 
Hekton E and chocolate. They are incubated at 37°C and reviewed by licensed medical 
technologists. Follow up tests inc1ude gram stain, various differential biochemical tests 
and commercially available kit called Api (Biomerieux, France). 
RNA Purification and Northern Blot Analysis: 
RNA from different tissues was isolated using Trizol (GibcoBRL) and 10 /lg from 
each sample was electrophoresed on formaldehyde agarose gels and processed for 
hybridization using a mixture of three 32P-Iabeled probes: two were the 2.1 kbp HindIII 
(nt 6026 to 8131) and the 400 bp BamHl-Mlul (nt 8401 to 8800) fragments of the 
HIV -INL4-3 genome, while the third one was the 820 bp Mlul-Notl fragment (nt 9320 to 
10140) of the SIV mac239 genome. 
Assessment of transgene expression by In situ hybridization (ISH) 
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ISH was performed on paraformaIdehyde perfusion fixed paraffin-
embedded tissues and cytospotted sorted peripheral CD4+ T cells, using a transgene 
specific 35S-UTP-Iabeled antisense and control sense RNA probes, as described 
previously 29,30. Tissues from non-Tg control animaIs hybridized with antisense probes, as 
weIl as Tg animal tissues hybridized with sense probes, failed to exhibit any specific 
hybridization signaI. 
Protein Extraction and Western Blot analysis: 
Protein extraction was accompli shed by lysing the cells or tissues in 20llL of 
RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCI, 1% sodium deoxycholate, 1% 
NP-40 and 0.1% SDS) containing inhibitors (Aprotinin (2Ilg/mL), Pepstatin (1Ilg/mL), 
TLCK (50llg/mL), Leupeptin (2Ilg/mL), Sodium ortho-vanadate (O. 37Ilg/mL) , Sodium 
floride (O.04Ilg/mL) and PMSF (lOOllg/mL), aIl from Sigma), using pellet pestles 
(Fisher). The lysates were left on ice for 30 min. and centrifugated for 15 min. at 4°C. The 
supematants were collected and the proteins were quantitated using a MicroBCA assay 
(Sigma). Proteins (100 /-lg) were loaded on 10% polyacrylamide gels and, following 
migration, were transferred to a PVDF membrane (Immobilon™-p , Millipore) using a 
semi-dry transfer apparatus (Schleicher&Schuell). A monoclonal antibody to SIV mac251 
Nefprotein (17.2) (#2659 Lot: 295016) was obtained from Kai Krohn and Vladimir Ovod 
through the AIDS Research and Reference Reagent Program, a division of AIDS, NIAID 
and used at aI: 1000 dilution. A secondary peroxidase-coupled anti-mouse 
Immunoglobulins (DAKO) was used (1:10000). Proteins were detected using the 
Renaissance™ enhanced chemiluminescent substrate (NEN™, Life Science Products). 
To confirm equaI protein loading, the membranes were stripped of antibodies by washing 
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for 30 min. at 55°C in a solution containing 2% SDS, 74.4 mM Tris-HCl pH 6.8, 0.7% B-
mercaptoethanol and blocked with 3% BSA before being re-probed with an anti-actin 
antibody (Sigma) (1:800) followed by a secondary peroxidase-coupled anti-rabbit 
Immunoglobulins (Sigma) (1: 10000). 
Cell Type Specificity of Transgene Expression 
Single cell suspensions of the thymus, peripherallymph nodes (LN), mesenteric 
LN and the spleen from Tg and non-Tg aged-matched controls were prepared by meshing 
the organs in RPMI (5% FBSI). The red blood cells were lysed by incubation in Gay's 
solution for 5 min. on ice. The cells were washed once, counted, resuspended in FACS 
blocking solution (PBS containing 20% FCSI and 0.02% azide) and left on ice for 1 hr. 
Afterwards, the cells were washed and resuspended in FACS buffer (PBS containing 2% 
FCSI and 0.01% azide) to be stained with the following mixture of antibodies: PE-
coupled anti-mouse CD8a monoclonal antibody (Ly2)/ FITC-coupled anti-mouse aBTcR 
monoclonal antibody/ biotin-coupled anti-mouse CD4 monoclonal antibody (all from 
Cedarlane) followed by streptavidin-APC (Pharmingen). Staining was also performed 
with PE-coupled anti-mouse B220 (Ly5) monoclonal antibody/ FITC-coupled anti-mouse 
IgM monoclonal antibody (both from Cedarlane). After staining by incubating for 45 min. 
on ice, the cells were resuspended in FACS buffer at a concentration of 15x106 cells/mL. 
The cells were than sorted to obtain B220+/IgM+ B-ceIls, CD4+TcRaB+ T ceIls, 
CD8+TcRaB+ T cells from the Tg and non-Tg mice, using a cell sorter (Moflo, 
Cytomation). Macrophages from the Tg and non-Tg mice were also obtained by a 
peritoneal lavage using a total of 10 mL of cold RPMI (lO%FBSI, 0.35 mM 2-
mercaptoethanol). Recovered cells were washed 3 times before plating on 100 mm Petri 
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dishes (Falcon) and incubated ovemight at 37°C to allow cell adherence. Macrophages 
were then harvested with a Costa? cell scraper. 
Flow Cytometry: 
Single cell suspensions of thymus, spleen and mesenteric lymph nodes (LN) were 
prepared from Tg and non-Tg aged-matched littermates. The same procedure as the one 
explained before was followed. The antibodies used in this study were: Phycoerythrin 
(PE)-coupled anti-mouse CD4 monoclonal antibody (L3ff4), PE-coupled anti-mouse 
CD8a. monoclonal antibody (Ly2), fluorescein isothiocyanate (FITC)-coupled anti-mouse 
CD8a. monoclonal antibody (Ly2) , FITC-coupled anti-mouse a.~TcR monoclonal 
antibody, FITC-coupled anti-mouse CD44 monoclonal antibody, FITC-coupled anti-
mouse B220 (Ly5) monoclonal antibody, PE-coupled anti-mouse CDllb, Mac-l 
monoclonal antibody, FITC-coupled anti-mouse Thy1.2 monoclonal antibody (all from 
Cederlane laboratories) and an FITC-coupled anti-mouse CD69 monoclonal antibody 
(Pharmingen Canada). After staining, the cells were resuspended in FACS buffer at a 
concentration of lx106 cells in 300 JlL. Flow cytometric analyses were performed with a 
FACScan (Becton Dickinson), the cells taking up propidium iodide (5Jlg /mL final 
concentration) were excluded by electronic gating. The FACS data were analyzed using 
Windows Multiple Document Interface for Flow Cytometry (WinMDI) version 2.8. 
Microscopie Analysis: 
Mice were sacrificed by CO2 asphyxiation and the organs (thymus, heart, liver, 
kidney, spleen and gut) were immediately collected and immersion fixed in 3.7% 
formaldehyde (Fisher) in PBS (lX). Organs to be assessed were embedded in parraffin, 
sectioned at 5 Jlm, and stained with hematoxylin and eosin, as described previously 29. Tg 
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and non-Tg tissues examined by Gram (detecting both Gram-positive and Gram-negative 
bacteria) and by Grocott staining were chosen at random. Tissues were examined by two 
investigators (D.K and S.J.). 
Preparation of Single Cell Suspensions and CD4+ T cell purification 
The peripheral (axillary, inguinal, popliteal and brachial) lymph nodes (LN) 
from Tg and non-Tg littermates were collected and single cell suspensions were prepared 
by gently disrupting the organ with a syringe plunger, pipetting several times up and 
down with a Pasteur pipet, and filtering through nylon mesh. Cells were incubated for 1 
hour at 37°C in a humidified 5% C02 incubator to remove adherent cells (dendritic cells 
and macrophages). After the incubation, the non-adherent cells were harvested, counted 
and resuspended (107 cells/mL) in PBS without fetal bovine serum, as described 33. The 
CD4+ T cell purification was done as we have previously published 33. In brief, the cells 
were purified by using sheep anti-rat coated magnetic beads (Dynabeads) after a pre-
incubation with an antibody cocktail of hybridoma supematants. The cocktail contained 
rat anti-B220 (RA36B2), a kind gift of R.Coffman, DNAX Research Institute of Cellular 
and Molecular Biology, Palo Alto, Calif., rat anti-MHC-II (M5-114) and rat anti-CD8 
(53.6.78) (American Type Culture Collection (Manassas, Va.). The purity of 
CD4+TcRaJ3+ as analyzed by Flow Cytometry was ~ 96% for the non-Tg controls. 
CFSE Fluorescent Dye Labeling and Cell Division Assay 
CFSE (5-and 6-carboxyfluorescein diacetate succinimidyl ester) was 
purchased from Molecular Probes Inc. (Eugene, Oreg.). The LN cell single suspension 
was labelled by adding CFSE at a final concentration of 1 JlM followed by incubation at 
room temperature for 10 min. The reaction was stopped by adding complete medium 
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(Iscove's_modified Dubelcco medium (IMDM, Gibco BRL, Life Technologies) 
supplemented with 5% FBSi (Gibco), 50 J,lM 2-ME (Sigma), penicillin [100U/mL] and 
streptomycin[100U/mL]). The cells were washed twice and cultured in anti-CD3 
(5J,lg/mL)-coated fiat bottom 96-well plates at 105 cells/well in 200 uL of complete 
medium for 3 days. After the 3 days culture, the cells were harvested and stained for 
FACS, as described above. The CFSE profiles were read on live CD4+ or CD8+ T cells, as 
described previously 33. 
Detection of DNA-specifie Immunoglobulins (Ig) 
Ig were detected by standard ELISA procedures using fiat bottom plates (Nalge 
Nunc International) coated with sonicated double-stranded human placenta DNA (200-
300 bp; 4 J..lg/mL), essentially as described previously 53. HRP-coupled goat anti-mouse 
IgM (1:500) and IgG l (1:1000) (Southern Biotechnology Associates) were used to reveal 
isotypes. OPD (Sigma) was used as a substrate. 
Miee immunization and Detection of OV A-specifie Ig 
Female Tg and non-Tg mice were used between 8-12 weeks of age. Mice 
were immunized with alum-precipitated ovalbumin (OV A) (Sigma) (300 J..lg 
administrated S.C.: 100 J..lg in neck and 50 J..lg per paw). To obtain a secondary response, 
mice were given the same immunization 14 days after the primary injection. Mice were 
either sacrificed 10 days postprimary injection or 5 days following the secondary 
immunization, as previously described 53. OVA-specific Ig were detected by standard 
ELISA procedures, as previously published 53, using fiat bottom plates (Nalge Nunc 
International) coated with OV A (1 J..lg/mL) (Sigma). HRP-coupled goat anti-mouse IgM 
(1:500), IgGl (1:1000), IgG2b (1:1000) and biotin-coupled goat anti-mouse IgG2a (1:300) 
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followed by streptavidin-HRP (1:1000) (Southern Biotechnology Associates) were used 
to reveal isotypes. OPD (Sigma) was used as a substrate. 
Statistical Analysis 
Statistical analysis was performed with Microsoft Excel using the Student's t-test: 
unpaired equal variance, two-tailed distribution. 
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RESULTS 
Construction of CD4C/SHIV -nef SIV Tg Mice 
Ta construct SIV Nef expressing Tg mice, nef coding sequences of SIV mac239 
were inserted into the NL4-3 HIV_I MutG genome, replacing the HIV-l nef (Fig.2.1). In 
this HIVMutG genome, the ORFs of all other known HIV -1 genes (gag, pol, env, vif, vpu, 
rev, tat and vpr) were interrupted 30. This SHIV-nefIV DNA fragment was ligated 
downstream of the CD4C regulatory sequences of the human CD4 gene (Fig. 2. 1). These 
CD4C sequences have been shown to drive expression of surrogate genes, including HIV-
1, in CD4+CDS- and CD4+CDS+thymocytes, as well as in peripheral CD4+ T-cells and in 
cells of the macrophage/dendritic lineages of Tg mice 29-32. 
Five founders (F) carrying this CD4C/SHIV-nefIV transgene (F55541, F57691, 
F57693, F57690, F61217) were produced. Southem blot analysis indicated that the 
structure of the transgene appeared to be grossly intact (data not shown). AlI founders 
showed a frequency of their Tg progeny to be lower than expected (Table 2.1), suggesting 
that these founders were mosaic. Independent Tg lines could be established with all 
founders. Mice from the two founders F57690 and F61217 were found by Northem 
analysis ta be negative for transgene expression (data not shown). Therefore, no further 
analysis of mice from these lines was carried out. Mice from three founders (F57691, 
F55541 and F57693) were studied. Progeny mice were genotyped and routinely examined 
for signs of disease. 
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Figure 2.1. Structure of the CD4C/SHIV _neCS1V transgene 
The mouse CD4 enhancer (mCD4 enh) , the human CD4 promoter (hCD4 prom), the 
HIV -1 NL4.3 mutant G genome and the polyadenylation sequences from simian virus 40 
(SV40) were ligated. Exl and Ex2 are the first two untranslated ex ons of the hCD4 gene; 
3'LTR is part of the 3'LTR of the HIV-l genome. The symbol (X) means that the ORF of 
the indicated HIV -1 gene was interrupted. 
Table 2.1. Characteristics of the CD4C/SHIV _nerIV Founders 
Founder# Sexa #of Tg mice/total # Mosaicism Expression level Line 
ofborn mice (according to established 
Western blotting)b 
F57690 F 14% (n= 6/42) Yes None Yes 
F61217 M 14% (n=5/35) Yes None Yes 
F55541 F 33 % (n=25176) Yes High Yes 
F57691 F 9 % (n=5/54) Yes Very high Yes 
F57693 F 26% (n=20177) Yes Medium-High Yes 
a M,male; F,female. 
b The expression were later correlated with the latent period before disease 
appearance. 
Transgene Expression in CD4C/SHIV _neF1V Tg Mice 
Transgene expression was first evaluated by Northern blot analysis. This analysis 
revealed the three main transcripts of the HIV-l genome (8.8 kb full-Iength, 4.3 kb env-
specifie and 2.0 kb multiply-spliced) at high levels in the thymus (Fig. 2.2A). Weaker 
transgene expression was detected in spleen, lungs, gut and kidneys (Fig.2.2B), most 
likely reflecting the expression in CD4+ T cells and/or in resident macrophages and 
dendritic ceIls, as previously documented 29,30. No transgene expression was detected in 
the heart or liver (Fig.2.2B). Expression was the highest in mice from founder F57691, 
moderate-high in mice from founder F55541 and lowest in mice from founder F57693 
(F57691 > F55541 > F57693). 
Assessment of transgene expression by ISH revealed that thymocytes, from both 
the cortex and the meduIla, expressed the transgene, with a higher level of expression 
being detected in the cortex (Fig.2.2 C). Transgene expressing cells were also detected in 
the T cell zones of the spleen and mesenteric LN as weIl as in F ACS-sorted purified 
peripheral CD4+ T cells (data not shown). In addition, mononuc1ear cells in the lamina 
propria of the intestine and infiltrating the interstitium of the kidney expressed the 
transgene (data not shown). No specific hybridization signal was detected in tissues from 
the Tg mice exposed to a sense probe or in non-Tg mice exposed to the antisense probe 
(Fig. 2.2 C and data not shown). 
SIV Nef protein expression was also analyzed in these Tg mice by Western blot. 
A medium-high to very high expression of the SIV Nef protein could be detected in Tg 
mice from the three founders expressing Tg RNA (F57691 > F55541 > F57693), while no 
SIV Nef protein could be detected in control non-Tg mice (Fig.2.3A and 2.3B). A similar 
experiment performed on sorted cells showed that Nef expression was detectable in 
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Figure 2.2. Expression ofSIVrnac239 ne/RNA in CD4C/SHIV-nefIV Tg mice 
(A, D) Northern blot analysis of RNA from thymuses of mice from Tg founders F57691, F5554l and 
F57693 (A) and from organs ofmice from the founder F57691 (D). Organs from non-Tg littermates were 
used as controls. RNAs were hybridized with 32P-labeled transgene-specific probes. The filters were then 
washed and rehybridized with the 18S ribosomal-specific probe. (C) ISH analysis. Thymus from Tg 
(panels A,8) or non-Tg mice (panel C) was probed with sense (panel A) or antisense (panels B,C) 
transgene-specific riboprobes. The left and right hand sides of each panel are the tissues in bright and dark-
field illumination, respectively. A strong and specifc hybridization signal was detected in panel B, being 
higher in cortical (C) relative to medullary (M) thymocytes. The scale bar in panel C equals 100 ~M and is 
valid for ail panels. Counterstain: hematoxylin and eosin. 
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Figure 2.3. Expression of SIV mac239 Nef protein in CD4C/SHIV -ner1v Tg mice 
(A) Total prote in extracts (100 ? g) from thymuses of one-month-old Tg lines (Founders 
F57691, F55541 and F57693) and non-Tg litterrnates were separated by SDS-PAGE and 
analyzed by Western blotting with a monoclonal antibody specifie to SIV Nef. Equal 
loading was confirrned by probing with an anti-actin antibody. 
(B) Semiquantitative analysis of SIV mac239 Nef protein. Thymie extracts of mice from 
Tg lines were serially diluted and compared to each other for the level of Nef expression. 
Note that 4X indicates that this well contains 4 times the amount of protein contained in 
the well marked 1 X. 
(C) Analysis of Nef expression in specifie cell populations. CD4+TcR? ? + (CD4+) T 
cells, and CDS+TcR? ? + (CDS+) T cells from spleen or peripheral (p) or mesenteric (m) 
LN, B220T lgMT B cells from spleen, double positive CD4T CDST thymocytes (thymus) 
and peritoneal macrophages (M<\» from Tg and non-Tg mice were obtained through cell 
sorting (or plating in the case of the macrophages) and cell extracts were processed for 
Western blotting with anti-NefmAb. The blots were stripped ofbound antibodies and re-
probed with anti-actin antibodies to assess the amount ofloaded protein. 
CD4+CD8+ thymocytes and in CD4+TcRa~+ T cells from the peripherallymphoid organs 
and in peritoneal macrophages of Tg mice, but not in Tg B220+IgM+ B-cells or in Tg 
CD8+TcRaB+ T ceIls, nor in any of these populations of the non-Tg mice (Fig.2.3C) 
Together, these results indicate a faithful and expected pattern of expression for 
these CD4C regulatory elements. This pattern of expression was indistinguishable from 
that observed previously in CD4CIHWWT and CD4CIHWMut Tg mice 29,30. 
Clinical Phenotypes of CD4C/SmV _neFIV Tg Mice 
Mice from the three expressor Hnes (F55541, F57691 and F57693) developed a 
fatal disease similar to the one described in the CD4CIHWWT and CD4CIHWMut Tg mice 
29,30. Disease progression varied between founders, being much faster in high expressing 
mice from the F57691 line (Fig. 2.4; Table 2.1), thus confirming an earlier observation 
with HW-I that disease latency was strongly correlated with levels of Nef expression 30. 
All Tg progeny (n=12) from the founder F57691 line died of severe disease within 45 to 
60 days. The founder itself (F57691) died at 17 months, of the same disease as its Tg 
offspring. This long latency most likely reflects its mosaicism. At necropsy, it was found 
to have splenomegaly, kidney disease, lung disease and an enlarged heart. It also had 
hepatomegaly and a peri-anal tumor, whose cell composition characterized by FACS was 
mostly consituted of B-cells (B220+ CD4-CD8-) (data not shown). Similarly, the mosaic 
founders F57693 and F55541 died later than their progeny: 8 vs 17 months and 4 vs 12 
months, respectively. 
Mice from the three expressor lines developed a similar disease except that the 
latency period was longer for mice from founders F55541 and F57693. Early on, mice 
from these latter two lines had no detectable clinical signs of disease. As they aged, they 
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Figure 2.4. Cumulative iucidence of death of CD4C/SHIV _nerIV Tg mice 
Each point represents the percentage of Tg mice which were found to be moribound or dead at a specifie 
time in each group. 
SymboI: n=number of animaIs in each group. 
became ill. Most Tg mice from founders F55541 (85%), F57691 (86%) and F57693 
(84%) exhibited a failure to thrive, being approximately two thirds of the size of their 
non-Tg littermates: [Non-Tg: 27.8g ± 7.7 (n=8); Tg (F55541): 19.1g ± 4.7 (n=5); Tg 
(F57691): 19.6g ± 12.5 (n=3); Tg (F57693): 32.6g ± 11.3 (n=3)]. Tg mice from alllines 
(94%) became hypoactive and weak, showed ruffled hair coat and developed a severe 
wasting syndrome (84% n=27/32), sometimes accompanied by edema (19% n=6/32) or 
diarrhea (40%). Non-Tg littermates housed in the same cages as the Tg mice did not 
develop any disease, indicating that these phenotypes were specific to the transgene. 
Pathological Assessment of CD4C/SHIV _ne~IV Tg Mice 
At necropsy, macroscopic observation confirmed the presence of wasting and 
edema and revealed phenotypes of enlarged heart (41 % n=13/32), splenomegaly (53% 
n=17/32) as weIl as thymic atrophy (97% n=31/32) and kidney disease (78% n=25/32) in 
Tg mice from the three expressor lines (Table 2.2). Again, no pathological changes were 
observed in the non-Tg mice. Moreover, no bacteria (except in the intestinal lumen) was 
detected by Gram stain in kidney, lung, liver and heart of Tg (n=9) and non-Tg (n=7) 
mice randomly chosen during this study (data not shown). Generally, when a gross 
pathological change was seen in one organ, other organs of the same mice were also 
affected. 
(i) Lymphoid Organs 
Thymus 
The majority of Tg mice (97% n=31/32) exhibited a gross thymie atrophy when 
eompared to aged-matched non-Tg controls. This atrophy could already be observed at 
birth (data not shown) or in very young Tg mice (Fig.2.5A), showing as much as a 20-
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Table 2.2. Incidence of Disease in CD4C/SHIV _neFIV Tg Mice 
No. with trait/total no.studiedb 
Pathology observeda F55541 F57691 F57693 Totald 
Tg nTt Tg nTg Tg nTg Tg nTg 
Hypoactivity and 18/20 0/51 7/7 0/49 5/5 0/57 30/32 0/157 
ruffled hair 
Small body size 17120 0/51 6/7 0/49 4/5 0/57 27/32 0/157 
Wasting 17/20 0/51 6/7 0/49 4/5 0/57 27/32 0/157 
SmaU or absent thymus 19120 0/51 7/7 0/49 5/5 0/57 31/32 0/157 
Splenomegaly 14/20 0/51 1/7 0/49 2/5 0/57 17/32 0/157 
Small and/or mottled 17120 0/51 5/7 0/49 3/5 0/57 25/32 0/157 
kidney 
Edema 5/20 0/51 1/7 0/49 0/5 0/57 6/32 0/157 
Enlarged heart 8120 0/51 4/7 0/49 1/5 0/57 13/32 0/157 
a See the text for a detailed description of the macroscopic disease. 
b The mice studied inc1ude the Tg founder itself as weIl as Tg and non-Tg 
offspring derived from each founder (F55541, F57691, F57693).Mice were 
studied when moribound. 
C For aU Tg lines studied, non-Tg mice were littermates of Tg mice kept in the 
same cages and sacrificed on the same day as the Tg mice. An equal or even 
larger number of non-Tg mice were autopsied. 
d Total numbers of animaIs assessed from aIllines. 
Figure 2.5. Pathology in Iymphoid organs of CD4C/SHIV -ner"lv Tg mice 
(A) Macroscopic view of the spleen and thymus. Splenomegaly is seen in Tg mouse (top) relative to non-
Tg mouse (bottom) and thymie atrophy is seen in the Tg mouse (right) relative to the non-Tg (left) (D-E) 
Histology of spleen. Note the splenomegaly and the altered architecture of the white pulp of Tg mouse and 
that both enlarged white and red pulp areas contribute to the splenomegaly (C). An apparent increase in 
megakaryocyte numbers (arrows) is seen in Tg spleens (E) relative to a non-Tg animal (D). (F,G) Lymph 
node (LN). Extensive depletion of the T cell zone and hypocellularity of the B cell cell zone in mesenteric 
LN of a Tg animal (G) as compared to non-Tg LN (F). (H,I) Thymus. Tg thymus (1) exhibits 
hypocellularity and loss of the cortico-medullary architecture, as compared to non-Tg thymus (H). 
Counterstain: Hematoxylin and eosin. Magnification panel A: 3 X., Panels: D,C: Il X, Panels: D-I: 43 x. 
fold decrease of thymocyte ceIl number at 21 days old (Table 2.3). Histological 
assessment of Tg thymuses showed a generalized hypocellularity and a loss of the 
corticomedullary junction (Fig. 2.5 1). FACS analysis, performed on total remaining 
thymocytes of Tg mice from founder F57693 and F5554l (Fig. 2.6,Table 2.4) revealed a 
dramatic downregulation of CDS ceIl surface expression, and to a lesser extent 
downregulation of CD4 cell surface expression. The relative percentages and absolute 
numbers of CD4+CDS+ and of single-positive thymocytes (CD4+CDS-, CD4-CDS+) were 
decreased in Tg mice when compared to non-Tg controls (Fig. 2.6 A), whereas the 
relative percentages of the Thy1.2+ ceIls (Table 2.4) were less affected. There was also a 
decrease of the percentage and absolute numbers of TcRa.~Hi cells (Fig.2.6 D, E) which 
represent the most mature stages in thymocyte development. These results suggested that 
Tg thymocytes are skewed towards an immature phenotype. 
Peripheral Lymphoid Organs 
Tg mesenteric lymph nodes (mLN) were usually of normal size, as determined by 
the recovery of a similar number of ceIls from Tg and non-Tg mLN (Table 2.3). 
However, the peripheral LN were usually severely atrophied (data not shown). Consistent 
with this observation, histological observation of Tg peripheral LN showed low cell 
density in the deep cortical zone, with a less frequently observed hypocellularity of the B 
ceIl zone (Fig.2.5 G). FACS analysis performed on the mLN of Tg mice of the founders 
F55541 and F57693 also showed a decrease in both the relative percentage and absolute 
number of CD4+ TcRa.~+ T cells (Fig.2.6 D and Table 2.5). Strikingly, an even greater 
decrease in both percentage and absolute cell numbers of CDS~cRa.~+ T cells of Tg 
mice was observed (Fig.2.6 E). This low number ofperipheral CD4+ and CD8+ T-cells 
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Figure 2.6. Cytofluorometric analysis of thymocytes, splenocytes and mesenteric Iymph node 
lymphocytes of young CD4C/SHIV -ner1v Tg mice 
Thymocytes, splenocytes and mesenteric lymph node (LN) lymphocytes from a representative Tg mouse 
(F57693) and a non-Tg control mouse were analyzed by flow cytometry. A) Two-color analysis for the 
expression ofCD4 and CD8. B,C) One-color analysis for the expression ofB220 (B) and Thy 1.2 (C). D,E) 
Two-color analysis for the expression of CD4 and TcRa[3 (0) as weil as CD8 and TcRa[3 (E). The 
percentages of cells found in each quadrant are indicated: 104 live cells were analyzed. 
Table 2.3. Quantitation of Cells of Lymphoid Organs of Control and CD4C/SHIV _nerIV 
Tg mice 
Mice Number of Cells (x 106) 
Th~musa S]2leenb Mesenteric LNb 
Non Tg (n=19) 118 ± 67.5 43.7 ± 17.2 9.4 ± 2.0 
Tg F55541 (n= 10) 5.99 ± 2.9*** 146.0 ± 5.7* 9.5 ± 5.7 
Tg F57693 (n= 6) 12.2 ± 6.8** 80± 17 6.8 ± 2.0 
Tg F27367 (n=7) 117±47.9 ND ND 
a Data for the thymus of Tg mice and non-Tg mice were obtained on 21 days old 
animaIs 
b Data for the spleen and mesenteric lymph nodes of the Tg mice and non-Tg mice 
were obtained on 3 to 16 weeks animaIs 
ND, not do ne 
Student's t test, *p:50.05; **p<O.OOI; ***p<O.OOOl 
Table 2.4. Thymic Cell Surface Marker Analysis of CD4C/SHIV _ne.,sIV Tg Mice 
Mice #mice 
Non-Tg 19 
Tg 
(F55541) 
Tg 
(F57693) 
10 
3 
Cell population (%) (absolute number of cells (X106) 
Thy 1.2+ CD4+CD8+ CD4+CD8- CD4-CDS+ Thy 1.2 CD4 CD8 
94.46 ± 2.2 88.9 ± 2.1 10.7 ± 1.6 4.1 ± 2.0 407 ± 125 1224 ± 332 1691 ± 927 
(113±64.9) (106±60.7) (9.7±7.1) (4.2±3.3) 
75.95 ± 13.9*** 33.1 ± 19.4*** 3.6 ± 0.6*** 3.0 ± 0.9* 498± 148 812±335** 469±214*** 
(18.1 ± 1.9)*** (5.0 ± 5.9)*** (0.25 ± 0.06)* (0.59 ± 0.06)* 
92.3 ± 1.7 78.4 ± 6.5*** 5.7 ±0.9*** 1.1 ± 0.6* 283±165 517±33** 359±187* 
(14.2 ± 3.3)* (12.2 ± 3.7)* (0.9 ± 0.09) (0.2 ± 0.1) 
Student's t test, *p$0.05; **p<O.OOl; ***p<O.OOOl 
Table 2.5: Spleen and Mesenteric Lymph Node Cell Surface Marker Analysis of CD4C/SHIV _neF1V Tg Mice 
Cell population (%) (absolute number of cells (X 106)) Mean fluorescence 
Organs Mice 
analysed #mice 
Thy 1.2+ CD4+ CD8+ B220+ Thy 1.2 CD4 CD8 
Spleen Non-Tg 6 31.0 ± 12.2 19.6 ±4.2 8.3±5.0 55.7 ± 7.2 260±153 931±482 1439±901 
(19.0 ± 14.3) (13.5 ± 7.9) (4.3±2.1) (23.1 ± 12.8) 
Spleen Tg 8 7.7 ± 1.8*** 4.5 ± 0.9 *** 0.7 ± 0.4** 66.0± 7.7* 146±53 144±116* 188±69* 
(F55541) (3.3 ±2.0)* (3.63 ± 3.3)* (0.8 ± 0.7)** (60.0 ± 40.0)* 
Spleen Tg 7 13.3 ± 3.3 6.6 ± 2.5*** 0.9 ± 0.8** 68.0 ± 6.4** 231±48 279±114* 140±89* 
(F57693) (10.5 ± 0.7) (3.4 ± 4.1)* (0.5 ± 0.8)** (23.3 ± 19.0) 
LN Non-Tg 6 63.6 ± 8.4 53.2 ± 10.4 20.0 ± 3.9 24.7 ± 7.6 178±180 569±130 380±92 
(5.57± 1.5) (4.8 ± 1.6) (1.8± 0.4) (2.1±o.60) 
LN Tg 8 19.8 ± 6.5*** 13.2 ± 5.7*** 1.8 ±0.9*** 66.5 ± 17.3** 133±91 247±207* 94±30*** 
(F55541) (1.7 ± 0.9)** (1.1 ± 0.5)** (0.2 ± 0.2)*** (7.0±5.8) 
LN Tg 3 46.3 ± 13.5 35.9 ± 14.0 5.4 ± 0.1** 47.9 ± 12.7* 222±30 451±206 171±30* 
(F57693) (3.3±1.9) (2.6±1.7) (0.4±0.09)** (3.2±o.07) 
Student's t test, *p:S;0.05; **p<O.OOI; ***p<O.OOOI 
was apparent early in life and there was no subsequent dramatic loss of these ceIl 
populations as the disease progressed. As noted for the total thymocytes, the expression 
of both CD4 and CDS cell surface markers was low, the CDS cell surface marker being 
again more affected (Fig.2.6 A). A decrease of the Thy1.2+ cells (Fig.2.6 A) and an 
increase of the B220+ cells (Fig.2.6 B) and Mac1+ ceIls (data not shown) were also noted 
in Tg mice. 
A significant fraction (53% n=17/32) of Tg mice had splenomegaly [Spleen 
weights: Non-Tg: 0.12g ± 0.04 (n=S); Tg (F55541): 0.29g ± 0.19 (n=5); Tg (F57691): 
0.36g ± 0.04 (n=3); Tg (F57693): 0.19g ± 0.03 (n=3)] (Fig. 2.5 A,Tables 2.2 and 2.3). 
The spleens of Tg mice were often enlarged with greater areas of both red and white pulp 
participating in the enlargement (Fig. 2.5 C). Several Tg spleens exhibited increased 
number of megakaryocytes (Fig.2.5 E). FACS analysis of splenocytes from mice of both 
F55541 and F57693 founders showed similar changes to those observed for the Tg mLN 
(Fig.2.6 A and Table 2.5). This analysis revealed a low number of CD4+ and CDS+ T ceIls 
with low and very low levels of CD4 and CDS cell surface expression respectively 
(Fig.2.6 A; Table 2.5). In addition, an accumulation of a high percentage of B cells and 
macrophages as found in mLN, and an increase of erythroid CD71 +Ter119+ progenitors 
was observed (data not shown). Further analysis showed that a CD4-CDS-CD3+ 
population was absent in the LN of Tg mice (data not shown), indicating that the low 
number of CDS+ T cells in peripheral lymphoid organs truly reflected their absence, 
rather than simply the inability to detect the CDS cell surface molecule. No difference in 
the expression of the CD44 or CD69 cell surface markers was found on T lymphocytes 
from the thymus, spleen and mLN of Tg and non-Tg mice (data not shown). Together, 
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these results demonstrate an early and severe thymic defect in these Tg mice, as well as 
profound changes in the cell populations of the peripherallymphoid organs. 
(ii) Kidneys 
In most Tg mice (78% n=25/32), the kidneys were markedly atrophie and paler 
with an irregular surface when compared to controls. Sorne mice (19% n=6/32) exhibited 
edema, which is seen in renal failure. 
The histopathological changes observed in the kidneys consisted of an interstitial 
nephritis and fibrosis with tubular atrophy and dilation with cystic changes (Fig. 2.7 B, 
C). More extensive glomerular changes were observed in the CD4C/SHIV _netIv Tg mice 
relative to their CD4CIHIV Tg mice counterparts 30. Thus expansion of Bowman's space, 
with occasional atrophy of the podocyte cell layer (Fig.2.7 E), and segmental 
giomeruiosclerosis were observed (Fig.2.7 G, H). These histopathological findings are 
consistent with those of a chronic tubulo-interstitial nephropathy. 
(iii) Lungs 
No gross changes in the Iungs were noticed upon dissection of the Tg mice when 
compared to the non-Tg Iittermates. However, histological examination revealed that 
several Tg animals exhibited a lymphocytic interstitial pneumonitis (LIP) which was 
sometimes extensive in nature (Fig.2.8 B,D,E). Tg Iungs (56%, n=9), but not the control 
non-Tg Iungs, were positive for Pneumocystis Carinii [22% having about 100-1000 
organisms and 34% having only a few (up to 100)] (Fig. 2.8 F-H), suggesting a state of 
severe immunodeficiency. Since sorne of the Tg animals still exhibited LIP without any 
signs of P. Carinii infection, it is likely that LIP develops as a consequence of Nef 
expression, rather than being caused by P. Carinii infection. 
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Figure 2.7. Pathology in Kidney of C04C/SHIV-ner1v Tg mice 
Non-Tg (A,O,F) or Tg (B,C,E,G,H) kidneys at low (A,B) and intermediate (C) or high (O-H) power. 
Kidneys of Tg mi ce exhibit tubular atrophy and dilation with cystic changes and interstitial nephritis. Note 
expansion of Bowman's space (E). As compared to non-Tg control mouse kidney (F) the renal cortex of Tg 
mice (G) has focal areas of interstitial fibrosis (blue areas). Sc1erosis is also present in glomerulus in the 
upper part of the panel. Occasional glomeruli in the kidney of Tg mice have segmental hyaline obliteration 
of capillary loops and cellular crescents (H). Trichrome stain (F,G); PAS stain (H). Hematoxylin and 
Eosin (A-E). Magnification: Panel A, B: 43 x. Panels C-G: 85 x; Panel H: 170 x. 
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Figure 2.8. Pathology in Lung of CD4C/SHIV _nef'lv Tg mice 
Non-Tg (A,C,F) or Tg (B,D,E,G) lungs at low (A,B) and intermediate (C-E) power. Lymphocytic 
interstitial pneumonitis observed in Tg animaIs (B,D,E). Note the widespread nature of the pathology seen 
in Panel B. Panels F,G are methamine silver (Grocott) stained tissues from non-Tg and Tg animais 
respectively. Note the presence of Pneumocystis Carinii particles in the lung from the Tg mouse (G, 
arrows). Counterstain: hematoxylin and eosin (A-E). Magnification panels A,B: Il X., Panels C-E: 85 x. 
The scale bar in F,G, represents 25 microns. 
(iv) Heart 
In about 34% (n=13/38) of the Tg mice, the heart was obviously enlarged (Fig.2.9 
B, Table 2.2). The pathology was multifocal in nature consisting of areas of myocytolysis 
and myocarditis (Fig.2.9 D). Despite the enlargement of the hearts, no c1ear evidence of 
widespread cardiomyocyte hypertrophy was seen. When observed, hypertrophic fibers 
were isolated as single or small c1usters of 2-3 fibers. No clear evidence of heart dilation 
could be documented histologically. 
Presence of Auto-Antibodies (Ab) and lack of T cell help in CD4C/SmV _net8IV Tg 
mice 
We recently reported that the CD4CIHIV Tg mice, which develop an 
AIDS-like disease very similar to the disease found in CD4C/SHIV -netIV Tg mice, show 
B cell activation, impaired germinal center formation and immunoglobulin (Ig) c1ass 
switching and produce auto-Ab 53. Similar assays were performed to determine whether 
CD4C/SHIV -netIV Tg mice show the same defects. 
First, peripheral T cells (total or purified CD4+ T cells) from Tg and non-Tg mice 
were compared for their proliferation capacity in vitro, following anti-CD3 stimulation, 
using CFSE labeling, as previously described 33. No major differences were noted 
between the groups, except for an increase of the proliferation capacity of both CD4 + and 
CD8+ T cells in sorne Tg mice (data not shown). 
Then, the sera of diseased Tg animals (i.e. those exhibiting thymic atrophy, kidney 
disease and large spleen) were assessed for the presence of anti-DNA auto-Ab. These Tg 
sera were found to have higher levels of anti-DNA IgM and lower levels of anti-DNA 
IgO than the non-Tg sera (Figure 2.lOA). The presence of auto-Ab of other specificities, 
and specifically for another tissue, was also studied by testing for decoration of heart 
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sections with endogenous Ig, using tissue staining with a-Ig Ab. This analysis revealed 
deposition of markedly high levels of anti-nuc1ear Ig deposition in the heart of a 
significant percentage of the Tg animals (43%, n=7), as compared to non-Tg mice 
(Fig.2.9 F). Finally, preliminary data did not show any difference between Tg and non-Tg 
mice in the number of CD5+ B cells (data not shown). Therefore these results indicated 
the presence of autoimmune responses in these Tg mice. 
The higher ratio of IgMlIgG anti-DNA Ab levels found in these Tg mice relative 
to their non-Tg controllittermates also suggested an impaired ability of Ig isotype c1ass 
switching. This latter phenomenon was studied further after immunization with 
ovalbumin (OV A). Sera of OV A-immunized mice (Tg and non-Tg) were tested for the 
presence of OVA-specific Ig. Ten days post-injection (primary response), Tg mice had 
lower levels of OVA-specific IgG I and higher levels of OVA-specific IgM than non-Tg 
mice (Fig. lOB). Similarly, after a secondary immunization, the levels of OV A-specific 
IgG1, IgG2a and IgG2b were much lower in Tg than in non-Tg mice, while the OVA-
specific IgM showed less difference (Fig. 2.10 C), thus confirming a severe incapacity of 
the T cell help-dependent Ig c1ass switching in Tg mice. 
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Figure 2.9. Pathology in Heart ofCD4C/SHIV-nef1v Tg mice 
Control non-Tg (A, C, E, G) and Tg (B,D,F,H) mice were studied. A,B) Macroscopic images ofhearts in 
situ. Note the enlargement of the Tg heart (B) as compared to non-Tg heart (A). C,D) Histology of hearts. 
Myocytolysis and myocarditis is observed in the left ventricle of a Tg heart (D) but not in that of the non-
Tg heart (C). (E-H) Detection of Ig deposition. Heart sections were probed with anti-mouse Ig (E,F) or 
with anti-rat Ig as negative control (G,H). Increased frequency of anti-nuclear autoantibody deposition 
(arrows) is observed in Tg heart (F) as compared to a non-Tg heart (E), when sections are probed with anti-
mouse Ig, but not when probed with anti-rat Ig. Counterstain: hematoxylin and eosin (C-D); hematoxylin 
(E-H). Magnification panel A,B: 3 x. Panels C,D: 85 x; Panels E-H: 170x. 
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Figure 2.10. Presence of Anti-DNA Antibodies (Abs) and Reduced OVA-Specific Ig 
Isotype Switching in CD4C/SHIV _neFIV Tg mice 
A) Anti-DNA IgM and IgG] Ab levels in sera of nonimmunized non-Tg and Tg mice 
were measured by ELISA. The data shown were normalized to the DNA reactivity 
observed with reference sera from NZB mice (arbitrarly established as 100%; filled 
squares). Each dot represents the serum of one mouse at the endpoint of the titration 
curve. The bars show the mean values from 5 different experiments. 
B, C) OVA-specific Ab levels in sera of non-Tg and Tg mice taken 10 days following a 
primary imunization (B) and 5 days following a secondary immunization (C). Each dot 
represents the serum of one mouse at the endpoint of the ELISA titration curve. The bars 
show the mean values from 3 different experiments. 
Student's t test, *p<0.05; **p<O.OOI; ***p<O.OOOl. 
DISCUSSION 
SIV Nef Induces a Fatal AIDS-Like Disease in Tg mice. 
This report shows that mice expressing the SIV mac239 nef gene under the 
regulation of the CD4C promoter (CD4C/SHIV-nefiIV) develop a severe AIDS-like 
disease. This disease is eharaeterized by premature death, wasting, failure to thrive, 
kidney disease (interstitial nephritis and glomerulosclerosis), lymphoeytie interstitial 
pneumonitis, eardiae disease, thymie atrophy, splenomegaly and low T cell number both 
in the thymus and in peripheral lymphoid organs. As previously diseussed extensively 
29,30,53, aH these phenotypes, including the eardiae disease (Kay et al. submitted) and 
exeept those of the lymphoid organs (see below), are very similar to the ones induced by 
the expression of HIV -1 nef in Tg mice, with ressemblance to human AIDS, especially to 
pediatrie AIDS. Since an allelic construct (CD4CIHIVMUtH) not expressing Nef was found 
unable to induee disease in Tg mice 30, it appears that SIV Nef is mainly responsible for 
inducing these phenotypes. 
This AIDS-like disease of CD4C/SHIV-nefiIV Tg mice is also very similar to 
simian AIDS (SAIDS) 17,18. Premature death is frequent in SAIDS 7,10,40. Wasting disease 
and failure to thrive, in the absence of detectable secondary pathogens has also been 
described in SAIDS 35,66, and it is usually correlated with a high incidence of diarrhea 7,36 
which is often caused by pathogenic bacteria or protozoa. In contrast, wasting without 
diarrhea was frequent in CD4C/SHIV -nefiIV Tg mice, most likely because they were 
housed in a SPF facility. Kidney 5,7,25,65 and lung 25,51 diseases have also been described in 
SAIDS. Similarly, cardiac disease is found in SIV -infected primates 60. Finally, thymic 
atrophy with preferential 10ss of CD4+CDS+ immature and CD4+CDS- mature 
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thymocytes, correlating with the progression of the infection has been reported in SAIDS 
46,47,70. In addition, the loss of both CD4+ and CD8+ peripheral T -cells late in the disease is 
typical of SAIDS 10. 
The similarity of the diseases developing in 'SIV or RIV -1 nef-expressing Tg mice 
29,30 indicates a strong functional resemblance between SIV and HIV -1 Nef. The 
functional relatedness of the two molecules has been noted previously in several assays, 
both in vitro [down-modulation of human CD4 1,6,9,22,24,54 and of human MHC cell surface 
class 1 molecules 59, enhanced viral replication 2,13,15,28,41,63], and in vivo where Nef is 
required for high virus loads in SIV infected primates 41 and in HIV -1 infected humans 
16,42. Our data extend these observations in demonstrating the functional resemblance of 
SIV and HIV-I Nef in an additional in vivo assay, in another species (mou se) and show 
that this functional similarity is independent of virus replication or of an immune 
response to the virus. In addition, the present results extend to the nef gene of another 
lentivirus (SIV) our previous findings that RIV -1 nef alone (CD4C/HIVMutG), is sufficient 
to induce an AIDS-like disease in mice 30. 
Development of SIV nef-Induced Disease in Tg Mice Correlates With the Level of its 
Expression 
The cell type specificity of the SIV nef transgene expression in Tg mice 
determined by the CD4C promoter is likely to contribute to the resemblance of the 
phenotype to human and simian AIDS. Indeed, other Tg mice expressing only RIV Nef 
under the regulation of the LTR or of other T-cell specifie promoter/enhancer elements 
11,19,20,48,62 or expressing SIV Nef under the regulation of the CMV promoter 45 do not 
exhibit the same multi-organ syndrome as that observed in CD4C/HIVMutG 30 or 
CD4C/SHIV -nef IV Tg mice. The CD4C promoter has been reported previously to drive 
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the expression of surrogate genes in mature and immature T -cells and in cells of the 
macrophage/dendritic lineages of Tg mice 29-32. The expression of the transgene in mice 
seems to be following the tissue specificity of this promoter, therefore targetting the same 
cell populations affected hy the virus in natural infections. 
Interestingly, the development of disease in CD4C/SHIV -ne:f IV Tg mice seems to 
be influenced not only by the promoter specificity but also by the level of SIV mac239 nef 
expression. Transgene expression in mice from the lines investigated correlated well with 
disease latency (F57691> F55541>F57693). In addition, disease progression seems 
clearly influenced by the number of target cells expressing the SIV Nef. Indeed, the three 
founder mice which were mosaic for the transgene expression, and which likely had a 
lower number of cells expressing the transgene, developed the disease much later than 
their non-mosaic offspring. Therefore, the Nef viralload in specific target cells appears to 
be important for the disease progression in these CD4C/SHIV -ne:fIV Tg mice. This 
biological parameter may also be quite critical in human and simian AIDS and may be 
partly reflected in the plasma viralload which is known to correlate so well with disease 
progression 64,67,69. We have previously observed a similar effect of levels of HIV-l Nef 
on disease progression in CD4CIHIV Tg mice 30. 
Sorne Phenotypes Distinguish SIV from HIV -1 Nef Expression in Tg Mice 
Although the disease arising in Tg mice expressing SIV nefis very similar to that 
of Tg mice expressing HIV-l nef 29,30, heart enlargement was observed at a higher 
penetrance and kidney glomerular pathology was greater in CD4C/SHIV _ne:fIV than in 
CD4CIHIV Tg mice. Moreover, three immune phenotypes are virtually unique to 
CD4C/SHIV -nef IV Tg mice: splenomegaly, early thymic atrophy and early onset of low 
number of peripheral T -cells. 
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Splenomegaly is frequent in CD4C/SHN -nef IV while it is rare in CD4CIHNWT 
or CD4CIHNMutG Tg mice, where spleen atrophy is more frequently observed 29,30. 
Splenomegaly has previously been reported in other Tg mice expressing HIV -1 Nef under 
the regulation of a T-cell specific promoter/enhancer element 48. Splenomegaly has been 
reported upon infection of rhesus macaques with SNmac239/YEnef 21,56 or SNsmmPBj14 
40, two particularly virulent alleles of Nef, and with SNmac251 64 or SIV/Delta 7. It has 
also been observed upon infection of pig tailed macaques with SNagm9063 36. The 
enlarged spleens in CD4C/SHN-nefIV Tg mice show a low number of T-cells, an 
accumulation of a high percentage of B cells and macrophages, as well as the presence of 
a large number of megakaryocytes (Fig.5E) and erythroid CD71+Ter119+ progenitors 
(data not shown). This phenotype is associated with the white appearance of the long 
bones (in contrast to their redish color in the non-Tg controls) (data not shown), 
suggesting the possibility of a bone marrow (BM) defect in the production of cells of the 
erythroid lineage. Therefore, this splenomegaly may reflect in part extra-medullary 
hematopoiesis, common in mice. Detailed investigation of hematopoietic precursors in 
spleens and in BM will be needed to determine whether a BM defect with compensatory 
splenic extra-medullary hematopoiesis exists in these Tg mice. 
Another intriguing and unexpected phenotype observed in these CD4C/SHN-
netIV Tg mice is the early appearance of low numbers of peripheral T-cells in 
combination with the low expression of the CD8 cell surface marker. Such a CD8 
phenotype is highly reproducible, is seen even in young mice and is observed in the three 
founder lines studied, ruling out an integration effect. This CD8 phenotype was not seen 
in CD4CIHNWT or CD4CIHNMut Tg mice 29,30 which are, in contrast to CD4C/SHN-
netIv Tg mice, born with a close-to-normal number of thymocytes and of peripheral T-
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cells and which rather show a progressive and preferentialloss of CD4+ T-cells. Onlyat 
the end stage of the disease do they show, as in humans AIDS, a loss of CDS+ T -cells 
29,30 
This dramatic low expression of the CDS and to a lesser extent of the CD4 cell 
surface marker in CD4C/SHN-neFIV Tg mice confirm earlier in vitro data showing that 
SN Nef can downregulate the mouse CDS, but not the CD4, cell surface marker 22. A 
similar, but less marked low expression of CDS cell surface molecule has been observed 
previously, in vivo, in other HN Nef-expressing Tg mice 11,48,62. The very low expression 
cell surface expression of CDS in CD4C+CDS+ thymocytes may reflect a downregulation 
caused by a strong interaction of Nef with the CDS molecule and would be expected to 
disrupt T cell differentiation in the thymus and consequently to lead to the generation of 
an abnormal peripheral CDS+ T cell pool. Consistent with this observation is the 
observation that peripheral CD8+ T cells are low in numbers and show very low CDS cell 
surface expression, while not expressing the transgene at detectable levels. 
Other findings also suggest that the profound changes in the cell populations of 
the peripheral lymphoid organs, including the low number of both CD4+ and CDS+ 
peripheral T cells in CD4C/SHN-neFIV Tg mice most likely reflects a defect of cell 
production in the thymus rather than their rapid loss. The CD4C/SHN-nefiIV Tg mice are 
born with a smaller thymus when compared to non-Tg controls. Moreover, at the age of 
21 days, CD4C/SHIV-neFIV Tg mice show a 2ü-fold lower number of thymocytes than 
age-matched non-Tg controls. These data strongly suggest that the CD4C/SHIV _nefiIV Tg 
mice are born with a severe thymic defect. In fact, this observed early thymie atrophy 
coupled with our preliminary ontogeny studies and fetalliver transplantation experiments 
confirm this thymus defect hypothesis (Simard, Chrobak et al., unpublished 
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observations). A similar phenotype, consisting of a transient, reversible 62 or a more 
chronic 11,48 suppression of the number of single-positive CD8+ T cells has previously 
been reported in other Tg mice expressing HIV -1 Nef under the regulation of T cell 
specific enhancer/promoter elements. In contrast, the CD4C/HIVMutG Tg mice do not 
exhibit such a phenotype and are born with a near-to-normal number of thymocytes and 
peripheral CD4+ T ceIls, which are progressively lost as the disease progresses 29,30. Loss 
of CD8+ T-cells together with loss of CD4+ T-cells is also common in the advanced stage 
of SAIDS, but is usually not observed in the early stage of the disease. Therefore, this 
remarkable low number of peripheral CD8+ T-cells and of CD4+ T-cells is unique to Tg 
mice expressing SIV Nef. This phenotype is reminiscent of the DiGeorge-like 
immunophenotype described in sorne children infected with HIV -1: the se children harbor 
low numbers of both CD4+ and CD8+ T -cells and are thought to have an HIV -1 induced 
thymic defect 44. 
The underlying cellular and molecular basis of this early thymic atrophy, dramatic 
low expression of CD8 cell surface expression and low numbers of CD4+ and CD8+ 
peripheral T cells is unc1ear. It could reflect subtle changes in transgene expression 
undetectable by the methods we used. We believe however this to be unlikely for three 
reasons : (a) this phenotype was observed in three distinct founder lines, thus ruling out 
an integration (positional) effect; (b) such a variation has not been observed in 19 
independent founder lines of the CD4C/HIV Tg mice expressing wild-type HIV -1 Nef 
(strain NL4-3) which all develop a very similar phenotype consisting of a progressive and 
preferential loss of peripheral CD4+ T -cells and an increase of CD8+ T -cells 29,30 (c) 
Alternatively, and most likely, this phenotype could either reflect functional differences 
between HIV -1 and SIV Nef or allelic variations. Future comparison of different HIV-l 
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and SIV nef alleles in the same in vivo Tg assay should help in determining whieh of 
these possibilities is the most likely. 
Therefore, the overall disease observed in these SIV-nef expressing Tg miee is 
remarkably similar to human and simian AIDS and especially to a subgroup of pediatrie 
AIDS. This Tg model represents a novel in vivo assay for SIV Nef whieh is likely to be 
instrumental in strueture-funetion studies as well as for understanding the pathogenesis of 
this disease. 
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APPENDICE 
We previously reported that Tg mice expressing the SIVrnac239 nefgene in 
the natural target cells of the virus, under the control of the CD4 promoter (CD4c), 
develop a severe AIDS-like disease, inc1uding premature death, failure to thrive/weight 
loss, wasting, thymic atrophy, exhibit an especially low number of peripheral CD8+ T 
cells as weIl as low number of peripheral CD4+ T cells, diarrhea, splenomegaly, kidney 
(interstitial nephritis, segmental glomerulosc1erosis), lung (lymphocytic interstitial 
pneumonitis) and heart disease 27 • 
We wanted to shed sorne light on the thymic defect found in these mice and 
therefore performed sorne ontogeny studies as well as fetalliver transplantion studies. 
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ABSTRACT 
We previously reported that CD4C/SHIV _nef'IV Tg mice expressing SIV mac239 
Nef developed an AIDS-like disease. This AIDS-like disease was similar to human AIDS. 
Low number of both peripheral CD4+ and CD8+ T -cells in these Tg mice resemble the 
DiGeorge-like immunophenotype described in sorne children infected with HIV -1 who 
are thought to have a thymic defect. 
Ontogeny studies have showed that the Tg mice are born with a smaller thymus 
and that this phenotype is not progressive in nature. As young as embryonic day 17, the 
thymic absolute cell numbers are lower in the Tg mice when compared to their non-Tg 
controls and there is a defect in thymocyte maturation in transition between DN3 and 
DN4, with a failure to generate normal numbers of DP cells. 
Petal liver transplantation studies have ruled out a significant impairment of the 
thymic epithelium and have suggested that this defect is likely a direct consequence of 
abnormal T cell progenitors in the thymus. 
Therefore, these CD4C/SHIV-ne:fIV Tg mice show a severe thymic defect, a 
phenotype associated with human AIDS and are going to be instrumental in studying the 
effect of SIV Nef on thymic function, by showing the phenotypes causes by that protein 
and which effectors are used in order to cause them. 
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INTRODUCTION 
During the earlier parts of life, the thymus is essential for formation of a proper T -
cell repertoire. Once full repertoire is attained, healthy children, adolescents and adults do 
not rely solely on the thymus anymore to replenish the cells lost during the daily turn-
over 9. 
Vnder extreme conditions of immune cell depletion, such as following bone-
marrow transplantation or RIV infection, people will again depend on the thymus to 
regenerate a diverse T -cell peripheral pool. Therefore, a thymic infection or disruption of 
thymic function in RIV+ individuals can be extremely deleterious 9. The fact that thymic 
function is being altered during RIV -1 infection, might explain why an immune 
reconstitution is not achieved despite lowering viral replication via high anti-retroviral 
therapy 18, as thymic function was assessed via measurement of T cell receptore 
rearrangement excision (Teaixeira 2001 p.1749). 
SIV infection of the thymus results in thymic involution 2,18,20 with a marked 
depletion of double (DP) thymocytes (CD4+CD8+) and CD4+ thymocytes 20-22. The same 
picture of thymic involution is detected in RIV -1 infection (pediatrie and adult cases) 
4,5,14,23,24 (Douek 1998 Nature p. 690, harris 2005 clinieal immunol) . 
Intrathymic rearrangement of T cell receptor genes leaves behind TCR 
rearrangement excision circles known as TRECs which are not replicated during cell 
division and persist in recent thymic emigrants (RTE). One circle known as the signal 
joint [sj] TREC produced by TCRD locus rearrangement is common to the majority of 
RTEs and is being quantified in peripheral blood by PCR 7. 
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In accordance with thymic involution, TREC measurements in HIV -infected 
individuals 7 and SIV -infected macaques 29 revealed a lower number of excision circles, 
correlating with a poor thymic function as consequence of HIV/SIV infection. Therefore, 
the SIV-induced thymic involution and loss of peripheral T-cell pool is not solely due to 
an increase in lymphocyte death but is also due to an impaired thymocyte proliferation 
and maturation 20. This lack of generation of new cells by the thymus explains, in part, the 
lack of restoration of peripheral CD4+ lymphocytes killed by HIV -lISIV 6. 
Transgenic mice expressing the Nef gene under the control of CD3 promoter 
showed a much lower number of CD4 T cells in the periphery, des pite having an 
expression 50-100 times lower than in the thymus. Further experiments showed that Nef 
preferentially disrupted development of the CD4+ T cell subset in the thymus 28. 
Transgenic mice expressing Nef under the control of the CD2 promoter also 
showed sorne alterations in thymocytes and peripheral T cell populations. In Tg animaIs, 
a decrease of single positive CD4 cells was seen, with an increase of DP cells whereas a 
similar number of DN cells and SP CDS cells was found. A downregulation of the cell 
surface receptor CD4 was also seen on developing T cells 3. 
Another model used to see the effects on the thymus of HIV is the SCID-hu 
mouse. Human foetalliver and thymus are implanted under the mouse kidney capsule and 
are either left unmanipulated or HIV -1 is injected in them. This resulted in depletion of 
mature and immature CD4+ cells and resulted in atrophie and hypocellular thymi when 
the implants were injected with HIV 1. Nef was found to severely impair thymopoiesis in 
an in vitro foetal thymic organ culture with infected human progenitors3o• 
We previously reported that Tg mice, expressing Nef in the natural target cells of 
the virus (immature CD4+CDS+ T cells, mature CD4+ T cells, macrophages and dendritic 
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cells) under the regulatory sequences of the human CD4 gene (CD4C), developed a 
severe disease with multiple phenotypes [premature death, wasting, diarrhea, atrophy of 
the lymphoid organs, progressive and preferential loss of CD4+ T ceIls, lymphocytic 
interstitial pneumonitis, interstitial nephritis and segmental glomerulosclerosis 11,12,12 and 
cardiac disease 15] resembling those reported in AIDS. 
Similarly, Tg mice expressing expressing the SIV mac239 nef gene in the natural 
target cells of the virus, under the control of the same promoter (CD4c), also develop a 
severe AIDS-like disease, including premature death, failure to thrive/weight loss, 
wasting, thymic atrophy, exhibit an especially low number of peripheral CD8+ T cells as 
weIl as low number of peripheral CD4+ T ceIls, diarrhea, splenomegaly, kidney 
(interstitial nephritis, segmental glomerulosclerosis), lung (lymphocytic interstitial 
pneumonitis) and heart disease 27. 
Therefore, it became quite important to study the effect of Nef on thymopoiesis, in 
absence of viral replication, retroviral therapy and opportunistic infections. We tested if 
SIVmac239 Nef would have an effect on establishment of a fully diverse T -cell 
repertoire, in Tg mice born with a thymus expressing the nef protein. This should shed 
sorne light on the mechanism responsible for destruction of the thymic capability to 
generate a proper T cell repertoire and help to address the question why there is abnormal 
regeneration despite an almost complete lack of replication in HIV+ patients on highly 
active anti-retroviral therapy (HAART). 
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MATERIAL AND METHODS 
Housing of the CD4C/SHIV _ner"IV mice 
The mice used for all the experiments described in this article were of the C3H 
background, bred as heterozygotes for transgene and were housed in an SPF facility. The 
conditions of our SPF facility housing have been previously described 27. 
Protein extraction and Western blot analysis 
The thymocyte proteins were extracted and the Western blot analysis was carried 
out as we have previously published 27. We used an SIV Nef specific monoclonal 
antibody (mAb) at a dilution of 1: 1000 followed by a peroxydase-coupled secondary 
antibody against mouse immunoglobulins (Ig) (DAKO) at a dilution of 1:10 000. The 
following reagent was obtained through the AIDS Research & Reference Reagent 
Program, Division of AIDS, NIAID, NIH: monoclonal Antibody to SIVmac 251 Nef 
(17.2), from Dr.Kai Krohn and Dr. Vladimir Ovod. 
F ACS analysis 
Flow cytometry analysis was performed on thymocytes prepared from NTg and 
Tg mice, as previously described 27. The following panel of antibodies was used to 
distinguish the DN cell population in the thymus: Biotin-coupled anti-mouse CD8a mAb, 
Biotin-coupled anti-mouse CD11c mAb, Biotin-coupled anti-mouse B220 mAb, Biotin-
coupled anti-mouse CD4 mAb, Biotin-coupled anti-mouse DX5 mAb, Biotin-coupled 
anti-mouse Gr-1 mAb, Biotin-coupled anti-mouse Mac1 mAb, Biotin-coupled anti-mouse 
TcRyd mAb followed by staining with an Allophycocyanin (APC)-coupled streptavidine 
conjugate, all from Pharmingen. The DN cell population was distinguished as the 
negatively stained population. Other mAbs include: PE-coupled anti-mouse CD4 mAb, 
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FITC-coupled anti-mouse CD8 mAb, FITC-coupled anti-mouse y8 TcR mAb, FITC-
coupled anti-mouse CD44 mAb, FITC-coupled anti-mouse CD45RB, FITC-coupled anti-
mouse H-2KK (MHCI), FITC-coupled anti-mouse CD24 (Heat Stable Antigen, HSA), 
FITC-coupled anti-mouse CD5, PE-coupled anti-mouse CD25 (IL-2R), all from 
Cedarlane and FITC-coupled anti-mouse CD69 mAb (Pharmingen). Acquisition of the 
data was done on the FACScan or FACSCalibur (BD Biosciences) and ceUs positive for 
staining with via-Probe™ (Pharmingen) were exc1uded by electronic gating. FACS data 
were analyzed using either programs: Windows Multiple Document Interface for Flow 
Cytometry (WinMDI) or the CeUQuest Pro (BD Biosciences). 
Cell viability was routinely assessed with propidium iodide (PI) as weU as staining 
of ceUs with 7- Amino actinomycin D (7-AAD) (Cedarlane). 
Cell sorting assay 
Thymuses from 3 Tg mice and 3 NTg mice were respectively pooled and the ceUs 
were dispersed in complete medium using a syringe plunger, the thymuses being covered 
with a nytex mesh (BSH Thompson, Montréal). The cells were washed once, filtered 
through a cell strainer (Falcon) and counted. The cells were then stained with the 
foUowing antibodies: FITC-coupled anti-mouse TcRy8 mAb (Pharmingen), PE-coupled 
anti-mouse CDSa mAb and APC-coupled anti-mouse CD4 mAb (both from Cedarlane), 
as previously described 27. After the staining, the ceUs were washed once and resuspended 
at a concentration of 5x 107 cells and processed for sorting on the Mofio cell sorter 
(Cytomation, Colorado) to obtain: TcRy8+ thymocytes, CD4-CD8-TcRy8- thymocytes and 
CD4+CDS+TcRy8- thymocytes. 
Fetal Liver Transplantation 
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Donors: Liver cells from each 14.5 days old fetus (NTg and Tg) were harvested 
and dispersed in RPMI medium supplemented with 10% heat inactivated fetal calf serum 
(FCSi), under sterile conditions, with a syringe plunger. The cells were filtered through a 
Nytex mesh (BSH Thompson, Montréal). The fetuses were typed for transgene 
expression using a rapid PCR method. When the typing result was known, the cells from 
Tg and NTg were respectively pooled. After one wash, the cells were counted (red blood 
cells were lysed in the counting aliquot, using Gay's solution) and resuspended in HBSS 
solution supplemented with 2% heat inactivated fetal bovine serum (FBSi) at a 
concentration of 20x 1 06 cells per mL. 
Hosts: NTg and Tg hosts (about 8 weeks old) were lethally irradiated (950 Rad) using the 
Mark I-68A1 irradiator(Cs-137, J.L. Shepherds & Associates). The hosts were injected, 
via the tail vein, with 4x106 foetalliver cells in 0.2 mL of HBSS solution supplemented 
with 2% FBSi. Hosts that did not receive any foetal li ver cells died within 2 weeks. 
Rapid PCR technique for typing of the foetuses 
A piece of the foetus is placed in 200 JlL of lysis buffer (O.lM NaCl, O.OlM 
EDTA, 0.05M Tris pH 7.5,0.5% Nonidet 40 and 0.05% of Tween 20) supplemented with 
10 JlL of proteinase K (10 mg/mL) and left to digest at 55°C for a period varying between 
20 min. and 2 hours, depending on the size of the piece taken. After the digestion, the 
lysate is centrifugated to pellet the non-digested pieces and 100 JlL of the supematant is 
taken (Note that this supematant is usually quite viscous). This aliquot is put at 100°C for 
8 min. and a dilution for the PCR is done (10 JlL in 200 JlL of water) and put at 55°C for 
30 minutes to assure a good resuspension. We then proceed to detect the transgene 
expression via a PCR. The following oligos were added to the DNA, PCR buffer and Taq 
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enzyme: To detect the transgene: sense oligo: TCTCCTTCT AGCCTCCGCT AGTC, 
antisense oligo: CTGCTCCT ACTCATTCCTTCC. Positive controls for the PCR 
reaction: the mouse gene Myb: sense oligo: CCAGTCACGTTCCCTATCCT, antisense 
oligo: GCCTGCTGTCCCTTCAGCTC. The PCR consisted of 40 seconds at 940C 
followed by 1 minute at 61oC, followed by 30 seconds at 72°C, for a total of 1 cycle as 
weIl as 40 seconds at 94°C, followed by 45 seconds at 61°C, followed by 1 minute at 72°C 
for a total of 25 cycles. Once the reaction was finished the products were kept at 4°C. 
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RESULTS 
Thymie expression of SIV mac239 Nef. 
We have previously reported that DP cells (CD4+CD8+TcRy<)") in the 
thymus of the CD4C/SHIV-nefIV Tg mice express the SIVrnac239 transgene at a very 
high level 27. We now report that sorted DN cells (CD4-CDSTcRgd-) and TcR y'i/ T 
thymocytes, using the Western blot technique with an SIV Nef specific antibody, both 
express the transgene (Fig.3.1). These data were supported by studies of CD4C/CD4 mice 
expressing the reporter human CD4 (hCD4) under the regulation of the same promoter 
(CD4C) as CD4C/SHIV-nefIV Tg mice. FACS analysis of DN thymocytes from 
CD4/CD4 Tg mice, revealed that 70% of sorted DN (CD4-, CDS-, TcRgd-, CDlle, DX5-
,Macl-, Orl- and B220-) expressed human CD4 expression (Fig. 3.2).). 
CD4C/SHIV -netsIV Tg miee are born with a smaller thymus 
Upon dissection of a CD4C/SHIV -netIV Tg mouse at any age, the thymus was 
always found to be dramatically smaller when compared to non-Tg controls. 
CD4C/SHIV-netIV Tg mice at 21 days old (F55541) have a thymic cellularity that is 
typically 26.3 times (median) lower than the one found in non-Tg controls (Table 3.I). 
The CD4C/SHIV -netIV Tg mice are born with already a considerably smaller thymus 
(data not shown) and ontogeny studies show that they already have a lower thymic 
cellularity on embryonic day 17. The Tg thymus harboring 50% less cells than non-Tg's 
thymus at that age (Table 3.I). With time the difference in cellularity between Tg and 
non-Tg thymuses accentuates (data not shown). 
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Thymus DP DN TcR y'ô 
Tg status + + + + 
Figure 3.1. Expression of SIV mac239 Nef protein in the CD4C/SHIV -nerlv Tg mice 
thymus cell populations 
Total protein extracts (100 ~g) from thymuses of a one-month-old Tg and a Non-Tg 
littermate (Lane 1 and 2) served as positive controls for the experiment. DP cells 
(CD4+CD8+TcRy'ô-), DN cells (CD4-CD8-TcRy'ô-) and TcRy'ô+ cells were obtained 
through cell sorting of the thymuses of3 Tg and 3 Non-Tg littermates. The proteins were 
separated by SDS-PAGE and analyzed by Western blotting with a monoclonal antibody 
specifie to SIV Nef. Equalloading was confirmed by probing with an anti-actin antibody. 
Non-Tg Tg 
0.3% 
ON 
0.3% 62% 
Total 
human C04 
Figure 3.2. CD4C promoter drives expression in DN thymocytes 
CD4C/CD4 and non-Tg thymoeytes were stained with mouse CD4, CD8, a panel of lineage specifie 
markers (TeRgd, Mael, B220, Dx5, CDIIe, Grl), and human CD4. Total and DN (mouse CD4, CD8, 
lineage negative) thymoeytes were analyzed for human CD4 expression. 
Table 3.1. Thymie Cell Surface Marker Analysis of CD4C/SHIV -neë1v Tg Mice 
Cell population (%) (absolute number of cells (X106) 
Mice Age No. of Absolute DP (CD4+CD8+) DN (CD4-CD8-) TeR y8+ 
mice cell number 
Non-Tg E17 5 8.1 ± 1.2 87.5 ± 3.0 4.3 ± 3.0 3.9 ± 0.7 
(7.1 ± 1.3) (0.3 ±0.1) (0.3 ±0.2) 
Tg E17 5 4.2 ± 0.9** 50.9 ± 0.9*** 20.4 ± 6.3** 11.7 ± 3.4** 
(2.2 ± 0.4)*** (0.9 ± 0.3)* (0.5 ± 0.06) 
Non-Tg 21D 18 133.0 ± 5.4 89.2 ± 2.3 1.9 ± 0.5 1.11 ± 0.4 
(123.0 ± 5.6) (2.2 ± 0.9) (1.5 ± 0.5) 
Tg 21D 15 5.9± 27.4 ± 8.7*** 58.7 ± 8.7*** 22.9 ± 3.6*** 
2.9*** (17.7 ± 0.8)*** (3.5 ± 1.9)* (1.4 ± 0.6) 
Student's t test, *p~0.05; **p<O.OOl; ***p<O.OOOl 
Thymus of CD4C/SHIV _neF1V Tg mice show marked decrease number of DP cells 
and no change in the amount of DN cells 
At aIl the ages studied, the DP compartment was aIways drasticaIly under-
represented in the Tg mice, the relative percentage being 23.4 ± 9.5 % in 21 day old Tg 
mice compared to 88.7 ± 2.1% in non-Tg controls (Table 3.1, Fig. 3.3). This lower 
relative percentage of DP cells in the Tg thymus is reflected in the lower absolute number 
of these cells in the thymus (1.2 ± 0.9 x 106 cells in the Tg compared to 123.0 ± 49.0 x 
106 cells in the non-Tg (Table 3.1)). Despite the dramatic increase of the DN percentage 
in the Tg thymus when compared to their littermates ( 57.6 ± 12.3 % in Tg vs 2.1 ± 0.6 % 
in non-Tg ), the absolute cell number of DN cells ( 2.9 ± 1.7 x 106 in Tg vs 2.5 ± 0.9 x 106 
in non-Tg) was not significantly different between Tg and non-Tg animaIs (Table 3.1). 
Staining with 7 AAD revealed an increase in cell death in the Tg populations, which was 
supported by increase in size, as judged by FSC plot (Fig.3.4). We aIso determined that 
the level of expression of MHCI on DP cells was elevated 7 fold on TG DP cells versus 
non-Tg DP cells at 21 days old (Fig.3.5). 
Analysis of the DN compartment in CD4C/SHIV _neF1V Tg mice 
FACS anaIysis of the DN cells (CD4-, CD8-, TcRgd-, CDlle, DXS-, Mac1-, Grl-
and B220-) shows that there is a similar number of DNI (CD44+CD25-), DN2 
(CD44+CD25+) and DN3 (CD44-CD25+) cells and a lower absolute cell number of DN4 
cells (CD44-CD25-), when compared to the non-Tg controls (Fig.3.6), raising possibility 
of impaired /3 selection. On the other hand, the TcRrO+ thymocytes always represent a 
higher percentage but a similar absolute number in the Tg mice, demonstrating that these 
cells are being generated without any major problems. 
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Figure 3.3. Cytofluorometric analysis of young CD4C/SHIvNefSIV Tg mice. 
Thymocytes from a representative Tg mou se (F55541) and a non-Tg control were analyzed by 
flow cytometry. Two-color analysis for the expression of CD4 and CD8 in a A) non-Tg mouse 
and B) Tg mouse of 21 days old. The percent ages of cells found in each quadrant are indicated: 
104 live cells were analyzed. 
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Figure 3.4 CD4C/SHIVNefSIV Tg mice thymocytes are prone to death 
Tg and non-Tg thymocytes were labeled with 7-AAD and analyzed by FACS. 
A) Forward scatter (FSC) profiles of non-Tg (black) and Tg (brown) thymocytes. 
B) Staining of thymocytes with 7-AAD. (Cell fragments were excluded using a 
FSC gate). Results represent one out of three littermate pairs analyzed at the same 
time. 
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Figure 3.5 MHCI upregulation on CD4C/SHIVNefSIV Tg mice DP ceUs 
Tg and non-Tg thymocytes were labeled with CD4 versus CD8 and cells were gated 
on DP cells (CD4+CD8+) and analyzed for MHCI expression by FACS. 
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Figure 3.6. CD4C/SHIvNefSIV Tg mice defect might be due to a block in the transition from DN3 to 
DN4. Thymocytes from Tg and non Tg were analyzed by cytofluorometry and absolute ceIl numbers for 
A) DNI (CD44+CD2Y) B) DN2 (CD44+CD2S+) C) DN3 (CD44-CD2S+) D) DN4 (CD44-CD2S-) were 
ca1culated. * P :5 0.05 
Killing of DP Cells via in vivo injection of the anti-CD3 antibody 
Mice that harbour a targeted disruption of the pre-TCR gene cannot forrn the 
essential pre-TCR components and therefore exhibit a drastic defect in T cell 
development. Mice such as Rag-I- mice which cannot rearrange their Ter loci will have 
their T cell development arrested at the CD2S+CD44-llow DN stage and DP cens will not 
be detectable 10,19,26. CD3 injection has been shown to bypass the pre-TCR signalling 
event and to lead to a strong proliferation of DN thymocytes and generation of essentially 
normal numbers of DP cens 13,25. If anti-CD3 injection helps generate DP cens in Tg 
thymus, we can hypothesize that Rag is not playing its proper role in these Tg mice and 
explore that pathway in Tg mice expressing Nef. 
When Tg mice were injected intra-peritoneally (i.p.) with anti-CD3 antibody, 8 of 11 
mice (72.7%) died within 7 days. Failure to generate DP cens in surviving (n=3) Tg mice 
was observed (Fig. 3.7). Henceforth, bypassing the pre-TCR signaling event does not 
seem to be sufficient to lead to DP cells generation and even seems to be deleterious to 
the mice in causing their death or worsening their thymic profile. 
The CD4C/SHIV _nerHV Tg mice thymic defect is cell autonomous 
Non-Tg mice lethally irradiated were transplanted with either non-Tg foetal 
liver cells or Tg liver cens. The non-Tg mice transplanted with non-Tg fetal liver cells 
harbored a perfectly reconstituted thymus, whereas the non-Tg mice transplanted with Tg 
foetal liver cells demonstrated a thymus that resembled the one found in CD4C/SHIV-
nef IV Tg mice. They had an increase of DN cells and a decrease of DP cells, in relative 
cell numbers as well as an increase in the percentage of TcR 'Yc/ T thymocytes. When the 
converse experiment was carried out, with Tg mice being lethally irradiated and 
transplanted with non-Tg foetal liver cens, the thymus was perfectly reconstituted, with 
142 
normal percentages (Fig. 3.8) and normal absolute cell numbers (data not shown) of DN, 
DP and SP populations as well as an absence of downregulation of CD4 and CD8 cell 
surface receptors, ruling out a major involvement of the thymie epihelium in the thymie 
defeet. (Fig. 3.8). 
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DISCUSSION 
SIV Nef Induees thymie defect in Tg miee. 
These experiments demonstrate that mice expressing the SIV mac239 nef gene 
under the regulation of the CD4C promoter (CD4C/SHIV-nefIV) suffer from a severe 
thymic defect. The thymic atrophy seen in the CD4C/SHIV -nefS IV Tg mice is similar to 
the one observed in Simian AIDS (SAIDS). This thymic atrophy is characterized by 
preferential loss of immature DP cells (CD4+CDS+) and mature SP cells (CD4+CDS-). 
This loss of immature and mature DP cells correlates with disease progression 16,17,31. 
The biologic basis of DP thymocyte decrease may involve effect on cell viability, 
as we have documented an increase in 7-AAD staining, as weIl as a block in DN to DP 
transition, which is indicated by the described DN3 to DN4 block as weIl as preliminary 
results showing a failure of anti-CD3 injection to generate a normal number of DP cens in 
the Tg thymus. 
Not only did this experiment fail in rescuing the low DP phenotype, it even 
resulted in further loss of these cens. Since the Tg mice still have sorne peripheral T -ceIls, 
it can explain why they reacted like the wild-type mice 8 by losing their DP cells and not 
like the Rag knock-out mice, which have no peripheral cens at all. This especially makes 
sense when we know that the cens in the periphery are in an activated state as 
demonstrated by the expression of activation markers (data not shown) and are therefore 
likely to produce more lymphokines. 
SIV -Nef indueed thymie defect is eell autonomous 17,31 
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This thymic defect seems to be due to Nef expression in immune cells of the 
thymus, with the thymic epithelium not playing a major role in this defect, as confirmed 
by the foetalliver transplant experiments. 
Role of MHCI upregulation in thymie defeet 
Upregulation of MHCI on thymic epithelial cells has been proposed to result in 
improper selection of CD8 thymocytes with a lower level of CD8 cell surface expression 
18, which could explain the presence of such cells in the periphery of Tg mice 27. These 
cells are thought to be non-functional and to be cells that should have died by neglect due 
to an improper level of interaction between the MHCI and the CD8 cell surface receptor. 
Our transplantation experiments indicate that the presence of the CD810 
CD3+ cells population in Tg mice is not due to intrinsically abnormal thymic epithelium 
as could have been expected. It is possible, for example, that an abnormality of thymic 
epithelium may be induced by an indirect effect requiring the presence of a Tg population 
replaced by transplantation. Altematively, these cells could be selected on Tg DP 
thymocytes, as has been recently shown for human CD4+ T cells. Finally, it is possible 
that this population is generated solely due to an abnormal cell autonomous signalling 
defect. 
In normal thymuses, the up-regulation of MHCI on thymocytes leads to 
death by apoptosis. The very low number of DP cells in the Tg mice might be due in part 
to the death of DP cells which have an up-regulated MHCI cell surface receptor, 
especially since more apoptotic cells could always be seen in Tg thymuses. The fact that 
these cells would die makes sense, especially when we consider that the low number of 
DP cells cannot be due to the formation of SP cells in a faster manner and to a more 
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efficient export mechanism to the periphery, since the peripheral organs of the Tg mice 
were also almost totall y depleted of mature T -cells 27. 
The thymic defect observed in these transgenic mice confirms the major role 
played by Nef in the disease progression and degree of severity of the disease. As this 
thymic defect resembles the one observed in sorne HIV-infected children, this Tg model 
is likely to be instrumental in understanding the disease progression and the major 
effectors involved in that subgroup of HIV -infected children. These results will tell us if 
Nef is a good therapeutic target and what other effectors Nef uses to cause these 
phenotypes might also be good therapeutic targets, for drugs or vaccines. 
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CHAPTER4 
Impaired T Cell Homeostasis in mv Transgenie Miee: Nef Disrupts 
Thymie Maturation of the CD4+ Lineage 
Simard, M.C., Chrobak, P., Hanna, Z., Dave, V., and Jolicoeur, P. 
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APPENDICE 
We previously reported that Tg mice, expressing Nef in the natural target cens of 
the virus (immature CD4+CD8+ T cens, mature CD4+ T cens, macrophages and dendritic 
cens) under the regulatory sequences of the human CD4 gene (CD4C), developed a 
severe disease with multiple phenotypes [premature death, wasting, diarrhea, atrophy of 
the lymphoid organs, progressive and preferential loss of CD4+ T cens, lymphocytic 
interstitial pneumonitis, interstitial nephritis and segmental glomerulosclerosis and 
cardiac disease] resembling those reported in AIDS 7. 
We wanted to shed sorne light on the thymic defect found in these mice and see if 
the block would be the same than the one found in the Tg mice expressing SIV Nef under 
the control ofthe same promoter (CD4c). 
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ABSTRACT 
The HIV-Nef protein is an important determinant of HIV pathogenicity. It has a 
role in T cell homeostasis, and can substantially influence thymic maturation. We have 
utilized the CD4CIHIV Nef transgenic mice, which develop a profound CD4+ T cell 
lymphopenia, to study T cell homeostasis with a particular focus on thymic development. 
Utilizing this mouse model we report that HIV-l Nef impairs maturation of CD4+ SP 
thymocytes. The phenotype can be reproduced by fetal liver transplantation, indicating 
that it is likely a consequence of Nef expression in T cell precursors. Such impairment 
could potentially also be present in human HIV -1 infection. 
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INTRODUCTION 
Disruption of thymopoiesis is thought to play an important role in failed T cell 
homeostasis seen in HW infection, especially in children 13,14. In agreement with this, a 
number of studies has implicated HW Nef as a major contributor of suppressed 
generation of T cens in the thymus 11,25. In the human fetal thymus/liver mouse severe 
combined immunodeficiency (SCID-hu) model, Nef induces thymocyte depletion l,S. It 
also causes depletion of CD4+ cens in the in vitro human fetal thymic organ culture 25. 
The CD4C/ HW Nef transgenic (Tg) mice generated by our group express HW Nef under 
the control of human CD4 regulatory elements in cens that are normally infected by HW 
(CD4+ thymocytes, CD4+ peripheral T ceIls, macrophages, dendritic cens). 
These Tg mice exhibit a complex phenotype, which mimics pediatric AIDS. A 
cardinal feature in these mice is a profound CD4+ T ceIllymphopenia. Other phenotypes, 
such as premature death, wasting, kidney, lung, and heart diseases can also be observed in 
these Tg mice, along with a severe thymic atrophy 7. The biologie basis of Nef impaired 
thymie maturation in our mouse model, and for that matter in other experimental systems 
is not clear. In our CUITent study we have utilized these Tg mice to further investigate the 
biologic basis of Nef mediated impairment of thymic function. 
We report that in this mouse model Nef impairs thymic maturation of thymic 
CD4+ T cens, contributing to the CD4+ observed lymphopenia. This defect can be 
transferred by fetal liver transplantation. Such impairment may exist in HW infected 
thymuses. Furthermore, our data further support the view that the thymus may not be a 
significant source of latently infected peripheral T cells. 
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MATERIAL AND METHODS 
Mice 
The CD4CIHIVMutG and CD4CIHIVMutA Tg (C3H, H-2k) (designated here 
CD4CIHIV Nef) have been described previously 7. Tg mice were bred as heterozygote for 
the transgene in aIl experiments, sex matched HIV non-Tg littermates were used as 
controls. AnimaIs were kept in a specific pathogen free (SPF) animaI facility. 
Antibodies and Reagents 
Antibodies against mouse CD4 PE, CD4 Biotin, CD4 APC, CD8a FITC, 
CD8~ FITC, CD8a Biotin, CD8a CyCh, CD8a APC, TcR~ FITC, TcR~ PE, TcR~ 
Biotin, CD24 (Heat Stable Antigen, HSA) FITC, CD5 FITC, B220 Biotin, I-A k FITC, 
TCRyo FITC, CD25 PE, and CD4 APC were purchased from Cedarlane. Anti mouse 
CD5 PE, CD69 PE, CD24 PE, Thy 1.2 Biotin, Grl Biotin, CDllc Biotin, CDllb Biotin, 
TcRyo Biotin, and Dx5 Biotin mAbs , and Streptavidin PE-Cy7 were purchased from BD 
Biosciences. Irrelevant isotypic control antibodies Rat IgG2a PE (Cedarlane), Rat IgG2b 
PE (Cedarlane), Armenian Hamster IgGl Biotin (BD Biosciences) followed by 
Streptavidin PE (Cedarlane) or Streptavidin PE-Cy7 (BD Biosciences) were used as 
negative controls. 7 AAD was purchased from Cedarlane. 
F ACS analysis 
Flow cytometry anaIysis was performed according to previously published 
protocol (8). DN thymocytes were phenotyped as lineage negative Lin- (B220-, Mac1-, 
CDllc-, TcRaW, TcRyo-, Dx-5-,Gr-l- ) CD4-, CD8-). Acquisition of at least 10,000 
events was performed. Dead cells were excluded from anaIysis based on FSC profiles and 
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PI or 7AAD positivity. Acquisition was performed on FACScan or FACSCaIibur (BD 
Biosciences) Data were analyzed using the CellQuest Pro (BD Biosciences) software. 
Fetal Liver Transplantation 
Donors: FetaI livers from non-Tg and Tg 14.5 day-old embryos (E14.5) were 
harvested. Single cell suspension was made in HBSS supplemented with 10% FBS, under 
sterile conditions, with a syringe plunger. Cell suspension was filtered through a Nytex 
mesh (BSH Thompson, MontreaI). Remaining fetaI tissues were typed for Tg expression 
by PCR. When typing was known, cells coming from Tg and non-Tg embryos were 
pooled. Cells were counted and then resuspended in HBSS solution supplemented with 
2% FBS at a concentration of 20x106 cells per mL. 
Hosts: C3H1HeN mice (8 to 12 weeks-old) were lethaIly irradiated (950 Rad) 
using Mark I-68A1 Irradiator (Cs-137, J.L. Shepherds & Associates). Then mice were 
injected, via the tail vein, with 4x106 fetaI liver cells in 0.2 mL of HBSS solution 
supplemented with 2% FBS 4-6 hours after irradiation. Transplanted mice were anaIyzed 
1 to 3 months after transplantation 
PCR Technique for Transgene Detection 
A piece of fetaI body was placed in 200 J..lL of lysis buffer (O.lM NaCI, O.OlM 
EDTA, 0.05M Tris pH 7.5,0.5% Nonidet-40 and 0.05% of Tween 20) supplemented with 
10 J..lL of proteinase K (10 mg/mL) and digested at 55°C for 20 min. to 2 hours. After 
digestion, lysates were centrifuged to pellet non-digested tissues and 100 J..lL of the 
supematant was taken. This aliquot was heated at 100°C for 8 min, further diluted (10 J..lL 
in 200 J..lL of water) and further heated at 55°C for 30 minutes. PCR reaction was 
performed with nef specifie primers (sense primer: 51-CATGGAGCAATCACAAGTAG, 
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antisense primer: 51-GGTACTAGCTTGAAGCACCA). Detection of the mouse Myb 
gene (sense primer: 51-CCAGTCACGTTCCCTATCCT and anti-sense primer: 51-
GCCTGCTGTCCCTTCAGCTC) was done as a control. The PCR was performed under 
the following conditions: (40 secon-ds at 94°C, 1 min at 54°C, 30 sec at 72°C for 1 cycle, 
followed by 40 sec at 94°C, 45 sec at 54oC, by 1 min at 72°C for a total of 24 cycles. 
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RESULTS 
Expression ofHIV-l in CD4CIHIV Nef Tg Thymocytes 
In previous work from our group, HN-l expression in CD4CIHNNef Tg mice 
was detected strongly in thymocytes and in peripheral CD4+ T cells. In thymus, 
expression was much stronger in cortical than in medullary thymocytes . To determine 
whether more immature thymocytes express the transgene, sorted DN (CD4-, CDS-
,TcRaW,yo-, Thy1.2+) thymocytes were analyzed by RT-PCR. Expression of HN-l was 
detected in this DN population (data not shown). We also evaluated the target cell 
specificity of this promoter by using CD4C/huCD4 Tg mice 9.10, and measuring the 
expression of human CD4 on Lin- DN thymocytes by FACS. 72% of DN thymocytes had 
detectable human CD4 expression on their cell surface, with the majority of these 
expressing high levels comparable to those ofDP cells (data not shown). 
CD4CIHIV Nef Tg Mice Show Early CD4+ T Cell Lymphopenia 
We have previously reported that CD4CIHN Tg mice, expressing either Nef 
alone (Mut G) or Nef, Env and Rev (Mut A) develop thymic atrophy and present with 
CD4+ T ceIlIymphopenia 7 26. In our cUITent study, the kinetics of these changes were 
characterized by FACS on young adult mice. Compared to non-Tg controIs, DP 
thymocytes from Tg mice aged 6 to S weeks, exhibited a previously reported decrease in 
the intensity of CD4 cell surface staining and to a lesser extent, a downregulation of the 
CDSa cell surface marker (Fig. 4.1 A,B). CD4 and CDSa cell surface markers were also 
downregulated on respectively CD4+ and CDS+ SP thymocytes (Fig. 4.1 A,B). Compared 
to controIs, the percentage of DP cells was not significantly different, but their absolute 
cell number was decreased (Fig. 4. 1 A,C). In contrast, both the percentage as well as the 
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absolute cell number of Tg CD4+SP and TcRa~hi CD4+ SP mature thymocytes was 
decreased (Fig. 4. 1 A, D). 
Next, younger mice (aged EI7.5, 1.5 and 3 week-old) were subjected to the same 
analysis. These experiments revealed that in these mice (up to 3 week-old), in contrast to 
6-8 week-old Tg mice, the absolute cell number of total thymocytes and of the DP subset 
was comparable to non-Tg mice (Fig. 4.1 C). However, the number of CD4+ SP, but not 
CD8+ SP thymocytes was significantly decreased (Fig. 4.1 D and data not shown). In 
addition, downregulation of CD4 and CD8a on DP (all age groups) and on respectively 
CD4+ and CD8+ SP thymocytes (1.5 and 3 week-old groups) was present in the se young 
Tg mice (data not shown). 
We have previously reported that peripheral CD4+ T cell lymphopenia is a 
characteristic phenotype of adult (3-6 months-old) Tg mice (7,8). This was confirmed 
here in 5-8 week-old Tg mice (Fig. 4.1 E). In addition, we found that peripheral CD4+ T 
cell lymphopenia was present even in 10 day-old Tg mice (Fig. 4.1 F), a phenotype 
consistent with the diminished number of Tg CD4+SP T cells observed at these ages. 
Compared to non-Tg controls, Tg mice also exhibited a decrease peripheral CD8+ T cells 
(Fig. 4.1 E,F). Similar results were observed in CD4CIHIVMutA mice, which express 
HIV-l Rev and Env in addition to Nef (data not shown). These data suggest that HIV Nef 
impairs maturation and/or survival of thymic CD4+ SP and CD8+ T cells. 
Tg Mice Show Increase of DN Thymocytes 
Analysis of the DN (CD4-, CD8-, Lin-) compartment revealed that the 
percent age of Tg DN thymocytes was modestly elevated, but this increase could not be 
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accounted for by an increase of TcRa~hi DN which remained in Tg mice at levels 
comparable to those seen in non-Tg mice. 
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Figure 4.1 Analysis of T cells from Thymus and Spleen of CD4C/HIVNef Tg Mice 
(A) Thymocytes from 6-week-old Tg and non-Tg thymuses were labeled with antibodies against 
TcR~, CD3E, CD4 and CDS, and analyzed by FACS. (8) Mean fluorescence intensity of CD4 and 
CDSa staining on DP, TcRa~hi CD4+SP (CD4+) and TcRa~hi CDS+SP (CDS+) thymocytes was 
eompared between Tg and non-Tg mice. (C,D) Absolute eell numbers of thymie populations from 
animais of different ages. (E,F) Absolute numbers of splenie T eell subsets. Data were obtained 
'~om (4-15) non-Tg and (4-12) Tg mice and are presented as means ± SD. Statistieal analysis was 
Jone using Student's T test (*p<O.05, ** p<O.01, *** p<O.001). 
mice (Fig. 4.1 A). Tg mice had an absolute increase in DN1, DN2, DN3 and DN4 
thymocytes compared to non-Tg mice (Fig. 4.2). In sorne Tg mice, there was a relatively 
bigger increase of the DN3 compartment compared to the DN4 subpopulation, however it 
did not reach statistical significance. 
Tg Mice Show Impaired CD4+ SP Thymocyte Maturation 
We next investigated the DP to SP thymocyte transition in these mice. This 
process involves selection and maturation steps, which are reflected by upregulation of 
multiple markers including TcR, CD69, CD2, CD5 and IL-7R. (9,10,11). FACS analysis 
showed an accumulation of a TcRa~ and CD3ê intermediate populations in Tg 
thymocytes (Fig. 4.1 A). Evaluation of developmental markers CD2, CD69, CD5, 
CD24, and IL-7R on selected thymocyte subsets (Fig. 4.3) revealed similar levels of 
expression on Tg DP thymocytes as in non-Tg mice, for all of them, except for CD5 and 
CD24, which had slightly higher staining. However, on TCRa~hiCD4+SP thymocytes, 
these markers were all down-modulated in a high proportion of these cells, and so was IL-
7R on CD4+ SP thymocytes. The fact that a higher percentage of TCRa~hiCD4+SP 
thymocytes was CD2410w may indicate entry of peripheral T cells into the thymus. On the 
TCRa~hiCD8+SP thymocyte subset, staining intensity with CD24 and CD5 was 
increased, and that of CD2 decreased, while that of IL-7R was variable, but in general 
higher (Fig. 4.3). The decrease of CD5 and CD2 cell surface staining was also observed 
on naïve peripheral CD4410w CD4+T cells (data not shown). 
Since the levels of CD5 on mature cells have been shown to correlate with the 
avidity of the selecting ligand 2, these data suggest that the Tg CD4+ SP thymocytes have 
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Figure 4.3 Dysregulation of Thymopoietic Markers on Thymocytes from CD4CIHIVNef Tg Mice 
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Thymocytes fram 6 ta 8 week-old CD4CIHIVNefTg mice and non-Tg contrallittermates were stained with antibodies against TCRb, CD4, CD8, 
and different maturation markers (CD2, CD5, HSA, CD69, IL-7R) as weIl as apprapriate isotypic contraIs, and were analyzed by FACS. Numbers 
represent average Tg/non-Tg ratios (means ± SD) based on MF!. Statistical analysis was performed with the student's t test (Tg n= 6, non-Tg n= 
8, for all except IL-7R (Tg n=5, non-Tg n=4)). 
been selected under lower avidity interactions than in non-Tg mice, and that Nef alters 
maturation of CD4+ T cells in the thymus in the se Tg mice. 
Thymie Phenotype of CD4C/HIVNef Tg Can Be Transferred by Fetal Liver (FL) 
Transplantation 
To determine if the thymie phenotype of CD4CIHIV Tg mice was transferable, we 
performed transplantation experiments, transferring FL cells from CD4CIHIVMutA 
embryos into lethally irradiated C3H non-Tg hosts. Evaluation of hosts showed that, 1 to 
2 months after transplantation, most thymocytes were donor derived (Fig. 4.4 A). Their 
thymic F ACS profiles were indistinguishable from those of CD4CIHIV Nef and 
CD4CIHIV MutA Tg mice, including a significant decrease of CD4+ SP thymocytes (Fig. 
4.4 Band C). These results suggest that the thymic defect in Tg mice is cell autonomous 
with the thymic epithelial stroma most likely not playing a major role. This phenotype 
and is likely caused by defective T cell precursors, but one cannot rule out the role of 
peripheral T cells secreting cytokines. 
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Figure 4.4 Thymic Phenotype Can Be Transferred by Fetal Liver Transplantation, and Tg thymocytes 
are at disadvantage relative to non-Tg mice 
(A-C) Thymocytes from lethally irradiated C3H mice reconstituted with Tg or non-Tg fetalliver cells were 
analyzed one month after transplantation. Detection of intracellular Nef Tg protein was performed, with 
anti-nef antiserum (or control rabbit serum, for control) followed by a secondary anti-rabbit PE secondary 
antibody and analysis by FACS (A). Thymocytes from reconstituted mice were also cell surface labeled with 
antibodies against different cell surface markers, and cell suspensions were analyzed by FACS (B). Absolute 
cell numbers of different thymocyte cell populations were determined (C). Statistical analysis was 
performed using Students' t test (* p<O.5). 
DISCUSSION 
The CD4C Nef transgenic mice develop a predominantly CD4+ T cell 
lymphopenia and thymic atrophy 7,26. The purpose of this study was to determine the 
effect of Nef on thymopoiesis in this mouse model. 
In our current studies we report that thymic atrophy develops gradually in 
CD4CIHNMutG and CD4CIHNMutA Tg mice, but the decrease of the CD4+SP 
thymocyte population is present from early on (in one to two-week old mice and at birth 
(data not shown)). The first week of life in mice is a period important for the initial 
population of the peripheral T cell pool 16. In contrast, the CD8+ T cells lineage seems to 
be less affected. These data lead us to conc1ude that initially there is not a significant 
early block in thymopoiesis or a general severe failure of positive selection in these Tg 
mice and secondly that the thymic CD4+ T celIlymphopenia likely contributes to the 
pathogenesis of the peripheral CD4+ T cell deficiency in our Tg mice. 
In-vitro human thymic cultures or the Thy-Liv hu/SCID mouse models show 
significant thymocyte depletion as a Nef associated phenotype 1,5,25. Our Tg mice 
reproduce this phenotype, although at an older age. The biological reason behind the 10ss 
of DP thymocytes in our mouse model is currently under investigation. Nef is likely 
expressed in the DN thymocytes in our HN Tg mice, as indicated by the detection of 
human CD4 on DN thymocytes in CD4C/CD4 Tg mice. In this regard our mice reflect the 
situation in human HN infection, where immature triple negative thymocytes were found 
to be permissive to the virus 24. Therefore, the decrease of DP thymocytes could be due to 
defective DN to DP transition. However, we were not able to document convincing 
evidence of impaired DN3 to DN4 transition, which represents the critical checkpoint of 
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DN to DP transition. The decrease of DP thymocytes could also be due to the effect of 
Nef on DP thymocyte survival (mediated by a direct or indirect effect). In fact we did 
document an increase of 7 AAD staining on Tg DP thymocytes, but again the difference 
did not reach statistical difference (data not shown). Our mouse model may be different 
from the above mentioned human models because of differences in the stage of Nef 
presence during thymic development, the level of Nef protein present, and also due to the 
presence of Nef negative cells in other systems which may be in competition with Nef 
expressing cells. Our thymic phenotype resembles pictures previously reported in other 
nef transgenic mice 4,15,21, however the periphery in our mice is severely depleted more 
predominantly of CD4+ T cells. Again differences in the expression of Nef in other cell 
lineages in addition to T cells in the CD4CIHN Tg mice (macrophages, dendritie cells) 
as well as differences in the level of Nef likely account for the distinctions. The thymic 
and peripheral T cell phenotype in the RN Tg mice also somewhat differs from the 
phenotype observed with the same CD4C promoter using SN -Nef instead of RN -Nef 20. 
The SN -Nef Tg mice exhibit a very early thymic deficiency, evidence of impaired DN3 
to DN4 transition and a severe deficiency of both CD8+ and CD4+ T cells 20. These 
differences indieate differences in biological activity between the same allele of RN and 
SN Nef. 
The thymic CD4+ SP deficiency in RN Tg mice can be explained by Nef effect 
on maturation and survival of this population. The DP to CD4+ SP maturation, judged by 
a variety of activation markers, su ch as CD5, CD2, CD69, IL7R, is altered. Rowever, Nef 
does affect not only the maturation, but also the survival of the thymie CD4+ T cell 
lineage, as we have previously documented a statistically significant increase in 
apoptosis/death at the CD4+SP thymic population (data not shown). Increased thymic 
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apoptosis in the context of RIV infection was reported in sorne instances 15,23, whereas it 
was not seen by other researchers 3,25. Breeding of the RIV Tg mice with Bcl-2 Tg mice 
did not reverse the thymic and peripheral 10ss of CD4 + cells and neither did it reverse the 
increase in cell death of C04 + T cells 17. In view of this data the down regulation of n.. 7R 
is not likely to be of significance in the development of the CD4+ T cell deficiency. This 
means that Nef impairs CD4+ cell survival by a Bcl-2 independent pathway, as Bcl-2 was 
shown to rescue T lymphopoiesis in n..-7 deficient mice. Rowever this data may also 
underscore the importance of the maturation impairment as weIl as the role of another 
RIV/SIV gene, Tat. 
Our fetal liver transplantation experiments indicate that the thymic CD4+ SP 
deficiency is not a consequence of inherently abnormal thymic epithelium. Studies 
investigating mechanisms implicated in Nef caused thymic pathogenesis have brought 
various conclusions, with sorne investigators describing that CD4 downregulation 
correlates with its pathogenic effect 12. The importance of CD4 levels in thymic 
maturation of CD4+ T cells is known, as evidenced by the CD4 knockout mice 18, studies 
where CD4-MRC class II has been disrupted 19 or in mice with down-regulation of CD46• 
Others report that Nef signaling function is causing this thymic defect, as 
demonstrated by mutations in the membrane anchor or the core domain of Nef preventing 
thymic depletion, rather than CD4 downregulation playing a central role in this phenotype 
22. In previous work from our Iaboratory we have documented that mutations which 
prevent CD4 downregulation, abrogated thymic depletion, loss of peripheral CD4+ T cells 
(partially) as well as development of AIDS specific organ disease 8. Regardless of the 
mechanisms involved, our current data demonstrate a detrimental effect of Nef on 
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thymopoiesis, in particular on thymic maturation of CD4+SP cells, and suggest that this 
latter biological process should be directly investigated in HIV infected patients. 
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APPENDICE 
Two models ofHIV-l Tg mice [Tg26 (29) and CD4CIHIV (30)], one model of SIV Tg 
mice (31) and one model ofHIV-l Tg rats (32) have been reported to develop 
cardiomyopathy. We wanted to summarize the cardiac phenotypes found in these Tg 
models. 
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INTRODUCTION 
The acquired immunodeficiency syndrome (AIDS) is induced by the 
human immunodeficiency virus (HIV-l) and represents a multiorgan disease (1-3). A 
major feature of the disease is the progressive loss of CD4+ T -cens with 
lymphadenopathy, thymic atrophy and destruction of the architecture of lymphoid organs. 
Other significant AIDS-related phenotypes include lung disease (lymphocytic interstitial 
pneumonitis) (4,5), renal disease (interstitial nephritis, segmental glomerulosclerosis) (6-
8), wasting (9,10), peripheral (11) and central (12-15) neurodegenerative diseases, 
hematological disorders 16 and cardiac disease. This latter cardiac disease is now 
recognized as a relatively frequent complication of HIV -1 infection and is characterized 
by a progressive, dilated cardiomyopathy sometimes accompanied by compensatory 
cardiac hypertrophy and functionalloss. A variety of histopathologicallesions have been 
observed in hearts of HIV -1 infected individuals, the most common being cardiomyocyte 
necrosis, often with fibrosis. Mononuclear cell infiltration is often observed with these 
lesions, but may be absent. Several reviews have appeared on the clinical and 
pathological aspects of the AIDS-associated cardiomyopathy (17-25). 
The pathogenesis of the AIDS-associated cardiac disease is not at an clear 
at the moment and animal models will undoubtedly help our understanding of its cellular 
and molecular basis. Rhesus macaques infected with an HIV-l related lentivirus, the 
simian immunodeficiency virus (SIV), have been one of the most widely used animal 
models for HIV -1 infection and AIDS (26,27). Cardiac disease develops in SIV-l 
infected macaques (28) and study of this simian model of cardiac disease is likely to shed 
light on its pathogenesis. Fortunately, in the last few years, cardiac disease has been 
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found to develop in transgenic (Tg) mice or rats expressing HIV-l gene products. The 
present review will focus on these Tg animal models. 
Cardiac disease in HIV -1 Tg mice or rats 
Two models of HIV-l Tg mice [Tg26 (29) and CD4CIHIV (30)], one 
model of SIV Tg mice (31) and one model of HIV-l Tg rats (32) have been reported to 
develop cardiomyopathy. 
Tg26 mice: 
A review of the main characteristics of the cardiomyopathy developing in 
Tg26 mice has recently been published (33). These Tg mice harbor an HIV-l genome 
(strain NlA-3) deleted of gag and pol sequences (34). Transgene viral RNA is expressed 
under the regulation of the HIV-l long terminal repeat (LTR) promoter and is 
widespread. The highest expression was documented in skin, muscle and tail, but was 
also detectable in thymus, intestine, kidney, eye, brain and spleen (34,35). However, 
heart, liver, pancreas and lung did not express the transgene (36). Hemizygous Tg26 mice 
develop a severe renal disease, as weIl as skin and ocular diseases (34,37,38), but do not 
show signs of CD4+ T -ceIlloss. Signs of renal disease (proteinuria) are seen early, by day 
(20-25) after birth (36,39). 
Intriguingly, novel phenotypes [cachexia, growth retardation, 
lymphoproliferation with an increased number of splenic CD4+ and CD8+ T-ceIls, thymic 
atrophy and early death (40)] were also observed in Tg26 mice homozygous for the 
transgene. Differences in transgene expression between homo- and heterozygote Tg26 
mice were not found in kidney, spleen and thymus, but were mainly observed in lymph 
nodes, suggesting that sorne and perhaps all the novel phenotypes may not be related to 
transgene expression. The appearance of novel phenotypes in homozygote Tg-positive 
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animals suggests the presence of a recessive host mutation induced by the chromosomal 
insertion of the transgene. This type of mutation is not rare during the construction of Tg 
mice (41-48). 
It was recently reported that hemizygous Tg26 mice show cardiac 
dysfunction and reduced cardiac expression of sarcoplasmic calcium ATPase (SERCA2), 
but no histological heart lesions as compared to normal non-Tg mice (29,49). "Decreases 
in the first derivative of the maximal change in LV systolic pressure with respect to time 
(+dP/dt)" and "an increased half-time of relaxation and ventricular relaxation (-dP/dt)" 
were reported in these Tg mice as compared to normal control mice (25,49). 
CD4C/HIV Tg mice: 
The CD4CIHIV Tg mice (50,51) express HIV-1 gene products under the 
regulation of the CD4C regulatory sequences from the human CD4 gene. Expression is 
targeted in CD4+ T-cells (both immature CD4+CD8+ thymic T-cells, and mature CD4+ 
T-ceIls) and in cells of the myeloid lineage (macrophages, Kupffer cells and dendritic 
cells). The CD4CIHIV Tg mice develop an AIDS-like disease very similar to human 
AIDS: weight loss/failure to thrive, wasting, early death, progressive and preferentialloss 
of CD4+ T-ceIls, thymic atrophy, lymphadenopathy, increased B cell numbers, increased 
numbers of CD8+ T -cells, inversion of CD4/CD8 ratio, activation of T - and B-cells, 
production of auto-antibodies, expansion of spleen marginal zone, impaired germinal 
center formation, lung disease (lymphocytic interstitial pneumonitis), kidney disease 
(interstitial nephritis, segmental glomerulosclerosis) and cardiac disease (30,50-52). 
The cardiac disease of CD4CIHIV Tg mice consists of histopathological 
les ions and functional abnormalities and develops in the absence of detectable transgene 
expression in either myocardium or cells of the vasculature (30). Heart enlargement was 
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frequent in the early backcrossing on the C3H background [from (C3H X C57BL/6)F2] 
but less so as inbreeding into the C3H background progressed. The lesions represent 
multifocal are as of myocytolysis (Fig. 1), sometimes associated with myocarditis. In the 
C3H background, calcifications also occur. In addition, both focal arid diffuse interstitial 
fibrosis (detected by Sirius Red staining) is observed in the heart of these Tg mice. 
CD4CIHIV Tg cardiomyocytes are decorated with endogenous immunoglobulin (Ig) 
which could represent anti-heart auto-antibodies. However, no disturbance of the 
dystrophin-associated glycoprotein (DAG) complex could be documented (Fig. 2). 
Two functional abnormalities were detected in these Tg mice (30). The 
coronary vasculature of CD4CIHIV Tg mice showed signs of enhanced vasospasm under 
stress or hypoxia. This arteriospasm affected mainly the medium and small coronary 
vessels. Echocardiography also revealed functional defects: an increased systolic left 
ventricular internal dimension and a decrease of the fractional shortening, the ejection 
fraction, the stroke volume and the cardiac output, indicating a compromised left 
ventricular function. 
Interestingly, the functional cardiac defects and the cardiac lesions may 
have a distinct pathogenesis, as both phenotypes tend to segregate independently during 
inbreeding on the C3H background. We noticed indeed that the penetrance of 
histopatological cardiac lesions in CD4CIHIV Tg mice decreased to -20-25% after 
inbreeding (>10 generations), while the penetrance of the functional abnormalities 
detected by echocardiography was high (30). 
CD4C/SHIV _netIV: 
Tg mice expressing SIV Nef under the CD4C regulatory sequences were 
also generated (31). These CD4C/SHIV-nefIV Tg mice develop an AIDS-like disease 
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very similar ta that of CD4CIHIV Tg mice, except that the kidney and eardiae diseases 
were more severe, and that a thymie developmental defeet was observed. Heart 
enlargement 
181 
non-Tg Tg 
Figure 5.1. Cardiac pathology in CD4C/HIVMutB Tg Mice. 
Hcart sections from non-Tg (A,C) and Tg (B,O) mice shown 
at low (A,B) and higher (C,O) power. 
Note the multifocallesions in the left ventricular wall of Tg heart, 
consisting of myocytolysis with calcifications. 
non-Tg Tg non-Tg Tg 
Control 
Figure 5.2. The dystrophin associated glycoprotein (DAG) complex is intact in the heart 
ofCD4C/HIV Tg mice. To assess thc integrity of the DAG complex, immunohistochemistry 
was performed with antibodies against sorne of its compone nt protcins, namely dystrobrevin 
(A,B), (C,D), (E,F) and (G,H) sarcoglycans, on heart sections from non-Tg (A,C,E,G) 
or Tg (B,D,F,H) hearts. No differcnces betwccn the staining patterns for any ofthesc proteins 
could be discerned bctwecn non-Tg and Tg animaIs. (1) Sccondary antibody control 
(for -sarcoglycan). No sarcolcmmal immunoreactivity was detccted with any of the 
secondary antibodies utilized. Magnification (aIl panels): IOOx. Countcrstain: hematoxylin. 
was very severe in CD4C/SIV Tg mice during early breeding on the C3R background. 
Ristopathologicallesions in the heart of these mice were also multifocal and were similar 
to those found in CD4CIHIV Tg mice. Data from echocardiography analysis are not yet 
available for these Tg mice. 
HIV -1 Tg rats: 
The RIV Tg rats harbor an RIV -1 genome (strain NlA-3) with a deletion of 
gag-pol sequences similar to that of Tg26 mice (32). Expression is controlled by the viral 
LTR and was documented in lymph nodes, thymus, liver, kidney and spleen. Tg rats 
developed several AIDS-like phenotypes: weight loss, neurological abnormalities (gliosis, 
neuronal cell death, capillary changes), interstitial pneumonia, lymphadenopathy, kidney 
disease (tubulointerstitial nephritis, glomerulolosclerosis), follicular hyperplasia of spleen 
and expansion of marginal zone, abnormal T -helper functions and cardiac disease. The 
Tg rats also exhibit sorne phenotypes usually not encountered in RIV-l infected 
individuals (cataracts, skin lesions). Unfortunately, the status of the CD4+ T-cell numbers 
was not reported. 
The cardiac disease of Tg rats consisted of myocardial inflammation 
(necrosis, mononuclear cell infiltrate and vascular abnormalities) and endocarditis. The 
penetrance of this phenotype was not specified. 
Pathogenesis of cardiac disease in HIV -1 Tg animais 
One of the striking features of the cardiac disease developing in CD4CIHIV 
or CD4C/SRIV-neFIV Tg mice, and possibly in RIV Tg rats, is the fact that it is induced 
distally by the expression of RIV -1 or SIV gene products in cells of the immune system, 
most likely by an indirect mechanism (30-32). This contrasts significantly with a number 
of other models of cardiomyopathy in mice (and in humans) in which disturbances 
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(enhanced or decreased expression, mutation) of expression of structural proteins of 
cardiomyocytes themselves are primarily involved in development of cardiac diseases 
(53-61). 
Two main populations of immune cells express the transgene in CD4CIHIV 
or CD4C/SHIV-ner"IV Tg mice through the CD4C promoter: CD4+ T-cells (both 
immature CD4+CD8+ thymie T-cells and mature CD4+ T-cells) and cells of the myeloid 
lineage (macrophages, Kupffer cells and dendritie cells) (50,51,62,63). In theory, 
reprogramming of any of these cell sub-populations by HIV -1 or SIV Nef could be 
responsible for initiating the cascade of events leading to the various cardiac lesions and 
cardiac dysfunctions observed. Experiments are in progress to determine the identity of 
the transgene-expressing cell population(s) responsible for eliciting these cardiac 
phenotypes. 
The most obvious proximal cause of the cardiac disease in CD4CIHIV, 
CD4C/SHIV-neFIV , Tg26 Tg mice and HIV Tg rats could be the kidney disease which 
develops in these strains and which is associated with moderately elevated blood pressure 
(hypertension), as documented at least in the CD4CIHIV Tg mice (Paradis et al., In 
preparation). Hypertension could contribute to at least sorne of the functional cardiac 
defects observed in CD4CIHIV and Tg26 Tg mice. However, in CD4CIHIV Tg mice 
bred on the C3H background, we have notieed a segregation of the cardiac lesion 
phenotype and the kidney disease (30), suggesting that kidney disease may not be 
responsible or may not be sufficient to induce the cardiac lesions. This notion is 
reinforced by the observation that in Tg 26 mice, severe kidney disease is not associated 
with cardiac lesions (29). 
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Another 1ike1y contributing factor to the cardiac disease of CD4CIHN and 
CD4C/SHN _nersIV Tg mice is the presence of immunog1obu1in (Ig) decorating the 
cardiomyocytes in these Tg mice (30,31). These may represent anti-heart autoantibodies. 
Heart disease induced by anti-heart antibodies has been described in humans (64) and in 
animal mode1s (65). We have also reported that these CD4CIHN and CD4C/SHIV-
neFIV Tg mice produce elevated anti-DNA antibodies (31,52). 
Final1y, a vascular prob1em may represent another proximal cause of the 
multifocal1esions observed in CD4CIHN Tg mice. A vasospasm affecting mainly the 
medium and small cardiac vesse1s and enhanced under hypoxia and stress was 
documented in these Tg mice (30). This type of mechanism cou1d exp1ain the multi-focal 
nature of the lesions. 
What have we learnt about HIV -1 cardiomyopathy from HIV -1 Tg animais? 
From the few mode1s of Tg animals avai1ab1e, already important knowledge 
about the HN -1 associated cardiomyopathy has emerged. 
First, this cardiomyopathy is 1ikely to be caused by HN -1 itself, directly or 
indirectly, and not by opportunistic infections. Indeed, Tg26 mice deve10p cardiac 
disease despite the fact that they do not show 10ss of CD4+ T-cells, while CD4CIHN, 
CD4C/SHN -nersIV Tg mice and HN Tg rats deve10p cardiac disease in SPF facilities in 
absence of obvious opportunistic infection. 
Second, since Tg26 develop functional cardiac abnormalities in absence of 
10ss of CD4+ T -ceIls, it appears that T -cell impairment may not be required to elicit such 
dysfunctions. Rather, perturbation of cells of the mye10id 1ineage by HN -1 gene 
products may affect the heart. 
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Third, cardiac disease develops in Tg26 mice (29) and HIV-l Tg rats (32) 
which do not express HIV -1 Gag and Pol proteins and in CD4CIHIVMutG 30 and 
CD4C/SHIV-netlV (31) Tg mice expressing only Nef. Therefore, Gag and Pol proteins 
are not involved in the development of cardiac disease in these animals and it appears that 
Nef harbors a major determinant of cardiac disease, at least in mice. In view of the fact 
that the several phenotypes of the AIDS-like disease of CD4CIHIV (51) clos el y mimic 
those in human AIDS, Nef is also likely to represent a major pathogenic factor for human 
hearts as weIl. 
Fourth, in CD4CIHIV Tg mice, cardiac disease arises in absence of 
detectable expression of HIV -1 in cardiomyocytes or coronary vasculature (30). 
Therefore, HIV -1 expression in cardiomyocytes or blood vessels may not be required in 
humans for the development of an HIV -1 associated cardiomyopathy. 
Fifth, in Tg26 mice, the presence of the HIV-l transgene appears to 
synergize with antiretroviral therapy to induce cardiac dysfunction and cardiomyocyte 
damage (29,49), indicating that the apparent cardiac toxicity of drug therapy in 
individuals with AIDS may, at least in part, be influenced by the metabolic milieu 
generated by HIV -1 infection itseIf. 
Sixth, in CD4CIHIV and CD4C/SHIV -neF IV Tg mice, cardiomyopathy 
develops as a consequence of expression of Nef in cens of the immune system (CD4+ T-
eens or cens of the myeloid lineage) (30,31). This suggests that reprogramming of sorne 
immune cens by Nef induces an environment which predisposes to cardiac disease. It is 
conceivable that other cardiae diseases in individuals not infected by HIV -1 may also 
originate from specifie disturbances of sorne of their immune CD4+ T-cells or myeloid 
cell subpopulations. These immune alterations could represent specifie mutations or 
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infection by other microbes mimicking molecularly the action of Nef in these cells. This 
could be independent of banefide cytotoxic T-cell (CTL) response or of anti-heart auto-
antibodies generally thought to be responsible for cardiomyopathy after viraI or bacterial 
infection. 
CONCLUSION 
Despite the fact that cardiac disease was recognized only recently as a 
consequence of HIV -1 expression in Tg animaIs, it is aIready apparent that these models 
mimic quite closely the human cardiac diseases arising in HIV -1 infected individuaIs with 
AIDS. It is expected that a study of these models will shed light on the pathogenesis of 
this human cardiomyopathy and hopefully wi111ead to a better therapy and ultimately to 
its prevention. 
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DISCUSSION 
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DISCUSSION 
SIVmac239 Nef can kill mice just like DIV -1 NL4-3 Nef 
Our experiment showed that using the SIV mac239 nef gene under the regulation of 
the CD4C promoter (CD4C/SHIV-netN ) leads to a very similar AIDS-like disease than 
the one seen when we use the HIV -1 Nef whieh in turn is very similar to human pediatrie 
AIDS 42,43,113. 
The features seen in the expressing CD4C/SHIV-neFN Tg animaIs are: premature 
death, severe wasting, failure to thrive, kidney disease (interstitial nephritis and focal 
segmental glomerulosclerosis), lymphoeytic interstitial pneumonitis, cardiac disease, 
thymic atrophy, splenomegaly and low T cell number both in the thymus and in 
peripheral lymphoid orgaos) 42,43,113. Therefore, one can say that the SIV model is 
pertinent to study humao AIDS and especially the role that Nef plays in this disease. 
We showed that Tg models expressing the whole HIV NL4-3 genome devoid of 
Nef (CD4CIHIVMutH), were found to be unable to induce the phenotypes seen in the Tg 
models expressing only HIV-l Nef under the control of the same promoter (CD4c). 
Therefore, it is evident that Nef is the protein responsible for inducing this AIDS-like 
disease in mice and that HIV-l Nef cao be replaced by SIV Nef. Therefore, our data 
validate the observations that HIV and SIV Nef have a strong functional resemblance, in 
vitro and in vivo, in another type of in vivo model (mouse), in the absence of viral 
replication and of an immune response to the virus. 
Positive correlation between the amount of Nef expressed and survival 
The development of the AIDS-like disease in aIl our Tg models seems to be 
influenced by the level of nef expression. The more Nef a Tg line did express, the shorter 
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was the latency and the faster they died. Death might have been caused by the severe 
renal disease or other causes. This is also seen in HIV -infected patients, where the plasma 
viral load correlates with progression of the disease and appearance of the features 
present in human AIDS 116,123,130. 
Expression of Nef in the appropriate target cell is critical for this model 
Not only the amount of Nef present in a Tg model is important for the 
development of the AIDS-like disease but appropriate cens must express the transgene. 
The promoter used in all our Tg models (CD4c) has been shown to drive the expression 
of surrogate genes in mature and immature T -cens and in cens of the 
macrophage/dendritic lineages of Tg mice44• The expression of the transgene in mice 
seems to be following the tissue specificity of this promoter, therefore targetting the same 
cell populations infected by the virus in natural infections of humans. This was even seen 
in the gut where the CD4+ cells did express the transgene (data not shown). This pattern 
of expression seems to explain the multi-organ syndrome observed in the Tg mice 42,43,113. 
One result that puzzled us at first was the fact that the DN cells in the thymus did 
express a high amount of the transgene. But more and more, its been lately reported in the 
literature that these cens are infected in vitro and in vivo and that this might play a 
prominent role in the incapacity of the immune system to regenerate itself 65. It can also 
explain the presence of viral DNA in CD8+ lymphocytes recently observed in patients, 
whereas in our Tg model, the majority of CD8+ cens do not express the Tg at detectable 
levels for Northern and Western blots or FACS. 
Not only Nef expression might lead to an early death, but this early death might be 
the result of the severe phenotypes seen in these Tg mice such as the kidney disease or 
heart disease. These phenotypes being still observed in the Tg lines that express less 
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transgene, might explain the presence of an early death syndrome in these moderate 
expressing lines. 
Wasting syndrome seen in Tg mice might be caused by malabsorption 
In patients infected with HIV, the degree of wasting correlates mainly with the 
reduction of the nutrients intake (anorexia that is drug induced or connected to a delay in 
food gastric emptying), and to a lesser extent with the severity of the diarrhea, but no 
direct correlation with malabsorption was seen 11,102,117,132. In our Tg model, since severe 
diarrhea is rarely seen and since anorexia was never reported in these mice (data not 
shown), the wasting syndrome might to sorne extent be caused by malabsorption. 
In order to be sure that malabsorption is really a prominent feature of the wasting 
syndrome, studies will have to be conducted in order to evaluate the brush border 
enzymatic activity as well as the absorption of various substances. On the other hand, one 
cannot dismiss the possibility that the wasting syndrome can be the result of increased 
cytokines being released by activated T cells, such as tumor necrotic factor, a cytokine 
that is known to cause wasting 11,117. 
As the Tg mice become moribund, they are so severely affected by their kidney 
disease, that wasting might only be secondary and not be directly caused by Nef 
expression. Experiments will have to be done in Tg mice were heart disease and kidney 
disease segregate and see if the extent of wasting is similar in these Tg mice. 
This wasting syndrome definitely has to be studied more as it was proven that 
wasting strongly predicts patients survival, independent of the CD4+ lymphocytes counts, 
as a weight 10ss of 34% of ideal body weight resulted in death 117,132. 
Diarrhea seen in Tg mice is not caused by bacteria overgrowth 
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Bacterial overgrowth is a significant feature of the diarrhea seen in HIV -1 + 
patients. In our model, stools were examined for the presence of bacteria and small 
intestine sections were stained for the presence of parasites and opportunistic micro-
organisms, without any positive results. The fact that the mice were kept in an SPF 
environment might have helped to prevent bacterial overgrowth. Therefore, the diarrhea 
seen in our Tg model is most likely caused by a disruption of the gut's milieu by the 
expression of Nef. Cytokines expression will have to be studied to see if it might explain 
the various phenotypes seen in the Tg gut such as shortening of the villi, hyperplasia of 
the Peyer's patches (data not shown) and diarrhea, sometimes observed in the Tg mice. 
Splenomegaly in the CD4C/SHIV -nef IV Tg mice 
The splenomegaly frequently seen in the CD4C/SHIV -nef IV Tg mice 113 was 
milder in CD4CIHIVWT or CD4CIHIVMutG Tg mice. In fact, spleen atrophy was more 
often reported 42,43. These enlarged spleens are mostlY composed of B cells, macrophages, 
megakaryocytes, erythroid progenitors (CD71+Ter119+) and a very small number of T 
cells. The large spleens always correlated with the presence of white long bones, whereas 
controls had redish ones. This suggested the presence of a bone marrow defects and an 
interference with production of cells of the erythroid lineage in the spleen (extra-
medullary hematopoiesis), as anemia is typical of HIV+ patients, since 70% of 
asymptomatic patients suffer from anemia 134. 
Extra-medullary hematopoiesis is a very common compensation phenomenon 
present in mice. More detailed investigations showed us that the transgene was expressed 
in the BM (data not shown). This expression seems to lead to a dysregulation of the 
production of hematopoietic precursors, confirming that there is a BM defect with 
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compensatory splenic extra-medullary hematopoiesis in this CD4C/SHIV -ne:FIV Tg 
model. 
Additional studies will be needed to determine the mechanism at play III 
perturbating the hematopoiesis in these mice and the extent of the BM defect. 
Enlarged heart in CD4C/SHIV -neë1v Tg mice 
Heart enlargement was commonly reported in these Tg mice 113 The 
histopathological lesions were multifocal areas of myocytolysis, sometimes_associated 
with myocarditis. This cardiac phenotype is most likely caused by an indirect 
mechanisms as the result of the expression of SIV Nef in immune cells. 
This striking phenotype might also be the result of the severe kidney disease 
observed in these mice 113. Segregation of these two phenotypes in a Tg would permit to 
shed light on that mechanism. 
One thing that was ruled out is the hypothesis that the cardiac phenotype might be 
the result of opportunistic infections. The mice are kept in an SPF environment and no 
obvious opportunistic infections were reported in these mice 113. 
Sine cardiomyocytes were decorated with immunoglobulin, these might represent anti-
heart autoantibodies that might be in part responsible for this observed cardiomyopathy, 
without the need for any of the cardymycoytes to express the transgene 113. 
Again, since no cardiac disease was reported in CD4C/SIVMutH who expresses the 
whole SIV genome devoid of Nef, it seems that Nef is sufficient to cause this phenotype 
and might be a major pathogenic factor for AIDS-related heart diseases 55. 
What's wrong with CDS T cells in CD4C/SHIV-neë1v Tg mice? 
In this Tg model, the CD8 cell surface receptor was always dramatically 
downregulated, even at a very young age and the CD8+ T cells were present in very low 
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numbers in the peripheraI organs of the Tg Inlce. This was expected for the cells 
expressing the CD4 cell surface receptor, but not for the cells expressing CD8. 
This feature might be the result of a strong interaction between Nef and the CD8 
molecule at the CD4+CD8+ thymocytes stage, since Nef is strongly expressed at that 
moment. Another possible explanation is the fact that Nef expression in the immune cells 
of the thymus, inc1uding the ones comprised in the thymic stroma, leads to a higher 
expression of the MHCI cell surface receptor, which permits a stronger interaction 
between the CD8 and the MHCI cell surface receptor. This in turns leads to the selection 
CD8 cells otherwise destined to die because of a low CD8 cell surface expression. 
Consequently it would lead to the generation of an abnormaI peripheraI CD8+ T cell pool, 
as the one found in peripheraI organs of Tg animaIs. 
Thymie defeet rather than eellloss in the CD4C/SHIV _ne~IV Tg miee 
The low number of CD4+ and CD8+ peripheraI T cells in CD4C/SHIV-neF1V Tg 
mice is most likely due to a defective production of DP thymocytes by a block at the DN 
stage rather than the death of the mature cells in the periphery. Preliminary studies 
showed a higher proportion of death in the immune organs of the Tg animaIs (data not 
shown), but the extent of the death could not account for the dramaticaIly low numbers of 
T cells seen in periphery. 
The CD4C/SHIV-neFIV Tg mice are born with a smaIler thymus and at any age, 
the SP cells in the thymus are aImost absent, suggesting that the DP cells are either not 
made or die right after their production. AdditionaI studies will have to be made to shed 
sorne light on the reasons why SP cells are aImost absent, but we aIready know that this 
phenotype is cell autonomous and that the thymic environment does not play a major role. 
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Experiments to observe the DN ceUs seem to hint at a blockade of the ceU 
maturation at the DN3 to DN4 stage, as a smaller number of DN4 was observed. This 
problem in generating DN4 might be the reason explaining the very small number of DP 
cells in the Tg mice. Further experiments will have to be done to determine whether a) 
DN4 are more prone to apoptosis; b) they are incapable of proliferating; c) they are 
blocked at that stage of maturation; and what are the effectors involved in the blockade. 
One effector that came to mind was Csk, the negative regulator of p56Lck. When 
Csk is inactivated, it abrogates the requirement for preTCR, a.~TCR and MHCII for the 
development of DP and CD4+ thymocytes as weIl as peripheral CD4 a.~ peripheral ceUs 
104. Henceforth, the hypothesis was that Nef might sequester Csk and allow unregulated 
p56 Lck activity leading to an early expression of CD4 on cells that should not be 
expressing that receptor, explaining the expression of the transgene in DN cells, as Nef 
would work as a transistor to augment the effect, as CD4 should already be expressed to 
permit Nef expression. The fact that the transgene driven by the CD4 promoter drove 
expression in DN ceUs in the absence of Nef negated that hypothesis. 
As SIV Nef activates LcK, and HIV inhibits LcK, one might make the hypothesis 
that SIV Nef and HIV Nef will not cause the same phenotype in the thymus, which is in 
fact the case in our Tg model. SIV Nef will cause a thymic defect at the DN to DP 
transition stage whereas HIV Nef will cause an impaired CD4+ SP thymus maturation, in 
agreement with the literature on LcK. 
The only discrepancy is that in our model, SIV Nef is found to cause a block in 
the DN to DP transition whereas, as Nef activates LcK and as constitutive expression of 
LcK will accelerates the transition from double-positive to the single-positive stage 
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{Sohn, 2001 42819 /id}, it shouid cause a higher generation of SP cells, which are in fact 
almost absent in the thymus or in the periphery. 
The phenotype seen in CD4C/SHIV-neFIV Tg mice resembles the one described 
in a subgroup of HIV -1 infected children. These children have dramatically low numbers 
ofboth CD4+ and CD8+ T cells and are thought to have a thymic defect induced by HIV. 
This thymic defect was designated as a Di-George like syndrome 66,133. 
Cell autonomous thymie defect 
Fetai liver experiments showed that the thymic epithelium does not seem to play 
any major role in this thymic defect. When provided with non-Tg cells, the Tg epithelium 
of Tg mice was capable of sustaining a near normal development of thymic ceIls, 
resulting in a proper thymie reconstitution. On the other hand, when provided with a 
normal environment (non-Tg epithelium), the Tg ceIls reconstituted a thymic exactly 
similar to the one seen in regular Tg mice. 
Anti-CD3 immunization fails to reseue the thymie defect phenotype 
Tg mice upon being immunized with an anti-CD3 antibody either died or lost their 
DP ceIls in the thymus. This might be explained by a massive production of lymphokines 
by the remaining peripheral T cells that are already in an activated state (data not shown), 
resulting in the death of the thymocytes, as seen when anti-CD3 antibodies are injected in 
healthy non-Tg mice . On the other hand, the very smali number of remaining peripheral 
ceIls precludes us from concluding to that hypothesis 
Since expression of Nef in aIl CD4 expressing ceIls throughout ontogeny 
dramatically differs from the reality of in vivo infection, in which only a small fraction of 
CD4 expressing cells are infected with HIV at anY moment. We have to be carefui before 
we extrapolate these results to the human mode!. Our mouse modei may be different from 
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the above mentioned infected humans because of differences in the stage of Nef presence 
during thymie development, the level of Nef protein present, and also due to the presence 
of uninfected (non expressing Nef) cells in humans. These latter uninfected cells may be 
in competition with Nef expressing cells. 
In fact, the Tg mice may serve as a model of in utero or pediatrie infection. The 
therapeutic implication of our Tg model would be the capacity to test various alleles of 
Nef, see if they all cause the same AIDS-like disease in the mouse, identify the effectors 
that are necessary for the AIDS-like disease to occur and at the same time identify 
possible targets for medication or pharmaceutical research. AIso, one cannot preclude that 
one alle1e might be totally nonpathogenic and represent a good vaccine candidate. 
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CHAPTER7 
Claims to original research 
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Claims to original research for the article comprised in chapter 2: 
1- For the first time, the SIVmac239 Nef protein was expressed in a transgenie mouse 
model to see if it would cause a disease similar to the one induced by HIV -1 NL4-3 
Nef protein. 
2- CD4C/SHIV-netIV . Tg mice suffer from an AIDS-like disease. This disease is 
characterized by premature death, wasting, failure to thrive, kidney disease 
(interstitial nephritis and glomerulosclerosis), lymphocytic interstitial pneumonitis, 
cardiac disease, thymic atrophy, splenomegaly and low T cell number both in the 
thymus and in peripherallymphoid organs. This disease is characterized by premature 
death, wasting, failure to thrive, kidney disease (interstitial nephritis and 
glomerulosc1erosis), lymphocytie interstitial pneumonitis, cardiac disease, thymic 
atrophy, splenomegaly and low T cell number both in the thymus and in peripheral 
lymphoid organs. 
3- SIVmac239Nef expression leve1 in Tg corre1ates with latency and severity of the 
AIDS-like disease just like with HIV-l NL4-3 Nef. 
4- SIVmac239 Nef protein causes downregulation of mouse CD8 cell surface receptor as 
well as mouse CD4 cell surface receptor. 
5- Expression of SIVmac239 Nef protein causes a severe thymic defect, similar to the 
one experienced by a subgroup of HIV -1 infected children. 
6- Sorne Phenotypes Distinguish SIV from HIV -1 Nef Expression in Tg Mice. The heart 
enlargement phenotype was observed, at a higher penetrance and kidney glomerular 
pathology was greater in CD4C/SHIV-netIV than in CD4CIHIV Tg mice. Moreover, 
three immune phenotypes are virtually unique to CD4C/SHIV -netIV Tg mice: 
splenomegaly, early thymic atrophy and early onset of low number of peripheral T-
cells. 
7 - Expression of SIVmac239 Nef in a mouse seems to cause anemia, a phenotype 
compensated by extra-medullary hematopoiesis revealed by the presence of 
splenomegal y. 
8- CD4C/SHIV _netIV Tg mice were found to develop auto-antibodies and to generate a 
lower immunologie response to immunization (OV A). 
Therefore this work represents the first evidence that the SIVmac239 Nef can cause an 
AIDS-like disease in the mouse, a disease similar to the one caused by HIV -1 Nef, 
suggesting that the HIV-l Nef and SIVmac239 Nef proteins possibly interact with the 
same effectors, effectors that are present in the mouse as weIl as in humans and primates. 
Claims to original research for the article comprised in chapter 3: 
1- For the first time it was proven that mice are born with the thymic defect caused by 
the SIVmac239 Nef protein. 
2- CD4C/SHIV -netIV Tg mice seems to suffer from a severe thymic defect that 
SIVmac239 seems suffieient to cause, as the whole SIVmac239 genome devoid of 
Nef is incapable of causing the same phenotype. 
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3- The thymic defect is cell autonomous and the thymic stroma epithelial cells do not 
seem to play a major role in this phenotype, as proven by fetal liver transplant 
experiments. 
4- Low thymic cellularity seems due to a lack of generation of double positive cells and 
possibly by a block between DN3 to DN4 development 
Claims to original research for the article comprised in chapter 4: 
1- SN Nef and HN Nef do not cause the same block in thymic maturation in a Tg model 
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PROSPECTIVE EXPERIMENTS 
In vitro generation of DP cells 
Sort DN cells (CD4-, CDS-, TcRgd-, CDllC, DX5-, Mac1-, Grr and B220-) and 
put them in culture overnight to monitor the spontaneous generation of DP cells. 
Transplantation of cells into thymectomized mice 
Isolate BM cells from Tg mice and transplant them into irradiated thymectomized 
Tg mice, in order to see if the peripheral cells present in the Tg mice are of thymie origin 
or mostly from peripheral expansion. 
Quantitation of possible Nef partners to cause the thymie block 
Do quantitative PCR to quantitate the following: SCL, E2A, LM02, HEB, TcR~, 
TcRa, pTa, RAG1, S16, LEF-l, TCF-l, lck, Csk, LcK, GATA-l, GATA-3 
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